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 Drug development aims at finding therapeutic compounds that possess 
desirable pharmacodynamic and pharmacokinetic properties and low toxicological 
profiles. Historically, inappropriate pharmacokinetic properties and side-effects have 
been the primary reasons for the failure of drug candidates in later stages of 
development. Thus tools for predicting pharmacokinetic and toxicological properties 
in early design stages are needed for fast elimination of compounds with undesirable 
properties so that development effort can be focused on the most promising 
candidates. As part of the effort for developing such tools, computational methods 
have been explored for predicting various pharmacokinetic and toxicological 
properties of pharmaceutical compounds. In particular, quantitative structure 
pharmacokinetic relationship (QSPkR) and qualitative structure pharmacokinetic 
relationship (qSPkR) methods have shown promising potential for performing these 
tasks by statistically analyzing the correlation between chemical structures and a 
specific pharmacokinetic, or toxicological (ADMET) property to derive statistical 
models or rules for predicting whether a drug candidate possesses a specific property 
or for predicting the activity level of the drug candidate.  
 Previously, QSPkR/qSPkR models were frequently built using datasets with a 
limited number of related compounds and by using linear statistical methods. Hence 
they may not be suitable for the prediction of ADMET properties of diverse groups of 
compounds and also ADMET properties that are controlled by multiple mechanisms. 
Thus it is of interest to examine the potential of using a larger number and more 
diverse groups of compounds and non-linear machine learning methods in improving 
the quality of QSPkR/qSPkR models. In this work, machine learning methods, such as 
support vector machines, support vector regression, and general regression neural 
 
 xi
network, consensus modeling methods, larger number and more diverse groups of 
compounds, as well as compounds with known human ADMET data were used to 
develop QSPkR/qSPkR models for various ADMET properties. A novel method for 
identification of relevant physicochemical and structural properties of a compound 
from non-linear QSPkR/qSPkR models, which are traditionally regarded as black 
boxes, is also introduced.  
 The results show that the quality of QSPkR/qSPkR models can be improved 
by using the methods discussed in this work. The prediction capabilities of 
QSPkR/qSPkR models developed in this work for human intestinal absorption, p-
glycoprotein substrates, blood-brain barrier penetration, human serum albumin 
binding, milk-plasma ratio, cytochrome isoenzymes substrates and inhibitors, total 
body clearance, and genotoxicity are higher than those developed in earlier studies. In 
addition, machine learning methods were found to be useful for developing qSPkR 
models for torsade de pointes, a rare but serious adverse drug reaction, which has not 
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 In Silico methods are increasingly employed to reduce the time and cost 
needed for evaluating the pharmacokinetics and toxicity of drug candidates. The most 
common In Silico methods are traditional linear statistical methods such as multiple 
linear regression. Recently, non-linear machine learning methods such as artificial 
neural networks and support vector machines have been evaluated for their 
usefulness for the prediction of pharmacokinetics and toxicological properties 
because of their success in many diverse fields such as data mining, image and speech 
recognition, and process control. The first section (section 1.1) of this chapter gives 
an overview of the application of in silico methods for pharmacokinetics and toxicity 
prediction. The motivation for this work and an outline of the structure of this 
document is given in the next two sections of this chapter (sections 1.2, 1.3). 
 
1.1 Application of in silico methods for pharmacokinetics and 
toxicity prediction 
1.1.1 Drug discovery process 
 Modern drug discovery efforts have primarily been based on the search and 
optimization of compounds that possess specific pharmacodynamic and 
pharmacokinetic properties, and on the test of their potential toxicological and side 
effects (Caldwell et al. 1995; Drews 2000; Park et al. 2000). Pharmacodynamics is 
the study of the biochemical and physiological effects of drugs and their mechanisms 
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of action (Hardman et al. 2002). For a drug to be effective, it must have optimal 
pharmacodynamic properties so that it can inhibit a disease process, correct the 
imbalances and brings about the normal functioning of the body. Pharmacokinetics is 
the study of the time course of a drug within the body and incorporates the processes 
of absorption, distribution, metabolism and excretion, which together with 
toxicological properties are referred to as ADMET properties (Smith et al. 2001b). A 
drug must have optimal pharmacokinetic properties so as to achieve sufficient 
concentration at target site while possibly limiting its distribution elsewhere so as to 
produce desired therapeutic action with minimum side effects.  
 The drug discovery process is typically a lengthy and costly process. The 
average time required for a drug to proceed from initial design effort to market 
approval is 13 years and the estimated average development cost of a new drug is 
US$802 million, with the preclinical phase and clinical phase costing US$335 million 
and US$467 million respectively (DiMasi et al. 2003). Traditionally, pharmacokinetic 
and toxicological properties of drug candidates have primarily been evaluated during 
later design stages, particularly in the expensive animal tests and clinical trials  (van 
de Waterbeemd et al. 2003). According to a recent report, approximately 40% of all 
drug failures during the clinical phase, excluding failures of anti-infectives, is due to 
poor pharmacokinetics (7%) or unacceptable toxicity (33%). If anti-infectives are 
considered, the percentage increases to approximately 60% with 39% and 21% due to 
poor pharmacokinetics and unacceptable toxicity respectively (Kubinyi 2003). To 
reduce the cost and time of drug development, there has been a paradigm shift such 
that ADMET properties are now considered and evaluated in increasingly earlier 
stages of drug discovery process. Thus methods for predicting these ADMET 
properties, particularly in the early design stages, are useful for facilitating drug 
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development and drug safety evaluation (Drews 2000; Ekins et al. 2000b; White 
2000). 
 
1.1.2 Application of quantitative structure pharmacokinetics relationship 
(QSPkR) and qualitative structure pharmacokinetics relationship (qSPkR) 
models in ADMET prediction 
 As part of an effort to accelerate and reduce the cost of drug discovery 
processes, computational methods have been explored for predicting compounds that 
possess specific pharmacodynamic, pharmacokinetic or toxicological 
property (Katritzky et al. 1997; Manallack et al. 1999; van de Waterbeemd et al. 2003; 
Hansch et al. 2004). In particular, statistical learning methods have shown promising 
potential for performing these tasks by statistically analyzing the structural and 
physicochemical features of the compounds known to possess a particular property to 
derive explicit or hidden statistical models or rules for predicting the activity or 
property of new compounds (Manallack et al. 1999; Burbidge et al. 2001; Trotter et al. 
2003).  
 The development of QSPkR models have been instrumental for the early 
testing of ADMET properties of drug candidates. Hansch is one of the pioneers in 
exploring the usefulness of QSPkR models (Hansch 1972). His work on the use of the 
partition coefficient, log P, to model drug metabolism has generated a significant 
interest in applying QSPkR models for prediction of other ADMET properties. The 
initial QSPkR models were usually built from small congeneric groups of compounds 
with known in vivo ADMET data (Hansch 1972; Seydel et al. 1981; Toon et al. 1983; 
Markin et al. 1988). The results of these studies suggested that QSPkR models are 
potentially useful for the prediction of ADMET properties. However, the small 
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amount of available in vivo ADMET data limits the widespread development of 
QSPkR models. Subsequently, the development of combinatorial chemistry and high-
throughput screening using in vitro assays enable large numbers of closely related 
compounds to be rapidly synthesized and screened for their ADMET properties. This 
creates a wealth of in vitro ADMET data, which enables the evaluation of in silico 
methods, thereby increasing the confidence in the results obtained when these 
methods are applied to scarce human data (Clark et al. 2003).  
  QSPkR/qSPkR models have now been built for a number of ADMET 
properties. These include cellular permeability (van de Waterbeembd et al. 1996), 
intestinal absorption (Stenberg et al. 2000), bioavailability (Mandagere et al. 2003), 
active transport processes (Ekins et al. 2000c) and skin permeability (Abraham et al. 
1999), blood-brain barrier penetration (Ecker et al. 2004), milk-plasma ratio (Meskin 
et al. 1985), serum protein binding (Toon et al. 1983), volume of distribution (Toon et 
al. 1983), P450 isoenzyme substrates and inhibitors (Koymans et al. 1992; Ekins et al. 
1999a), first pass (Watari et al. 1988), total clearance (Toon et al. 1983), renal 
clearance (Toon et al. 1983), half-life (Markin et al. 1988), genotoxicity (Mosier et al. 
2003), carcinogenicity (Benigni et al. 2000), mutagenicity (Benigni et al. 2000), and 
QT prolongation (Muzikant et al. 2002). Table 1.1 and Table 1.2 give a list of some of 
these QSPkR/qSPkR models. There are many applications of these QSPkR/qSPkR 
models. Some qSPkR models, such as the Lipinski’s rule of five (Lipinski et al. 1997), 
are useful as computational filters for the high-throughput screening of chemical 
libraries for potential drug leads with acceptable ADMET properties. QSPkR/qSPkR 
models that identify pharmacophoric models of metabolic enzymes are useful in the 
rational design of drug candidates to avoid potential drug-drug interactions (Ekins et 
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such as the bioavailability (Mandagere et al. 2003) and milk-plasma 
ratio (Agatonovic-Kustrin et al. 2002), are useful for determining the appropriate 
starting dose during the clinical phase or to evaluate the potential risk to the infant.  























SE (%) SP (%) Q (%)
Reference 
LDA TOPS-MODE 82 Validation set (127) 95.5 76.5 92.9  (Pérez et al. 2004) 
C-SAR Simple physicochemical parameters 977 Training set (977) 97.0 81.7 95.7  (Zmuidinavicius et al. 
2003) 




SVM Simple molecular properties, molecular 
connectivity and shape, E-state, Q-C, 
GEO 
196 5 fold CV (196) 90.0 80.7 86.7  (Xue et al. 2004b) 
ORMUCS Log P, structural 232 Validation set (40) - - 60.0  (Yoshida et al. 2000) Bioavailability 
 Adaptive fuzzy 
partition 
CON, information, TOP, E-state, 
physicochemical, ELE 
352 Validation set (75) - - 64.0  (Pintore et al. 2003) 
P-gp substrate SVM Simple molecular properties, molecular 
connectivity and shape, E-state, Q-C, 
GEO 
142 Validation set (25) 84.2 66.7 80.0  (Xue et al. 2004c) 
 
 MLR Daylight, thermodynamic, spatial, 
structural, TOP, charge 
48 Validation set (150) 81.0 95.8 88.0  (Lobell et al. 2003a) 
Discrimination 
function analysis 
TOP, substructures, GEO, Q-C 28 LOO (28) 100.0 91.7 96.4  (Basak et al. 1996) 
PLS Log P, PSA, E-state 58 Validation set (181) 85.7 46.7 66.3  (Subramanian et al. 2003) 
PLS-DA ADME screen, geometry, topology, 
VAMP electronic parameters, VAMP 
energy parameters, Sybyl surface areas
1696 Validation set (82) 90.0 92.0 91.0  (Adenot et al. 2004) 
SUBSTRUCT Substructures 8678 10 fold CV (8678) 83.3 71.2 76.3  (Engkvist et al. 2003) 
Bayesian neural 
network 
CON, log P, ISIS fingerprint >73000 Validation set (84) 94.7 73.9 83.3  (Ajay et al. 1999) 
PCA VolSurf 110 Validation set (120) 90.9 64.8 71.7  (Crivori et al. 2000) 
Structural 172 Validation set (304) 78.9 60.4 76.0  (Trotter et al. 2001) 





MW, lipophilicity, H-bond 274 Validation set (50) 82.7 80.2 81.5  (Doniger et al. 2002) 
CYP3A4 
inhibitor 
PLS CATS, TOP, ELE, count, structural, 
atom types 
311 Validation set 1 (50) 
























 ANN Unity fingerprint 218 Validation set (72) 91.7 88.9 90.3  (Molnar et al. 2002) 




TOP, E-state, physicochemical, 
fragment keys, 1D similarity scores 
100 Validation set (51) 100 76.0 80.0  (Susnow et al. 2003) CYP2D6 
inhibitor 
 
Consensus SVM DRAGON 602 Validation set (100) 90.0 95.0 94.0  (Yap et al. 2005a) 
CYP2C9 
inhibitor 
Consensus SVM DRAGON 602 Validation set (100) 88.9 96.3 95.0  (Yap et al. 2005a) 
CYP2D6 
substrate 
Consensus SVM DRAGON 602 Validation set (100) 98.2 90.9 95.0  (Yap et al. 2005a) 
CYP3A4 
substrate 
Consensus SVM DRAGON 602 Validation set (100) 96.6 94.4 95.0  (Yap et al. 2005a) 
CYP2C9 
substrate 
Consensus SVM DRAGON 602 Validation set (100) 85.7 98.8 97.0  (Yap et al. 2005a) 
KNN TOP, GEO, ELE, PSA 120 Validation set (20) 66.7 92.9 85.0  (Mosier et al. 2003) Genotoxic  
 Consensus KNN TOP, GEO, ELE, Q-C, CPSA, H-bond, 
nitrogen-specific 

















 Consensus model 
(KNN, LDA, PNN) 
TOP, GEO, ELE, CPSA, H-bond 227 3 fold CV (227) 73.8 84.3 81.2  (He et al. 2003) 
SVM Simple molecular properties, molecular 
connectivity and shape, E-state, Q-C, 
GEO 




















Abbreviations: C-SAR - classification structure-activity relations; ORMUCS – ordered multicategorical classification method using the simplex technique; 
PLS-DA – partial least squares-discriminant analysis; TOPS-MODE – topological substructural molecular design; MR – molar refractivity; TOP – 
topological; E-state – electrotopological state indices; Q-C – quantum-chemical; GEO – geometrical; CON – constitutional; ELE – electronic; PSA – polar 
surface area; MW – molecular weight; H-bond – hydrogen bonding capabilities; CPSA – charged polar surface area; LSER – linear solvation energy 
relationship; CV – cross validation 
a – number in parenthesis denotes the number of compounds used for model validation. 
 

















Property Activity Method Molecular descriptors Validation methoda Reported prediction statistics Reference 
LSER Training set (38) 
Validation set (131) 
r2=0.82, q2=0.77, SE=15, F=53 
RMSE=14, MAE=11 
 (Zhao et al. 2001) MLR 
 
Physicochemical, structural fragment Training set (417) 
Validation set (50) 
r2=0.79, SE=12.34, F=38.83 
r2=0.79, SE=12.32 
 (Klopman et al. 
2002) 
Sigmoidal PSA Training set (20) r2=0.94, RMSE=9.2%  (Palm et al. 1997) 
Log P, molecular size, H-bond, counts Training set (16) 
Validation set (63) 
r2=0.55, q2=0.45 
RMSE=28.6 




Atom type Training set (169) r2=0.921, q2=0.787  (Sun 2004) 
TOP, ELE, GEO, CPSA, H-bond Training set (67) 
Validation set (10) 
RMSE=0.4, MAE=6.7 
RMSE=16.0, MAE=11.0 
 (Wessel et al. 
1998) 
CON, TOP, chemical, GEO, Q-C Training set (67) 












TOP Training set (396) 
Validation set (185) 
r2=0.92, RMSE=9.1, MAE=7.3 
r2=0.80, RMSE=11.8, MAE=9.8 
 (Votano et al. 
2004) 
 
 GRNN Log P, MR, TOP Training set (67) 
Validation set (10) 
RMSE=6.5 
RMSE=22.8 
 (Niwa 2003) 
FA CART Structural Training set (899) 
Validation set 1 (362) 
Validation set 2 (67) 
Validation set 3 (90) 






 (Bai et al. 2004) 
MolSurf Training set (13) 
Validation set (7) 
r2=0.903, q2=0.685, RMSE=0.523 
RMSE=0.488 




TOP Training set (13) 
Validation set (7) 
r2=0.903, q2=0.818, RMSE=0.523 
RMSE=0.413 








 (Norinder 2003) 
Regression Substructure counts Training set (591) 
2000 runs of 80/20
splits (591) 
 r
r2=0.71, q2=0.63, RMSE=17.92 
2=0.58, RMSE=20.40 







































Q-C, CON, TOP Validation set (10) r2=0.72 2003a) 
ANN CON, TOP, chemical, GEO, Q-C, bulk 
properties, solubility parameters 
Training set (137) 
Validation set (15) 
r2=0.736, RMSE=19.21 
r2=0.680, RMSE=20.47 




CODES Training set (28) q2=0.90  (Dorronsoro et al. 
2004) 
P-gp inhibitor log(1/EC50) PLS SIBAR Training set (100) r2=0.731, q2=0.661  (Klein et al. 2002) 
MW, log P Training set (20) r2=0.691, SE=0.439, F=40.23  (Young et al. 
1988) 
LSER Training set (57) r2=0.907, SE=0.197, F=99.2  (Abraham et al. 
1994) 
Solvation energy Training set (55) r2=0.672, SE=0.41, F=108.3  (Lombardo et al. 
1996) 
MW, log P Training set (33) r2=0.897, SE=0.126, F=131.1  (Kaliszan et al. 
1996) 




























PSA, log P Training set (55) 
Validation set 1 (5) 
Validation set 2 (5) 
r2=0.787, SE=0.354, F=95.8 
MAE=0.14 
MAE=0.24 
 (Clark 1999) 
PSA Training set (45) r2=0.95  (Ertl et al. 2000) 
Solvation free energy Training set (55) 
Validation set 1 (7) 
Validation set 2 (5) 





 (Keserü et al. 
2001) 
MW, molecular lipoaffinity Training set (55) 
Validation set (11) 
r2=0.790, q2=0.763, SE=0.35, F=97.7 
r2=0.838, SE=0.30 
 (Liu et al. 2001) 
LSER Training set 1 (148) 
2 fold CV (148) 
5 runs of 80/20 splits
(148) 
 r
r2=0.745, q2=0.711, SE=0.343, F=69 
r2=0.718, SE=0.381 
2=0.733, SE=0.356 
 (Platts et al. 2001) 
Hydrogen bonding, molecular volume, 
solvent-accessible surface area 
Training set (76) r2=0.94, SE=0.173, F=311.307  (Kaznessis et al. 
2001) 
 
 Spatial, structural, thermodynamic Training set (59) 
Validation set (12) 
Validation set (21) 
r2=0.757, q2=0.701, SE=0.408, F=42.135 
RMSE=0.29 
RMSE=0.50 
 (Hou et al. 2002) 
E-state Training set (102) 
Validation set (20) 
5 fold CV (102) 
r2=0.66, q2=0.62, SE=0.45, F=62.4 
RMSE=0.38, MAE=0.32 
RMSE=0.47, MAE=0.38 
 (Rose et al. 2002) 
Solute aqueous dissolution and 
solvation, solute-membrane interaction, 
general intramolecular solute 
Training set (56) 
Validation set (7) 
r2=0.845, q2=0.795 
RMSE=0.449, MAE=0.398 
 (Iyer et al. 2002) 
Daylight, thermodynamic, spatial, 
structural, TOP, charge 
Training set (48) 
Validation set (17) 
r2=0.837, q2=0.786, MAE=0.26, SE=0.19
r2=0.68, MAE=0.41 




Training set (78) 
Validation set 1 (13) 
Validation set 2 (22) 
r2=0.767, q2=0.736, SE=0.364, F=81.5 
r2=0.88, RMSE=0.26, MAE=0.16 
r2=0.61, RMSE=0.48, MAE=0.39 
 (Hou et al. 2003) 
4D molecular similarity measures Training set (104) 
Validation set (46) 
r2=0.69, q2=0.64 
r2=0.56 
 (Pan et al. 2004) 

















 Validation set 1 (13) 







 Training set (86) r2=0.89, RMSE=0.31  (Cheng et al. 
2002) 
Log P, H-bond, PSA Training set (61) 
Validation set 1 (14) 
Validation set 2 (25) 
r2=0.730, q2=0.688, RMSE=0.424 
r2=0.576, RMSE=0.628 
r2=0.616, RMSE=0.789 




Atomic contributions to van der Waals 
surface area, log P, MR, partial charge 
Training set (75) r2=0.83, q2=0.73, RMSE=0.32  (Labute 2000) 
MolSurf Training set (28) 
Validation set 1 (28) 
Validation set 2 (6) 
r2=0.862, q2=0.782, RMSE=0.288 
RMSE=0.353 
RMSE=0.473 
 (Norinder et al. 
1998) 
TOP, molecular volume, MW, CON, 
H-bond 
Training set (58) 
Validation set 1 (12) 
Validation set 2 (22) 
r2=0.850, q2=0.752, SE=0.318, F=102 
RMSE=0.235 
RMSE=0.408 
 (Luco 1999) 
PLS 
 

































Validation set (30) RMSE=0.375 2001) 
Log P, MW, MR, molar volume, H-
bond 
Training set (19) 
Validation set (37) 
r2=0.905, q2=0.791, RMSE=0.287 
RMSE=0.338 
 (Osterberg et al. 
2001) 
VolSurf Training set (79) r2=0.78, q2=0.65  (Ooms et al. 
2002) 
Log P, PSA, E-state Training set (58) 
Validation set (39) 
r2=0.846, RMSE=0.308, MAE=0.232 
r2=0.617, RMSE=0.413, MAE=0.499 
 (Subramanian et 
al. 2003) 
Atom type Training set (57) 
Validation set (13) 
r2=0.910, RMSE=0.502 
RMSE=0.326 
 (Sun 2004) 
CODES neural 
network 




Property-based, TOP indices, CIMI, 
atomic charges 
Training set (106) r2=0.76, q2=0.65, SE=0.54  (Winkler et al. 
2004) 
GRNN DRAGON Validation set (30) r2=0.701, RMSE=0.361  (Yap et al. 2005b) 




 (Norinder 2003) 


















10% CV (84) 
Validation set (10) 
r2=0.68 
r2=0.74, RMSE=0.32, MAE=0.31 
 
ELE, TOP, information-content, 
spatial, structural, thermodynamic 
Training set (84) 
Validation set (10) 
r2=0.78, q2=0.73 
r2=0.88 
 (Colmenarejo et 
al. 2001) 
GRNN DRAGON Validation set (18) r2=0.851, RMSE=0.202  (Yap et al. 2005b) 
  
SVR CON, TOP, GEO, electrostatic, Q-C Training set (84) 
Validation set (10) 
r2=0.94, RMSE=0.124 
r2=0.89, RMSE=0.222 
 (Xue et al. 2004a) 
log((1-fu)/fu) MLR Log P Training set (226) 
Validation set (94) 
r2=0.68, MAE=0.45 
r2=0.51, MAE=0.53 




Log P Training set 1 (84) 
Training set 2 (44) 









fb ANN Atom and functional group counts, 
connectivity index differences, 
connectivity index quotients, charge 
indices, vertex counts, ramifications, 
Wiener number, MW, Log P 




















ANN CON, TOP, molecular connectivity, 
GEO, Q-C, physicochemical, liquid 
properties 
Training set (123) r2=0.61, RMSE=0.781  (Agatonovic-







GRNN DRAGON Validation set (20) r2=0.677, RMSE=0.454  (Yap et al. 2005b) 
KNN TOP, physical properties, partial 
charge, pharmacophore feature, 
potential energy 
Training set (32) 
Validation set (6) 
q2=0.77 
r2=0.94 
 (Ng et al. 2004) 
ANN Atom and functional group counts, 
connectivity index differences, 
connectivity index quotients, charge 
indices, vertex counts, ramifications, 
Wiener number, MW, Log P 






GRNN Lipophilicity, ionization, molecular 
size, H-bond 
Training set (23) r2=0.775, q2=0.731  (Karalis et al. 
2003) 
Abbreviations: FA – fraction absorbed; F – bioavailability; BB – ratio of concentration of drug in brain to concentration of drug in blood; Khsa – binding 
affinity of drug to human serum albumin; fu – fraction of drug unbound in plasma; fb – fraction of drug bound in plasma; CART – classification regression 
tree; PCR – principal component regression; SIBAR – similarity based structure activity relationship; CIMI – chemically intuitive molecular index; 
3DMoRSE – 3D molecule representation of structures based on electron diffraction; ATS – Moreau-Broto autocorrelation; GETAWAY - geometry, 
topology, and atom-weights assembly; RDF – radial distribution function; WHIM – weighted holistic invariant molecular descriptors 
a – number in parenthesis denotes the number of compounds used for model validation. 
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1.1.3 In silico methods 
 There are a number of in silico methods that have been used to develop 
QSPkR/qSPkR models. Traditional statistical methods, such multiple linear regression 
and partial least squares, have been widely adopted for the development of 
QSPkR/qSPkR models because they can be easily used and the derived models can be 
easily interpreted. These methods are highly successful in developing QSPkR/qSPkR 
models by using small groups of congeneric compounds, which can be used in the 
modification of drug leads by identifying important physicochemical and structural 
properties which affect the ADMET properties. Studies have been conducted to apply 
these methods to develop QSPkR/qSPkR models by using larger and more diverse 
groups of compounds. The derived QSPkR/qSPkR models usually have lower 
prediction accuracies than those of QSPkR/qSPkR models developed by using small 
groups of congeneric compounds (Herman et al. 1994). This suggests that multiple 
mechanisms are involved in determining the ADMET properties of diverse groups of 
compounds and thus recent studies have explored methods based on non-linear 
relationships, such as machine learning methods, for constructing QSPkR/qSPkR 
models (Smith et al. 2001a).  
 Machine learning is the study of computer prediction, classification or analysis 
algorithms that improve automatically through experience (Mitchell 1997). Machine 
learning methods have been successfully used in many diverse fields with numerous 
applications such as pharmacodynamic properties prediction (Czerminski et al. 2001; 
Livingstone et al. 2003), protein function prediction (Cai et al. 2003), medical 
decision making (Veropoulos 2001), spam categorization (Drucker et al. 1999), 
detection of oil spills (Kubat et al. 1998), and speech recognition (Nuttakorn et al. 
2001). A reason for the widespread adoption of machine learning methods in different 
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fields is that they do not make any assumption about the nature of the relationship 
between the property to be predicted and the factors affecting that property. This 
enables complex relationships to be modeled accurately and thus improves the 
prediction accuracies of these models.  
 ‘Traditional’ machine learning methods, such as artificial neural networks and 
decision trees, have been explored for the development of QSPkR/qSPkR models for 
a number of ADMET properties. These include human intestinal absorption (Wessel 
et al. 1998; Bai et al. 2004; Wegner et al. 2004), bioavailability (Yoshida et al. 2000; 
Pintore et al. 2003; Turner et al. 2004a), blood-brain barrier penetration (Ajay et al. 
1999; Winkler et al. 2004), milk-plasma ratio (Agatonovic-Kustrin et al. 2002), serum 
protein binding (Gobburu et al. 1995; Turner et al. 2004b), volume of 
distribution (Gobburu et al. 1995; Turner et al. 2004b), P450 isoenzyme substrates 
and inhibitors  (Molnar et al. 2002; Susnow et al. 2003; Balakin et al. 2004), total 
clearance (Turner et al. 2004b), and genotoxicity (Maran et al. 2003; Mattioni et al. 
2003). The prediction or classification accuracies of these QSPkR/qSPkR models are 
usually better than those of QSPkR/qSPkR models developed by using traditional 
statistical methods (Manallack et al. 1999; Svetnik et al. 2005).  
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1.2 Motivation 
 There are three main objectives of this work. The first is to improve the 
quality of previous QSPkR/qSPkR models for ADMET prediction. In this work, four 
strategies will be used to achieve this objective. The first strategy is to apply newer 
machine learning methods, such as support vector machine (SVM), support vector 
regression (SVR), and general regression neural network (GRNN), for the 
development of QSPkR/qSPkR models. These methods have shown promising 
potential for predicting pharmacodynamic properties of drugs (Burbidge et al. 2001; 
Czerminski et al. 2001; Mosier et al. 2002; Huang et al. 2003) and it is of interest to 
compare these newer methods with ‘traditional’ machine learning methods, such as 
artificial neural networks and decision trees, for the prediction of ADMET properties. 
The second strategy is to employ consensus modeling to combine different 
QSPkR/qSPkR models. There may be several QSPkR/qSPkR models for prediction of 
a single ADMET property that are developed by using different in silico methods or 
different descriptors. Thus it is of interest to determine if combining these models into 
a consensus model will improve the overall prediction accuracies for the ADMET 
property. The third strategy is to use a larger number and more diverse groups of 
compounds for developing QSPkR/qSPkR models. Some of the previous 
QSPkR/qSPkR models were built using datasets with a limited number of related 
compounds and thus may are not suitable for prediction of ADMET properties of 
diverse groups of compounds. The last strategy is to use compounds with known 
human ADMET data for developing QSPkR/qSPkR models. The large number of 
QSPkR/qSPkR models developed by using in vitro or animal ADMET data has 
helped to improve the in silico methods and descriptors for developing QSPkR/qSPkR 
models. However, there are large, non-systemic variations of ADMET properties 
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across species for individual compounds and thus these previous QSPkR/qSPkR 
models may not be suitable for prediction of human ADMET properties. 
 The second objective is to improve on the interpretability of QSPkR models 
developed by machine learning methods. A common problem with these QSPkR 
models is that they are often complex with multiple parameters and weights. Thus it is 
difficult to determine which physicochemical and structural properties of a compound 
are important in determining its ADMET properties. Hence it will be useful to have a 
method which can identify the important physicochemical and structural properties. 
 The last objective of this work is to construct qSPkR models for important 
ADMET properties which have not received sufficient attention. An example of such 
ADMET properties is the potential of drug candidates to cause torsade de pointes, 
which is a rare but serious adverse drug reaction. 
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1.3 Thesis structure 
 A QSPkR/qSPkR model consists of three main components: (1) ADMET data, 
(2) physicochemical and structural descriptions of a compound, and (3) a statistical 
learning technique to correlate the first two components. In chapter 2, these three 
components are described and the methods used in this work for developing 
QSPkR/qSPkR models are given. Methods that are used for checking the validity and 
usefulness of QSPkR/qSPkR models are also described. 
 A new machine learning library, YMLL, and a Microsoft Windows software, 
PHAKISO, is introduced in chapter 3. YMLL contains algorithms that are essential 
for performing a QSPkR/qSPkR experiment. PHAKISO provides a graphical user 
interface to the algorithms in YMLL so that a QSPkR/qSPkR model can be developed 
and validated easily with just a few mouse clicks. Both YMLL and PHAKISO are 
available freely on the PHAKISO website (http://www.phakiso.com) for non-
commercial uses. 
 The prediction of absorption-related processes, in particular, human intestinal 
absorption, and p-glycoprotein substrates, is presented in chapter 4. SVM was used to 
develop classification systems for identifying compounds that are absorbable by 
human intestine and compounds that are substrates of the p-glycoprotein transporter. 
The effect of recursive feature elimination (RFE), a method for identifying relevant 
descriptors, on the classification accuracies of the SVM classification systems is 
discussed. Analysis of the RFE-selected descriptors and comparison with other 
classification studies are also presented.  
 Chapter 5 describes the prediction of a few important distribution processes, 
such as blood-brain barrier penetration, human serum albumin binding and milk-
plasma ratio by using GRNN. The prediction accuracies of the GRNN-developed 
 
CHAPTER 1: INTRODUCTION 24
models were compared with those of QSPkR models developed by using MLR and 
MLFN. A new method for interpreting GRNN-developed QSPkR models, which 
enables relevant physicochemical and structural properties of a compound to be 
identified, is also introduced. 
 The use of consensus SVM model strategy to improve the prediction 
accuracies of substrates and inhibitors of three cytochrome P450 isoenzymes, 3A4, 
2D6 and 2C9 is presented in chapter 6. Physicochemical and structural properties of 
compounds that are important for the identification of substrates and inhibitors and 
factors that may affect the prediction accuracies are discussed.  
 Chapter 7 describes three machine learning approaches for the prediction of 
total clearance. Several different sets of descriptors are compared for their usefulness 
in modeling total clearance. Important physicochemical and structural properties of a 
compound are also identified by using the new method that is introduced in Chapter 5.  
 Chapter 8 describes two important drug toxicities: genotoxicity and torsade de 
pointes. The classification accuracies of the qSPkR models for prediction of genotoxic 
potential and torsade-causing potential of compounds developed by using SVM and 
other classification methods are presented. The possible reasons for misclassification 
of some compounds are also discussed. 
 Chapter 9 summarizes the major findings and contributions of this work to the 
progress of using machine learning approaches for pharmacokinetics and toxicity 
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Chapter 2 
Quantitative/Qualitative Structure Pharmacokinetics 
Relationship (QSPkR/qSPkR) 
 
 A QSPkR/qSPkR model consists of three main components: (1) ADMET data 
(section 2.2), (2) physicochemical and structural descriptions of a compound (section 
2.3), and (3) a statistical learning technique to correlate the first two components 
(section 2.4). In this chapter, these three components are described and the methods 
used in this work for developing QSPkR/qSPkR models are given. Methods that are 
used for checking the validity and usefulness of QSPkR/qSPkR models are also 
described (section 2.5). 
 
2.1 Introduction 
 A QSPkR/qSPkR model is a mathematical model which approximates the 
relationship between an ADMET property of a compound and its structure-derived 
physicochemical and structural features (Johnson et al. 1990). The two main 
objectives of QSPkR/qSPkR modeling are to allow prediction of the ADMET 
properties of a not yet biologically tested, but chemically characterized compound and 
to extract clues as to which molecular characteristics of a compound are important for 
the ADMET properties. In this work, the term “QSPkR model” is used to refer to 
quantitative models (regression problems), and the term “qSPkR model” will be used 
to refer to qualitative models (classification problems). 
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Figure 2.1 Flowchart showing the various processes during the development of a 
QSPkR/qSPkR model. 
ADMET data Remove poor quality data
Statistical 
















 Figure 2.1 shows a basic scheme for developing a QSPkR/qSPkR model. The 
initial step is the collection of relevant ADMET data and the elimination of low 
quality data that are likely to affect the quality of the model. The next step is the 
selection of representative compounds into a training set and a validation set to 
calibrate and evaluate the QSPkR/qSPkR model respectively. Molecular descriptors 
are then computed for representing the physicochemical and structural properties of 
the compounds studied and those that are redundant or contained little information are 
removed prior to the modeling process. A machine learning method is then used to 
develop a model that relates the ADMET property to the physicochemical and 
structural properties of the compounds. During a modeling process, optimization of 
the essential parameters of the machine learning methods and the selection of relevant 
descriptor subsets are conducted simultaneously. The optimum set of parameters and 
descriptor subset are used to construct a final QSPkR/qSPkR model, which is 
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2.2 Dataset 
2.2.1 Quality analysis 
 The development of reliable QSPkR/qSPkR models depends on the 
availability of high quality ADMET data that have low experimental errors (Cronin et 
al. 2003). Ideally, these ADMET properties should be measured by a single protocol 
so that different compounds can be reliably compared with each other. However, 
human ADMET data have been determined only for a limited number of compounds 
and these data are rarely determined by the same protocol. Thus data selection has 
been primarily based on such considerations as the comparison of the data of the 
compounds commonly studied by different protocols, and the incorporation of 
additional experimental information. 
 In this work, several methods are adopted to ensure that interlaboratory 
variations in experimental protocols do not significantly affect the quality of the 
training sets. The sources for the ADMET data for each compound were investigated 
to ensure that there were no wide variations in experimental protocol from those of 
the majority of the compounds in the training set. Compounds that were investigated 
in more than one source are used to estimate the quality of each source. It is assumed 
that sources which give ADMET data that are closer to the median of the values from 
the different sources are more accurate. In classification problems, the most common 
range of the ADMET data for the compounds investigated in more than one source 
was used to select compounds for the different classes (Susnow et al. 2003). 
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2.2.2 Statistical molecular design 
2.2.2.1 Introduction 
 The use of an external independent validation set, which has been collected 
independently of the training set, is widely regarded as the best way to assess the 
quality of a QSPkR/qSPkR model (Wold et al. 1995) (details on model validation will 
be described in section 2.5). However, it is usually difficult to find additional sources 
of ADMET data to construct an independent validation set and thus the typical 
method is to split the original dataset into two different sets, a training set for 
developing the QSPkR/qSPkR model and a validation set for evaluating the model 
performance (Gramatica et al. 2004). The training set should contain compounds of 
diverse structures that can adequately represent all of the compounds that possess a 
particular ADMET property  (Rajer-Kanduc et al. 2003; Schultz et al. 2003). The 
validation set also needs to be sufficiently diverse and representative of the 
compounds studied in order to accurately assess the accuracies of the QSPkR/qSPkR 
models (Rajer-Kanduc et al. 2003; Schultz et al. 2003).  
 There are a number of approaches for creating diverse training sets and 
representative validation sets from the datasets, which are given in Table 2.1. These 
include random selection, cluster-based methods, dissimilarity-based methods, cell-
based methods, stochastic techniques, statistical experimental designs and neural 
networks (Daszykowski et al. 2002; Leach et al. 2003). Studies have shown that 
dissimilarity-based methods, such as Kennard and Stone algorithm and removal-until-
done algorithm, are more effective than other algorithms in selecting diverse training 
sets and representative validation sets for developing and validating QSPkR/qSPkR 
models (Snarey et al. 1997; Rajer-Kanduc et al. 2003). Thus these two methods are 
used in this work to select training and validation sets.  
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Table 2.1 Methods for selecting training and validation sets 
Cluster-based methods 
Hierarchical Non-hierarchical 
Single linkage (Leach et al. 2003) 
Complete linkage (Leach et al. 2003) 
Group average (Leach et al. 2003) 
Wards method (Leach et al. 2003) 
Centroid method (Leach et al. 2003) 
Median method (Leach et al. 2003) 
K-means (Forgy 1965) 
Jarvis-Patrick clustering (Jarvis et al. 1973) 
DBSCAN (Ester et al. 1996) 
OPTICS (Ankrest et al. 1999) 
DENCLUE (Han et al. 2001) 
Dissimilarity-based methods 
MaxSum (Snarey et al. 1997)  
Kennard and Stone algorithm (Kennard et al. 
1969) 
Removal-until-done  (Hobohm et al. 1992) 
Sphere exclusion (Hudson et al. 1996) 
OptiSim (Clark 1997) 
IcePick (Mount et al. 1999) 
Minimum spanning tree error 
function (Waldman et al. 2000) 
Cell-based methods 
Cummins algorithm (Cummins et al. 1996) 
Menard algorithm (Menard et al. 1998) 
Uniform cell coverage (Lam et al. 2002) 
Stochastic techniques 
Techniques using Monte Carlo sampling (Agrafiotis 1996; Hassan et al. 1996) 
Techniques using genetic algorithms (Sheridan et al. 2000; Gillet et al. 2002) 
Statistical experimental designs 
D-optimal design (Mitchell 1974) 
Factorial design (Box et al. 1978) 
Others 
Random selection 
Kohonen’s self-organizing map 
Informative design (Miller et al. 2002) 
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2.2.2.2 Kennard and Stone algorithm 
 Two compounds with the largest Euclidean distance apart were initially 
selected for the training set. The remaining compounds for the training set were 
selected by maximizing the minimum distances between the compounds in the 
training set and the rest of the compounds in the dataset. This selection process 
continues until the desired number of compounds was selected for the training set. 
The remaining compounds in the dataset will be used as the validation set (Kennard et 
al. 1969). 
 
2.2.2.3 Removal-until-done algorithm 
 Compounds are sequentially removed from the dataset in pairs and placed in 
the training and validation sets until a defined similarity threshold or desired number 
of compounds was selected for the validation set. The selection of the compounds to 
be removed was based on their distribution in the chemical space. Here, chemical 
space is defined by the structural and chemical descriptors used to represent a 
compound and each descriptor value is a point in a multidimensional space. Each 
compound occupies a particular location in this chemical space. All possible pairs of 
the compounds in the dataset were generated and a similarity score was computed for 
each pair. These pairs were then ranked in terms of their similarity scores, based on 
which compounds of similar structural and chemical features were evenly assigned 
into the training and validation sets. For those compounds without enough structurally 
and chemically similar counterparts, they were assigned to the training set. 
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2.2.3 Diversity and representativity of datasets 
 The diversity of a dataset can be estimated by a diversity index (DI) which is 
the average value of the similarity between all of the pairs of compounds in that 
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      (2.1) 
where sim(i,j) is a measure of the similarity between compound i and j, and n is the 
number of compounds in a dataset. The diversity of a dataset increases with 
decreasing DI. The similarity between two compound i and j is commonly described 
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    (2.2)  
where p is the number of descriptors of the compounds in the dataset. The mean 
maximum Tanimoto coefficient of the compounds in dataset A and those in dataset B 
can be used as a representativity index (RI) to measure the extent to which dataset B 
is representative of dataset A. Dataset B is more representative of dataset A if the RI 
value between dataset A and B is higher. 
 
2.3 Molecular descriptors 
2.3.1 Types 
 A descriptor is “the final result of a logical and mathematical procedure which 
transforms chemical information encoded within a symbolic representation of a 
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compound into an useful number or the result of some standardized 
experiment” (Todeschini et al. 2000). There are currently over 3,700 types of 
descriptors, which are classified into three broad categories: 1-, 2- and 3-D descriptors 
that encode chemical composition, topology, and 3D shape and functionality 
respectively  (Todeschini et al. 2000; Farnum et al. 2003). A descriptor can be simple, 
like molecular volume, which encode only one feature of a compound, or can be 
complex, like 3D-MoRSE, which encode multiple physicochemical and structural 
properties of a compound. Several computer programs have been developed for 
deriving molecular descriptors of a compound. Examples of the most popularly used 
and internet accessible programs are DRAGON (Todeschini et al. 2005), Molconn-
Z (Hall et al.), JOELib (Wegner 2005), and MODEL (Li et al. 2005b). Table 2.2 
below lists some of the common types of descriptors used in QSPkR/qSPkR studies.  
 
Table 2.2 Common descriptors used in QSPkR/qSPkR studies 
Constitutional Hydrophobic 
Functional groups 
Molecular weight  
Simple counts e.g. number of atoms, bonds, rings 
Topological 
Aromaticity indices (Randic 1975) 




Charton steric parameter (Charton 1975) 
Molar refractivity (Pauling et al. 1945) 
Parachor (McGowan 1963) 
Taft steric parameter (Taft 1952) 
Quantum chemical (Karelson et al. 1996) 
Atom-pairs (Carhart et al. 1985) 
Balaban index (Balaban 1986)  
BCUT (Pearlman et al. 1999) 
Information content indices (Basak et al. 1983) 
Kappa shape indices (Kier 1997) 
Kier and Hall connectivity indices (Kier et al. 
1986) 
Kier flexibility index (Kier 1990) 
Kier shape indices (Kier 1990) 
Charges 
HOMO and LUMO energies 
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Molecular walk counts (Rücker et al. 1993) 
Randic indices (Randic 1991) 
Wiener index (Nikolic et al. 1995) 
Geometric 




Dipole moments and polarity indices 
Energies 
Combination 
Gravitation index (Katritzky et al. 1996) 
Molecular surface area 
Molecular volume (Higo et al. 1989) 
Shadow indices (Rohrbaugh et al. 1987) 
Solvent accessible molecular surface area 
Electrostatic 
Charged polar surface area (Stanton et al. 1990) 
Galvez topological charge indices (Galvez et al. 
1994) 
Hydrogen bonding capacities 
Maximum and minimum partial 
charges (Kirpichenok et al. 1987) 
Molecular polarizabilities (Dewar et al. 1984) 
Fingerprints 
Daylight (Craig et al. 2005) 
MDL keys (Durant et al. 2002) 
UNITY (Patterson et al. 1996) 
3D-MoRSE (Schuur et al. 1996) 
Electrotopological state indices (Kier et al. 
1999) 
GETAWAY (Consonni et al. 2002) 
LSER  (Platts et al. 1999) 
MolSurf (Sjoberg 1997) 
Moreau-Broto topological 
autocorrelation (Moreau et al. 1980) 
Randic molecular profiles (Randic 1995) 
RDF (Hemmer et al. 1999) 
VolSurf (Cruciani et al. 2000b) 
WHIM (Bravi et al. 1997) 
 
 In this work, descriptors were computed from the 3D structure of the 
compounds. The 2D structure of each of the compounds studied was generated by 
using DS ViewerPro 5.0 (Accelrys 2005), which was subsequently converted into 3D 
structure by using CONCORD (Pearlman). The 3D structure of each compound was 
manually inspected to ensure that the chirality of each chiral compound is properly 
represented after the CONCORD’s transformation. All salts and elements, such as 
sodium or calcium, were removed prior to descriptor calculation. 
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2.3.2 Scaling 
 Molecular descriptors are usually scaled before they are used for 
QSPkR/qSPkR modeling. This is to ensure that all descriptors have equal potential to 
affect the QSPkR/qSPkR model (Livingstone 1995b). There are four main types of 
descriptor scaling: autoscaling (Livingstone 1995a), range scaling (Livingstone 
1995a), feature weighting (Livingstone 1995a) and Pareto scaling (Eriksson et al. 
2001a). Autoscaling and range scaling are the two most common types of descriptor 
scaling methods used in QSPkR/qSPkR modeling. 
 
2.3.2.1 Autoscaling 
 In autoscaling, the mean is subtracted from the descriptor values and the 
resultant values are divided by the standard deviation: 




−=        (2.3) 
where  is the new scaled value for descriptor j of compound i and 'ijX jX  and jσ  are 
the mean and standard deviation of descriptor j respectively. The autoscaled 
descriptors have a mean of zero and a standard deviation of one. The advantage of 
autoscaling is that it is less susceptible to effects of compounds with extreme values 
because they are mean centred. In addition, variance of one is useful in variance-
related methods since they each contribute one unit of variance to the overall variance 
of a dataset. 
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2.3.2.2 Range scaling (Normalization) 
 In range scaling, the minimum value of the descriptor is subtracted from the 









−= − −       (2.4) 
where Xj,min and Xj,max are the minimum and maximum value of descriptor j 
respectively. The range-scaled descriptors have a minimum and maximum value of -1 
and 1 respectively. Range scaling can be carried out over any preferred range by 
multiplication of the range-scaled values by a factor. The disadvantage of range 
scaling is that it is dependent on the minimum and maximum values of the descriptors, 
which makes it very sensitive to outliers. 
 
2.3.3 Selection 
 The purpose of descriptor selection is to remove descriptors irrelevant or 
negligible to an ADMET property of the compounds, so as to improve computation 
speed, performance and interpretability of predictive models. Irrelevant and redundant 
descriptors are removed either by using a filter or a wrapper approach or a 
combination of these approaches. The filter approach is independent of the in silico 
method and is frequently used to remove redundant descriptors or descriptors of low 
information content. Descriptors are chosen or removed based on one or more of the 
following considerations: prior knowledge of factors affecting a particular ADMET 
property, the properties of the descriptors (e.g. variance), the correlation between 
different descriptors, and the distribution of the descriptor values in different data 
classes. In the wrapper approach, a descriptor selection algorithm is incorporated into 
an in silico classification method (Guyon et al. 2003).  
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 In many cases, it is difficult to uniquely select an optimum set of descriptors 
due to the high redundancy and overlapping of many descriptors (Gramatica et al. 
2004). Separate sets of descriptors containing different members of redundant 
descriptor classes have been found to give similar prediction accuracies (Izrailev et al. 
2004). The interpretation of the prediction results in these cases should be more 
appropriately conducted at the descriptor class level where redundant and overlapping 
descriptors are grouped into one class. Table 2.3 gives a list of the common descriptor 
selection methods used in QSPkR/qSPkR studies.  
 
Table 2.3 Common descriptor selection methods used in QSPkR studies 
Filter methods Wrapper methods 
Remove descriptors with low variance 
Remove highly correlated descriptors 
CORCHOP (Livingstone et al. 1989) 
Decision tree (Cardie 1993) 
FOCUS (Almuallim et al. 1994) 
LVF (Brassard et al. 1996) 
RELIEF (Kononenko 1994) 
Discrimination scores (Guyon et al. 2002) 
Information gain (Liu 2004) 
Mutual information (Liu 2004) 
χ2-test (Liu 2004) 
Odds ratio (Liu 2004) 
GSS coefficient (Liu 2004) 
Forward selection (Xu et al. 2001) 
Backward elimination (Xu et al. 2001) 
Stepwise regression (Xu et al. 2001) 
Branch and bound (Narendra et al. 1977) 
Floating search (Pudil et al. 1994) 
Adaptive floating search (Somol et al. 1999) 
Oscillating search (Somol et al. 2000) 
Tabu search (Glover 1989) 
Simulated annealing (Sutter et al. 1993) 
Genetic algorithm (Siedlecki et al. 1989) 
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2.3.3.2 Genetic algorithm-based descriptor selection 
 The scheme for the genetic algorithm-based descriptor selection method used 
in this work is shown in Figure 2.2. It comprises of four phases: initialization, 
evaluation, exploitation and exploration. The initialization phase involves 
constructing an initial population of 50 randomly selected descriptor subsets. During 
the evaluation phase, each descriptor subset is evaluated by calculating its fitness 
score, which indicates the relevance of a descriptor subset to the ADMET property. In 
the exploitation phase, the descriptor subsets were first ranked by their fitness value. 
The higher ranked descriptor subsets were given a higher probability of being chosen 
for reproduction. The top 40 selected descriptor subsets were then used to replace the 
40 lowest ranking descriptor subsets in the population. These 40 new descriptor 
subsets, together with the 10 highest ranked descriptor subsets in the current 
generation, form a new generation of descriptor subsets. In the last phase, which is the 
exploration phase, the 40 new descriptor subsets were subjected to one point 
crossover and mutation to increase the diversity of the population. In the mutation 
process, descriptors might be randomly added to or deleted from a descriptor subset. 
After the exploration phase, the genetic algorithm returns to the evaluation phase and 
the cycle repeats until at least 100 generations have passed and the highest ranked 
descriptor subset remains the same for 20 generations. The highest ranked descriptor 
subset was used to construct the final QSPkR/qSPkR model.  
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2.3.3.3 Recursive feature elimination (RFE) 
 It has been suggested that the ranking criterion for descriptor selection can be 
formulated from the variation in an objective function upon removing each 
descriptor (Kohavi et al. 1997). In order to improve the efficiency of support vector 
machine (SVM) training, this objective function is represented by a cost function J for 
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the i-th descriptor and it is computed by using the training set only. When the i-th 
descriptor is removed or its weight wi is reduced to zero, the variation of the cost 










∂=       (2.5) 
The case of Dwi = wi - 0 corresponds to the removal of descriptor i.  
 Guyon et al have used RFE to reduce the descriptors of a linear SVM 
classification system for cancer detection from gene selection data (Guyon et al. 
2002). In the corresponding linear SVM classifier, the cost function is  
 21
2
TJ = −w α l        (2.6) 
where l is an m dimensional identity vector (m is the number of compounds in the 
training set). Therefore DJ(i) = (1/2) wi2 and wi2 can be used as a descriptor ranking 
criterion. Yu et al have used RFE to reduce the descriptors of a non-linear SVM 
classification system of polynomial kernels for prediction of drug activity (Yu et al. 
2003). However, because of the diversity and complexity of the compounds to be 
classed, the use of linear and polynomial kernels may not always be sufficient for 
accurate prediction of various pharmaceutical and biological properties. Thus, in this 
work, SVM classification systems of Gaussian kernels were used. In this case, the 





J = −α Hα α 1T        (2.7) 
where H is the matrix with elements y i y j exp(-||xi - xj|| 2/(2σ2)). 
 To compute the variation in the cost function upon removal of input 
component i, the parameters αs were kept unchanged and the matrix H was re-
computed. The resulting ranking coefficient is 
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 T T1 1( ) ( )
2 2
DJ i i= − −α Hα α H α      (2.8) 
where H(-i) is the matrix computed by using the same method as that of matrix H but 
with its i-th component removed. One or more of the descriptors with the smallest 
DJ(i) can thus be eliminated.  
 
2.4 Machine learning methods 
2.4.1 Methods for classification problems 
2.4.1.1 Support vector machine (SVM) 
 SVM is based on the structural risk minimization principle from statistical 
learning theory (Vapnik 1995; Burges 1998; Evgeniou et al. 2001). A compound is 
represented by a vector xi which is its molecular descriptors. In linearly separable 
cases, SVM constructs a hyperplane which separates two data classes of compounds 
with a maximum margin. This is accomplished by finding another vector w and a 
parameter b that minimizes 2w  and satisfies the following conditions: 
  Class 1 (D+)    (2.9) 1,  for 1i b y⋅ + ≥ + = +w x  i
 i  Class 2 (D–)    (2.10) 1,  for 1i b y⋅ + ≤ − = −w x
where yi is the data class index of compound i, w is a vector normal to the hyperplane, 
/b w  is the perpendicular distance from the hyperplane to the origin and 2w  is the 
Euclidean norm of w. After the determination of w and b, a given compound with 
vector x can be classified by: 
        (2.11) ˆ [( ) ]y sign b= ⋅w x +
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 In non-linearly separable cases, SVM maps the vectors into a higher 
dimensional feature space using a kernel function K(xi, xj). Table 2.4 below lists three 
different types of kernel functions which are commonly used. The Gaussian radial 
basis function kernel has been extensively used in a number of different studies with 
good results (Burbidge et al. 2001; Czerminski et al. 2001; Trotter et al. 2001). 
 
Table 2.4 Commonly used kernel functions 
Kernel Equation 
Polynomial ( )( , ) 1 pi j i jK = ⋅ +x x x x  
Gaussian radial basis function 2 2/ 2( , ) j ii jK e
σ− −= x xx x  
Sigmoidal ( )( , ) tanhi j i jK κ δ= ⋅ −x x x x  
 
Linear support vector machine is applied to this feature space and then the decision 
function is given by:  
      (2.12) 0
1




y sign y K bα
=
= ∑ x x )+
where l is the number of support vectors and the coefficients αi0 and b are determined 
by maximizing the following Langrangian expression:  
 
1 1 1
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2
l l l
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i i j
y y Kα α α
= = =
−∑ ∑∑ x xi j      (2.13) 
under the following conditions:  








=∑         (2.15) 
where C is a penalty for training errors. A positive or negative value from equation 
(2.12) indicates that the compound with vector x belongs to the positive (D+) or 
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negative data class (D–) respectively. Figure 2.3 below shows a schematic diagram 
illustrating the process of the prediction of compounds with a particular ADMET 
property from its structure by using SVM. 
 
Figure 2.3 Schematic diagram illustrating the process of the prediction of compounds 
with a particular ADMET property from its structure by using SVM method. A,B: 
feature vectors of compounds with the property; E,F: feature vectors of compounds 
without the property; feature vector (hj, pj, vj,…) represents such structural and 
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2.4.1.2 Probabilistic neural network (PNN) 
 PNN was introduced by Specht in 1990 (Specht 1990) and is a form of neural 
network designed for classification through the use of Bayes’ optimal decision rule: 
        (2.16) ( ) ( )i i i j j jh c f h c f>x x
where hi and hj are the prior probabilities, ci and cj are the costs of misclassification 
and fi(x) and fj(x) are the probability density function for data class i and j respectively. 
A given compound with vector x is classified into data class i if the product of all the 
three terms is greater for data class i than for any other data class j not equal to i. In 
most applications, the prior probabilities and costs of misclassifications are treated as 
being equal. The probability density function for each data class for a univariate case 
can be estimated by the Parzen’s nonparametric estimator (Parzen 1962): 
 
1




x xg x W
nσ σ=
−= ∑       (2.17) 
where n is the sample size, σ is a scaling parameter which defines the width of the 
bell curve that surrounds each compound, W(d) is a weight function which has its 
largest value at d = 0 and (x – xi) is the distance between a given compound and a 
compound in the training set. The Parzen’s nonparametric estimator was later 
expanded by Cacoullos (Cacoullos 1966) for the multivariate case. 
 ,1 1,1
11 1






g x x W
nσ σ σ σ=
−−= ∑… … …   (2.18) 
The Gaussian function is frequently used as the weight function because it is well 
behaved, easily calculated and satisfies the conditions required by Parzen’s estimator. 












⎛ ⎞−= − ⎜⎜⎝ ⎠∑ ∑x ⎟⎟      (2.19) 
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To simplify the equation, a single σ that is common to all the descriptors (single-
sigma model) can be used instead of an individual σ for each descriptor (multi-sigma 
model). Single-sigma models could be computed faster and can produce reasonable 
models when all the descriptors are of approximately equal importance. However, 
multi-sigma models are more general than single-sigma model and are useful when 
descriptors are of different nature and importance (Masters 1995). 
 PNN can be implemented as a neural network (Masters 1995), which is shown 
in Figure 2.4. The network architecture of a PNN is determined by the number of 
compounds and descriptors in the training set. There are 4 layers in a PNN. The input 
layer provides input values to all neurons in the pattern layer and has as many neurons 
as the number of descriptors in the training set. The number of pattern neurons is 
determined by the total number of compounds in the training set. Each pattern neuron 
computes a distance measure between the input compound and the training compound 
represented by that neuron and then subjects the distance measure to the Parzen’s 
nonparameteric estimator. The summation layer has a neuron for each data class and 
the neurons sum all the pattern neurons’ output corresponding to members of that 
summation neuron’s data class to obtain the estimated probability density function for 
that data class. The single neuron in the output layer then determines the final data 
class of the input compound by comparing all the probability density functions from 
the summation neurons and choosing the data class with the highest value for the 
probability density function. 
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2.4.1.3 k nearest neighbour (kNN) 
kNN is a basic instance-based method and was introduced by Fix and 
Hodges (Fix et al. 1951). kNN measures the Euclidean distance between a given 
compound with vector x and each compound in the training set with individual vector 
xi  (Fix et al. 1951; Johnson et al. 1982). The Euclidean distances for the vector pairs 
are calculated using the following formula: 
 2iD = −x x        (2.20) 
A total of k number of training compounds nearest to the given compound is used to 
determine its data class: 
1






= ∑ v y       (2.21) 
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where δ(a,b)=1 if a=b and δ(a,b)=0 if a≠b, argmax is the maximum of the function, V 
is a finite set of data classes. k is usually an odd number to prevent ambiguity in the 
estimation of . yˆ
2.4.1.4 C4.5 decision tree (DT) 
 C4.5 DT is a branch-test-based classifier (Quinlan 1993). A branch in a 
decision tree corresponds to a group of data classes and a leaf represents a specific 
data class. A decision node specifies a test to be conducted on a single descriptor 
value, with one branch and its subsequent data classes as possible outcomes of the test. 
A given compound with vector x is classified by starting at the root of the tree and 
moving through the tree until a leaf is encountered. At each non-leaf decision node, a 
test is conducted and the classification process proceeds to the branch selected by the 
test. Upon reaching the destination leaf, the data class of the given compound is 
predicted to be that associated with the leaf.  
 The algorithm is a recursive greedy heuristic that selects descriptors for 
membership within the tree. It uses recursive partitioning to examine every descriptor 
of the compounds in the training set and rank them according to their ability to 
partition the remaining compounds, thereby constructing a decision tree. Whether or 
not a descriptor is included within the tree is based on the value of its information 
gain. As a statistical property, information gain measures how well the descriptor 
separate training cases into subsets in which the data class is homogeneous. For 
descriptors with continuous values, a threshold value had to be established within 
each descriptor so that it could partition the training cases into subsets. These 
threshold values for each descriptor were established by rank ordering the values 
within each descriptor from lowest to highest and repeatedly calculating the 
information gain using the arithmetical midpoint between all successive values within 
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the rank order. The midpoint value with the highest information gain was selected as 
the threshold value for the descriptor. That descriptor with the highest information 
gain (information being the most useful for classification) was then selected for 
inclusion in the DT. The algorithm continued to build the tree in this manner until it 
accounted for all training cases. Ties between descriptors that were equal in terms of 
information gain were broken randomly  (Carnahan et al. 2003). 
 
2.4.2 Methods for regression problems 
2.4.2.1 Support vector regression (SVR) 
 The theoretical background of SVR is similar to that of SVM (Smola et al.; 
Vapnik 1995; Yuan et al. 2004). In SVR, the kernel function is used to map the 
vectors into a higher dimensional feature space and linear regression is then 
conducted in this space. The optimal regression function can be represented by: 
       (2.22) *
1
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where ŷ represents the predicted value of an ADMET property, and the coefficients α, 
α* and bias b are determined by maximizing the following Langrangian expression:  
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under the following conditions:  
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2.4.2.2 General regression neural network (GRNN) 
 GRNN is a modification of PNN for regression problems (Specht 1991). For 
GRNN, the predicted value of the ADMET property is the most probable value, 















       (2.26) 
where f(x,y) is the joint density and can be estimated by using Parzen’s nonparametric 
estimator (equation (2.17) or (2.18)). Substituting Parzen’s nonparametric estimator 
for f(x,y) and performing the integrations leads to the fundamental equation of GRNN. 
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⎛ ⎞−= ⎜⎜⎝ ⎠∑x x ⎟⎟       (2.28) 
 The network architecture of a GRNN is similar to that of a PNN except that its 
summation layer has two neurons that calculate the numerator and denominator of 
equation (2.27). The single neuron in the output layer then performs a division of the 
two summation neurons to obtain the predicted ADMET value of the given compound. 
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2.4.2.3 k nearest neighbour (kNN) 
 kNN can be modified for regression problems by replacing equation (2.21) 










        (2.29) 
The predicted ADMET value of the given compound is the average of the ADMET 
values of its k nearest neighbours. Unlike kNN that is used for classification problems, 
k need not be an odd number in this case.  
2.4.3 Optimization of the parameters of machine learning methods 
 Different machine learning methods have different types of parameters that 
must be optimized. In this work, SVM and SVR are trained by using a Gaussian 
kernel function which has an adjustable parameter σ. For PNN and GRNN, the only 
parameter to be optimized is a scaling parameter, σ. In kNN, the optimum number of 
nearest neighbours, k, needs to be derived for each training set.  
 Optimization of the parameter for each of these statistical learning methods is 
conducted by scanning the parameter through a range of values. The set of parameters 
that produces the best QSPkR/qSPkR model, which is determined by using cross-
validation methods, such as 5-fold cross-validation, 10-fold cross-validation or a 
modeling testing set, is used to construct a final QSPkR/qSPkR model which is then 
further validated to ensure that it is valid and useful for the ADMET property (see 
section 2.5).   
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2.5 Model validation 
2.5.1 Performance evaluation of a QSPkR/qSPkR model 
 One of the objectives of QSPkR/qSPkR modeling is to allow prediction of the 
ADMET properties of compounds which have not been biologically tested. Thus it is 
important to determine the ability of the developed QSPkR/qSPkR model to predict 
the ADMET properties of compounds that are not present in the training set. There 
are two methods which are commonly used to determine the predictive capability of a 
QSPkR/qSPkR model (Wold et al. 1995). The first method is the use of cross-
validation, which includes leave-one-out (LOO) and k-fold cross-validation. In LOO, 
a compound is left out of the training set and the remaining compounds are used to 
train the machine learning method. The derived QSPkR/qSPkR model is then used to 
predict the ADMET property of the left-out compound. This process is repeated until 
every compound in the training set has been left out once. In k-fold cross-validation, 
the training set was randomly divided into k mutually exclusive subsets of 
approximately equal size. k-minus-one of the subsets were combined to form a 
modeling training set for developing a QSPkR/qSPkR model. The remaining subset 
was used as a modeling testing set to assess the predictive capability of the 
QSPkR/qSPkR model. This process was repeated until k QSPkR/qSPkR models were 
developed and each subset had been used as a modeling testing set once. 
 There are reports of the lack of correlation between cross-validation methods 
and the prediction capability of a QSPkR/qSPkR model (Golbraikh et al. 2002; Kozak 
et al. 2003; Reunanen 2003; Olsson et al. 2004). Moreover, cross-validation methods 
have a tendency of underestimating the prediction capability of a QSPkR/qSPkR 
model, especially if important molecular features are present in only a minority of the 
compounds in the training set (Mosier et al. 2002; Hawkins et al. 2004). Thus a model 
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having low cross-validation results can still be quite predictive (Mosier et al. 2002). 
This lead to some studies which suggests that an independent validation set may 
provide a more reliable estimate of the prediction capability of a QSPkR/qSPkR 
model (Wold et al. 1995; Golbraikh et al. 2002). Despite these disadvantages, cross-
validation methods are still useful for assessing QSPkR/qSPkR models during 
optimization of parameters of machine learning methods and during descriptor 
selection. 
 A validation set should ideally be obtained independently of the training set. 
However, validation sets are usually constructed by using statistical molecular design 
(section 2.2.2) because of the limited availability of high-quality ADMET data. 
Regardless of the method used to obtain a validation set, a good validation set should 
be representative of the training set so that it can properly assess the prediction 
capabilities of the QSPkR/qSPkR model (Tropsha et al. 2003). 
 
2.5.1.1 Methods for measuring predictive capability of qSPkR models 
 The following statistics are usually calculated to determine the predictive 
capability of a qSPkR model.  
 TPSensitivity (SE) = 100%
TP+FN
×      (2.30) 
 TNSpecificity (SP) = 100%
TN+FP
×      (2.31) 
 TP+TNOverall accuracy (Q) = 100%
TP+FN+TN+FP
×    (2.32) 
 
( )( )( )( )
TP TN FN FPMCC
TP FN TP FP TN FN TN FP
× − ×= + + + +   (2.33) 
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where MCC is the Matthews correlation coefficient (Matthews 1975), TP is number 
of the true positives, TN is the number of true negatives, FP is number of the false 
positives and FN is the number of false negatives. Sensitivity (SE) and specificity (SP) 
are the classification accuracies of a qSPkR model for the positive and negative data 
classes respectively. Overall accuracy (Q) is the classification accuracy of the qSPkR 
model for both positive and negative data classes. The shortcoming of the overall 
accuracy is that an imbalance in the data classes may result in a high overall accuracy 
even if either sensitivity or specificity is low. For example, a qSPkR model which has 
a sensitivity of 100% and specificity of 0% will have an overall accuracy of 90% for a 
validation set that have 9 times more compounds of the positive data class than 
compounds of the negative data class. Thus MCC, which is a weighted measure, is 
increasingly being used to measure the predictive capability of qSPkR models. A 
MCC value of 1 indicates that the qSPkR model can predict the data classes of 
unknown compounds perfectly, a MCC value of 0 is expected for a qSPkR model that 
is not better than random guessing, and a MCC value of -1 indicates total 
disagreement between the predicted data classes and the actual data classes. For the 
above example, MCC will give a value of 0, which is a more accurate representation 
of the predictive capability of the model. 
 
2.5.1.2 Methods for measuring predictive capability of QSPkR models 
 The following statistics are commonly calculated to determine the predictive 
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The r2 value measures the explained variance between the predicted and actual 
ADMET values. The fold-error of a compound measures the degree of overprediction 
or underprediction for a compound and is useful for identifying chemical structures 
which are not well-represented by the QSPkR model. The average-fold error avoids 
the cases in which poor overpredictions are cancelled by equally poor 
underpredictions. A QSPkR model that predicts a ADMET property perfectly gives an 
average-fold error of 1 and a model with an average-fold error of less than 2 is 
considered to be a successful one (Obach et al. 1997). 
 
2.5.2 Overfitting 
 It is not sufficient for a QSPkR/qSPkR model to have good predictive 
capability. A second requirement for a good quality QSPkR/qSPkR model is that it 
must not suffer from overfitting. There are two main types of overfitting: (1) using a 
model that is more flexible than it needs to be and (2) using a model that includes 
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irrelevant descriptors (Hawkins 2004). There are various methods that can be used to 
prevent or to check for these two types of overfitting. 
 A number of different QSPkR/qSPkR models can be developed using machine 
learning methods of varying complexities. The QSPkR/qSPkR model with the best 
balance between complexity of the machine learning method used and its predictive 
capability is the one that is most suitable for predicting the ADMET property of 
interest. This method prevents the use of a QSPkR/qSPkR model that is more flexible 
than is necessary.  
 A frequently used method for checking whether a QSPkR/qSPkR model is 
overfitted is to compare its prediction capability determined by using cross-validation 
methods with those determined by using independent validation sets (Hawkins 2004). 
Even though cross-validation methods tend to give a pessimistic estimate of the 
predictive capability of a QSPkR/qSPkR model, a model that is not overfitted should 
not have large differences in the estimates of its predictive capability from cross-
validation methods and independent validation sets.  
 Y-randomization is commonly used to determine the probability of chance 
correlation during descriptor selection (Manly 1997; Leardia et al. 1998). In 
classification problems, a portion of D+ compounds in the training set is randomly 
exchanged with D– compounds in the training set, creating new training sets with 
false D+ and D– compounds. For regression problems, the ADMET properties of all 
the compounds in the training set are randomly rearranged. The machine learning 
method is trained using this scrambled training set. The randomization is repeated a 
number of times and prediction capabilities of the new scrambled QSPkR/qSPkR 
model from each run are compared to that of the original QSPkR/qSPkR model. If the 
scrambled training set gives significantly lower prediction capabilities than the 
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original training set, it can be concluded that the original QSPkR/qSPkR model was 
relevant and unlikely to arise as a result of chance correlation. 
 In order to determine whether the selected descriptors of the original 
QSPkR/qSPkR model include those irrelevant for the prediction of an ADMET 
property, different groups of QSPkR/qSPkR models, each containing different 
number of descriptors, can be generated by using the descriptor selection method. 
Each group contains a fixed number of QSPkR/qSPkR models having the same 
number of descriptors. The prediction capabilities of the QSPkR/qSPkR models in 
each group are determined and the average prediction capabilities of all the groups are 
compared and used to determine the optimal number of descriptors for the particular 
ADMET property. If the optimal number of descriptors coincide with the number of 
descriptors in the original QSPkR/qSPkR model, the original model is unlikely to 
contain irrelevant descriptors.  
 
2.5.3 Functional dependence study of QSPkR models 
 A functional dependence study can provide insights on the type of molecular 
characteristics that are important for a particular ADMET property and how changes 
in these molecular characteristics affect the ADMET property. This information is 
useful for guiding structural changes during computer-aided drug design so that the 
desired ADMET property can be obtained. It is also useful for validating a QSPkR 
model. A valid QSPkR model should be consistent with previous findings of 
important factors that affect the ADMET property. 
 For QSPkR models developed from linear modeling methods, the descriptors 
are either positively or negatively correlated to ADMET properties in a linear 
relationship. In contrast, descriptors in models developed by using machine learning 
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methods correlate to ADMET properties in a non-linear relationship. Thus these 
models can potentially provide more information about the relationships between 
descriptors and ADMET properties.  
 The relationships between descriptors and ADMET properties can be obtained 
by using functional dependence plots where the value of a single descriptor is varied 
through its range, while all other descriptors are held constant at a certain 
value (Wessel et al. 1998). However, QSPkR models usually contain descriptors that 
are correlated with one another and these intercorrelations can drastically alter the 
shape of a functional dependence plot if the values of the descriptors that are held 
constant are changed (Andrea et al. 1991). In addition, descriptors may encode 
multiple physicochemical and structural aspects of the molecule. This makes it 
difficult to determine the relationship between a specific molecular characteristic and 
an ADMET property.  
 In this work, principal component analysis (PCA) is used to overcome both 
problems. PCA can extract dominant patterns in the descriptor subsets and group 
similar descriptors under a single principal component (PC). Different PCs encode 
different molecular characteristics and the orthogonality among the PCs can be 
exploited to determine the correlation between a molecular characteristic and an 
ADMET property without the influence of other molecular characteristics. A 
descriptor may belong to multiple PCs and the explained variations of a descriptor in 
each PC can be used to determine its level of contribution in the PCs (Eriksson et al. 
2001b). Artificial testing sets are created to determine the relationship between the 
PCs and ADMET property. Each artificial testing set contains 1000 artificial 
compounds and initially used PCs as descriptors. The PC to be evaluated is varied 
uniformly from -5 to 5 while all of the other PCs are assigned a value of zero. The 
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loadings derived from PCA are then used to transform the PCs back to the original 
molecular descriptors. Artificial compounds with molecular descriptors outside the 
range of the corresponding descriptor in the training set are removed to prevent 
extrapolation of the model. The values of the ADMET property of the remaining 
artificial compounds are predicted by using the developed QSPkR models. Functional 
dependence plots of the ADMET property against the PCs can then be used to find the 
trends between various molecular characteristics and the ADMET property. In this 
work, PCA and the transformation of the PCs back to the original molecular 
descriptors were carried out using the software PHAKISO. 
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Chapter 3 
Machine Learning Library 
 
 A new machine learning library, YMLL (section 3.2), and a Microsoft 
Windows software, PHAKISO (section 3.3), is introduced in this chapter. YMLL 
contains algorithms that are essential for performing a QSPkR/qSPkR experiment. 
PHAKISO provides a graphical user interface to the algorithms in YMLL so that a 
QSPkR/qSPkR model can be developed and validated easily with just a few mouse 
clicks. Both YMLL and PHAKISO are available freely on the PHAKISO website 
(http://www.phakiso.com) for non-commercial uses. 
 
3.1 Introduction 
 One of the fundamental requirements for the conduct of an in silico 
QSPkR/qSPkR experiment is the availability of appropriate software. A good 
software for QSPkR/qSPkR experiments should possess the following features: 
1. Ease of data entry. 
2. Containing several common statistical molecular design algorithms so that 
appropriate training and testing sets can be obtained from the original 
datasets. 
3. Containing several common machine learning methods so that the best 
machine learning method for developing QSPkR/qSPkR model of a 
particular ADMET property can be determined.  
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4. Containing several common descriptor selection methods so that a relevant 
descriptor subset for a particular ADMET property can be determined. 
5. Containing several common methods to validate QSPkR/qSPkR models to 
ensure that the models are valid and useful.  
 When this work was started, there is no freely available QSPkR/qSPkR 
software except a few machine learning freeware available. Two such machine 
learning software are Torch (Collobert et al. 2002) and Weka (Witten et al. 2005). 
Torch is a machine learning library, written in C++, which is under a Berkeley 
Software Distribution (BSD) licence. Its objective is to apply machine learning 
algorithms for both static and dynamic problems. There are four important concepts in 
Torch: DataSet, Machine, Trainer, Measurer. The DataSet produces one training 
example which is given to a Machine to compute an output by using the Measurer. 
The Trainer will use the output for tuning the Machine.  
 Weka is a collection of machine learning algorithms for data mining tasks 
written in Java. It contains tools for data pre-processing, classification, regression, 
clustering, association rules, and visualization. Weka is open source software issued 
under the GNU General Public License. Weka is organized in a hierarchy of packages. 
Each package contains a collection of related classes. There are packages for core 
components, associations, attribute selection, classifiers, clusterers, estimators, filters, 
experiments and graphical user interface. 
 Both Torch and Weka have several disadvantages which make them 
unsuitable for conducting QSPkR/qSPkR experiments. In Torch, there are no 
graphical user interface or pre-compiled programs, thus it is not easily usable without 
additional programming. In addition, Torch only contains a limited number of 
machines learning methods. Algorithms for statistical molecular design are not 
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available for both Torch and Weka. Both software also have a limited number of 
descriptor selection methods, especially wrapper methods, and have a limited number 
of methods to measure prediction capabilities of QSPkR/qSPkR models. Hence 
modifications to the two software are needed in order to use them for QSPkR/qSPkR 
experiments. However, there are two difficulties in modifying the two software. 
Firstly, the design and naming of Torch’s C++ classes are different from the usual 
QSPkR terminologies, which create a steep learning curve in using the library. 
Secondly, both software are continuously being improved by their original authors 
and thus any modifications may become obsolete and become unusable in the newer 
versions. Hence a new software specifically for conducting QSPkR/qSPkR 
experiments is needed. 
 In this work, a machine learning library, YMLL, and a Microsoft Windows 
software, PHAKISO, were designed and created from scratch to enable 
QSPkR/qSPkR experiments to be conducted easily. Both YMLL and PHAKISO were 
coded in C++. Most of the algorithms in YMLL were implemented based on 
algorithms that were provided in the literatures. The remaining algorithms were 
implemented by either translation of existing freely available source codes to C++ or 
creating C++ wrappers around the existing freely available source codes. Table 3.1 
lists the different types of machine learning algorithms that were implemented in 
YMLL, Torch and Weka 
 
 
CHAPTER 3: MACHINE LEARNING LIBRARY 61
Table 3.1 Types of machine learning algorithms in YMLL, Torch and Weka 
YMLL Torch Weka 
1. Multiple linear regression 
for classification problems 
2. Logistic regression 
3. Partial least squares for 
classification problems 
4. Linear discriminant analysis 
5. C4.5 decision tree 
6. C4.5 decision rules 
7. k nearest neighbour 
8. AnnieNN for classification 
problems 




network for classification 
problems 
11. Probabilistic neural 
network 






17. Multiple linear regression 
18. Principal component 
regression 
1. Bayes classifier 
2. MLP 
3. Speech MLP 
4. K-Means 
5. MAP Diagonal GMM 
6. MAP HMM 
7. Speech HMM 
8. Simple decoder speech 
HMM 
9. KNN 
10. Parzen machine 
11. SVM classification 
12. SVM regression 
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19. Partial least squares 
20. Continuum power 
regression 






25. General regression neural 
network 
26. Master’s general regression 
neural network 
27. SVMlight for regression 
problems 
28. LibSVM for regression 
problems 
















































 The source codes for both YMLL and PHAKISO are currently not available 
because of certain proprietary algorithms that were developed by the Bioinformatics 
and Drug Design (BIDD) group. However, the code and documentation of the header 
files, precompiled libraries of YMLL for various systems and the executable for 
PHAKISO are available freely on the PHAKISO website (http://www.phakiso.com) 
for non-commercial uses. In addition, certain parts of the source codes will be made 
available in the next release of YMLL and PHAKISO to aid in the development of 
additional algorithms by other programmers. The following sections describe the 
design and main features of YMLL and PHAKISO. A more detailed explanation of 
the usage of both YMLL and PHAKISO is provided on the PHAKISO website. 
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3.2 YMLL Organization 
3.2.1 Overview 
 YMLL contains different modules which interact with one another to develop 
a QSPkR/qSPkR model. The modules in YMLL are Dataset, DataLoad, DataSave, 
DatasetSplit, DatasetCluster, DiversityMetric, Outlier, Machine, DescriptorFilter, 
DescriptorSelection, Scale, DistanceMeasurer, PerformanceMeasurer, Reporter, 
ObjectiveFunction and Trainer. Each module defines a standard interface to interact 
with other modules. The standardization of a module’s interface enables different 
algorithms in the same module to work seamlessly with those in other modules and 
allow new algorithms to be easily added. The relationships between the different 
modules are shown in Figure 3.1. For example, to conduct a simple QSPkR/qSPkR 
experiment, we simply link the Dataset, DataLoad, Machine, and Reporter modules 
together. These modules will load a dataset into memory and pass to a machine 
learning algorithm to develop a QSPkR/qSPkR model. The prediction capability of 
the QSPkR/qSPkR model is then gauged and reported to the user. The programmer 
can choose different algorithms from the four different modules and the different 
algorithms are guaranteed to work with one another since they have to conform to the 
standard interface that is defined by their module.  
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Figure 3.1 Relationships between the different modules in YMLL. An arrow from 

















3.2.2 Dataset, DataLoad, DataSave, DiversityMetric, DatasetSplit, 
DatasetCluster, and Outlier 
 The Dataset module is the most important in YMLL. Its main purpose is to 
store ADMET properties and descriptors of different compounds and to provide this 
information to other modules. The Dataset module also contains useful functions for 
merging of different datasets, removing of a portion of the dataset, changing of 
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descriptor set, removing of a portion of the descriptors and removing of compounds 
with the same descriptor values in the dataset. 
 DataLoad and DataSave modules contain multiple algorithms which enables 
information to be loaded from and saved to a variety of file formats, which includes 
comma-separated value (CSV) files, Microsoft Excel files, extensible markup 
language (XML) files, SVMlight (Joachims 1999) files, Torch (Collobert et al. 2002) 
files, and Weka (Witten et al. 2005) files. 
 A DiversityMetric module is available to compute the diversity of the dataset. 
Three popular diversity measures are provided: mean intermolecular 
dissimilarity (Perez 2005), average nearest neighbours (Agrafiotis et al. 1999) and 
cumulative property distribution (Agrafiotis 2001).  
 The aim of the DatasetSplit module is to divide a dataset into smaller portions. 
These smaller datasets can be used as training sets to train the machine learning 
method, or as testing sets to aid in the optimization of the descriptor subsets or 
machine learning parameters, or as validation sets to assess the prediction capability 
of the final QSPkR/qSPkR models. Currently, the dataset can be divided using simple 
methods like random selection and select every N compound, or using various 
statistical molecular design algorithms like Kennard and Stone  (Kennard et al. 1969), 
sphere exclusion (Hudson et al. 1996), removal-until-done  (Hobohm et al. 1992), and 
D-optimal design (Mitchell 1974), or using cross-validation methods like leave-one-
out, k fold cross-validation, and bootstrap.  
 The DatasetCluster module can be used to separate the dataset into different 
clusters based on either hierarchical or non-hierarchical methods. Hierarchical 
methods include single linkage, complete linkage, group average, Wards, centroid and 
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median (Leach et al. 2003). Non-hierarchical methods include k-means (Forgy 1965) 
and a method proposed by Butina (Butina 1999). 
 The Outlier module is used to detect and remove outliers from a dataset. 
Presently, there is an algorithm proposed by Hadi (Hadi 1992), and three other 
algorithms proposed by Lu et al (Lu et al. 2003). 
 
3.2.3 Machine 
 The Machine module contains various machine learning algorithms for both 
classification and regression problems. For classification problems, these include 
Bayes linear discriminant analysis (Tabachnick et al. 2000), logistic 
regression (Tabachnick et al. 2000), C4.5 decision tree (Quinlan 1993), C4.5 decision 
rules (Quinlan 1993), k nearest neighbours (Fix et al. 1951), probabilistic neural 
networks (Specht 1990), and support vector machine (Vapnik 1995). The C4.5 
decision tree and C4.5 decision rules is a translation of the original Quinlan source 
codes from C to C++. Two different versions of probabilistic neural networks were 
provided. One is the implementation based on the algorithm that is provided in the 
literature and the other is a C++ wrapper for the source codes provided by 
Masters (Masters 1995). There are three four different versions of the support vector 
machine. The first is SVMStar, which is developed by the BIDD group and the rest 
are C++ wrappers for SVMlight (Joachims 1999), LibSVM (Chang et al. 2001) and 
SVMTorch (Collobert et al. 2002). 
 For regression problems, there are multiple linear regression (Tabachnick et al. 
2000), principal component regression (Tabachnick et al. 2000), partial least 
squares (Geladi et al. 1986), continuum regression (de Jong et al. 2001), feedforward 
backpropagation neural network (Welstead 1994), general regression neural 
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network (Specht 1991) and support vector regression (Vapnik 1995). There are three 
different versions of feedforward backpropagation neural network. One is an 
implementation based on the algorithm that is provided in the literature and the other 
two are C++ wrappers for Annie (Shankar et al. 2004) and TorchMLP (Collobert et al. 
2002).. There are two versions of the general regression neural network. The first is 
the implementation based on the algorithm that is provided in the literature and the 
second is a C++ wrapper for the source codes provided by Masters (Masters 1995). 
There are three different version of support vector regression. These are basically C++ 
wrappers for SVMlight (Joachims 1999), LibSVM (Chang et al. 2001) and 
SVMTorch (Collobert et al. 2002). 
 
3.2.4 DescriptorFilter, DescriptorSelection, Scale 
 The DescriptorFilter and DescriptorSelection modules, which are used for 
descriptor selection, contain filter and wrapper algorithms respectively. For filter 
methods, there are CORCHOP (Livingstone et al. 1989), discrimination score (Guyon 
et al. 2002) and RELIEFF (Kononenko 1994). For wrapper methods, there are 
forward selection (Xu et al. 2001), backward elimination (Xu et al. 2001), stepwise 
regression (Xu et al. 2001), sequential floating forward selection (Pudil et al. 1994), 
generalized simulated annealing (Sutter et al. 1993), reverse elimination method of 
tabu search (Glover 1989), genetic algorithm (Siedlecki et al. 1989) and recursive 
feature elimination (Guyon et al. 2002). These wrapper methods are commonly used 
to select relevant descriptors (Sutter et al. 1993; Kohavi et al. 1997; Xu et al. 2001; 
Molina et al. 2002; Guyon et al. 2003). However, most of these algorithms were not 
present in Torch or Weka. Thus the implementation of these algorithms in YMLL is 
necessary to facilitate the development of relevant QSPkR/qSPkR models. All the 
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implementations of the wrapper methods are based on algorithms that were described 
in the literature. The genetic algorithm wrapper method is implemented with the help 
of GALib (Wall 2005).  
 A Scale module is also provided to enable ease of scaling of descriptors. The 
types of scaling methods that are available includes autoscaling, range scaling from 0 
to 1, range scaling from -1 to 1, natural logarithm scaling, logarithm base 10 scaling, 
mean scaling and variance scaling. 
 
3.2.5 DistanceMeasurer 
 The DistanceMeasurer module measures the distance or similarity 
(dissimilarity) between two compounds. Available distance metrics include Euclidean 
distance (Willett et al. 1998), Manhattan distance (Willett et al. 1998), Soergel 
distance (Willett et al. 1998), Gaussian distance (Zaknich 1999), Quadratic 
distance (Zaknich 1999), Tophat distance (Zaknich 1999) and Triangular 
distance (Zaknich 1999). Algorithms for similarity measures include Tanimoto 
coefficient (Willett et al. 1998), Dice coefficient (Willett et al. 1998), Cosine 
coefficient (Willett et al. 1998) and Pearson correlation coefficient (Weisstein). 
 
3.2.6 PerformanceMeasurer and Reporter 
 The purpose of the PerformanceMeasurer module is to compute various 
statistics for assessing the prediction capability of QSPkR/qSPkR models. Statistics 
that can be computed for classification problems include sensitivity, specificity, 
concordance, absolute error rate, relative error rate, Matthews correlation 
coefficient (Matthews 1975) and Cohen Kappa coefficient (Chohan et al. 2005). For 
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regression problems, the following statistics can be calculated: correlation coefficient, 
coefficient of determination, adjusted coefficient of determination, mean absolute 
error, mean square error, root mean square error, Spearman rho coefficient, standard 
deviation, F statistics and average fold error (Obach et al. 1997). 
 The Reporter module is used to provide a report of the prediction capability of 
the QSPkR/qSPkR models to either the screen or to a file. 
 
3.2.7 Trainer and ObjectiveFunction 
 The Trainer module is used for optimizing of the parameters for a machine 
learning method. Currently, the module can only optimize machine learning methods 
with a single parameter. 
 The ObjectiveFunction module is used to provide performance evaluation of a 
QSPkR/qSPkR model to the DescriptorSelection module or the Trainer module.  
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3.3 PHAKISO 
3.3.1 Introduction 
 PHAKISO is a Microsoft Windows software, which uses the YMLL library, 
for performing QSPkR/qSPkR experiments. The aim of PHAKISO is to streamline 
the development of QSPkR/qSPkR models by offering a graphical user interface 
(GUI), which is shown in Figure 3.2, to the algorithms that are implemented in the 
YMLL library. This enables researchers to easily transform their data to a 
QSPkR/qSPkR model with just a few mouse clicks. 
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3.3.2 Features 
 Table 3.2 lists the standard features of PHAKISO, which are the GUI versions 
of the algorithms in YMLL library. Table 3.3 lists some additional features of 
PHAKISO which are not found in the YMLL library. 
 
Table 3.2 Standard features of PHAKISO 
Measurement of dataset diversity 
Determination of compound clusters in dataset 
Determination of outliers in dataset 
Statistical molecular design 
Y-randomization of dataset 
Scaling of descriptors 
Objective descriptor selection 
Subjective descriptor selection 
Construction of a QSPkR/qSPkR model 
Optimization of parameters for machine learning methods 
Assess prediction capability of QSPkR/qSPkR models on other datasets 
Validation of QSPkR/qSPkR models 
 
Table 3.3 Additional features of PHAKISO 
Display information on descriptors (mean, standard deviation, minimum and maximum values, etc) 
Automatic filling in of values for descriptors with missing values 
Principal component analysis 
 
3.3.3 Organization 
 All the features of PHAKISO are organized into a few menu headings: 
‘Dataset’, ‘Descriptors’, ‘Train’, ‘Trainers’, ‘Predict’, ‘Validation’, and ‘Options’. 
Some of the menu headings are initially disabled and will only be activated when the 
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features under the menu heading becomes available. For example, the ‘Predict’ menu 
will only be activated when a QSPkR/qSPkR model has been developed.  
 
3.3.3.1 ‘Dataset’ menu 
 The ‘Dataset’ menu contains algorithms for diversity measurement, finding 
clusters of compounds in the dataset, removal of duplicate compounds, removal of 
outlier compounds, statistical molecular design, y-randomization and calculating basic 
statistics for the dataset.  
 
3.3.3.2 ‘Descriptor’ menu 
 The ‘Descriptor’ menu contains algorithms for adding and removing 
descriptors, calculating correlation among the descriptors, calculating basic statistics 
for the descriptors, filling in of missing descriptor values, principal component 
analysis, scaling of the descriptors, objective descriptor selection and subjective 
descriptor selection. 
 
3.3.3.3 ‘Train’ menu 
 The ‘Train’ menu contains all the machine learning methods which are 
available for developing a QSPkR/qSPkR model from a training set. Once a 
QSPkR/qSPkR models has been developed, the ‘Predict’ menu will be activated.  
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3.3.3.4 ‘Trainers’ menu 
 The ‘Trainers’ menu contains algorithms for determining the optimum 
parameter values for the machine learning methods. Currently, the algorithms are only 
able to optimize a single parameter for the machine learning methods.  
 
3.3.3.5 ‘Predict’ menu 
 The ‘Predict’ menu contains algorithms for assessing the prediction capability 
of the developed QSPkR/qSPkR models. The QSPkR/qSPkR models can be used to 
predict the target property of compounds in the training set, testing set or a validation 
set.  
 
3.3.3.6 ‘Validation’ menu 
 The ‘Validation’ menu contains algorithms for validating the developed 
QSPkR/qSPkR models. The models can be validated by using cross-validation, 
bootstrapping, validation set or y-randomization.  
 
3.3.3.7 ‘Options’ menu 
 The ‘Options’ menu is used to adjust the parameters for all the machine 
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Chapter 4 
Prediction of Drug Absorption 
 
  The prediction of absorption-related processes, in particular, human 
intestinal absorption (section 4.1), and p-glycoprotein substrates (section 4.2), is 
presented in this chapter. SVM was used to develop classification systems for 
identifying compounds that are absorbable by human intestine and compounds that 
are substrates of the p-glycoprotein transporter. The effect of recursive feature 
elimination (RFE), a method for identifying relevant descriptors, on the classification 
accuracies of the SVM classification systems is discussed (sections 4.1.3.1 and 4.2.3). 
Analysis of the RFE-selected descriptors and comparison with other classification 
studies are also presented (sections 4.1.3.2, 4.1.3.3 and 4.2.3). 
 
4.1 Human intestinal absorption (HIA) 
4.1.1 Introduction 
 Absorption is defined as the process by which unchanged drug proceeds from 
site of administration to site of measurement within the body. The oral route is the 
most convenient and widely used method of drug administration. Thus it is of interest 
during drug discovery to identify compounds that are suitable for this route of 
delivery. Drug absorption from the gastrointestinal (GI) tract is complex process. It 
primarily involves passive transport with a small portion of compounds being 
absorbed by active transport through various transporters (Pelkonen et al. 2001). A 
large number of factors, which can be classified into three categories, i.e. 
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physicochemical, physiological, and formulation related, affect GI absorption. Since 
formulation related factors are usually optimized experimentally while physiological 
factors cannot be controlled, prediction interests are centered on the extent of 
absorption as a function of physicochemical properties of the compounds (Boobis et 
al. 2002). 
 qSPkR models have been developed to determine compounds absorbable 
(HIA+) or nonabsorbable (HIA-) by human intestine. The overall accuracies of these 
ranged from 80.0% to 95.7% (Bergstrom et al. 2003; Niwa 2003; Zmuidinavicius et 
al. 2003; Pérez et al. 2004). These models employ a variety of molecular descriptors 
to characterize structural and physicochemical properties of molecules. Some of these 
descriptors were initially developed for the construction of quantitative structure 
activity relationship (QSAR) and quantitative structure property relationship (QSPR) 
of structurally related compounds. Thus these descriptors may not be universally 
applicable for other compounds or for the prediction of other properties. For instance, 
descriptors for the QSAR of relatively small sets of related compounds are not 
applicable for the analysis of chemical diversity (Bayada et al. 1999). The use of 
descriptors unrelated to a particular type of properties or biological activity will 
generate noise in a machine learning system, which may affect the prediction 
accuracy of that system (Bayada et al. 1999). In some cases, it is difficult to manually 
select descriptors useful for a particular property. Thus methods capable of automatic 
selection of molecular descriptors are desirable. The redundancy in molecular 
descriptors can be partially reduced by means of feature selection methods. It is thus 
of interest to examine whether feature selection methods can be explored for 
automatic selection of molecular descriptors and for improvement of the prediction 
accuracy of ADMET properties by machine learning method.  
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 In this work, recursive feature elimination (RFE) is used as a feature selection 
method to automatically select molecular descriptors for support vector machine 
(SVM) prediction of HIA. The computed results are compared to those of earlier 
studies to examine whether our selected descriptors are capable of giving similar or 
better classification performance with respect to those derived from a preselected set 
of descriptors.  
 
4.1.2 Methods 
4.1.2.1 Selection of datasets 
 A “measured absorption rate” of 70% is used as the criterion for dividing 
compounds into HIA+ and HIA- classes (Zhao et al. 2001; Abraham et al. 2002). A 
total of 131 HIA+ and 65 HIA- compounds are collected. In general, a relatively 
smaller number of compounds with low intestinal absorption is specifically reported 
in the literature (Klopman et al. 2002). Thus, the number of known HIA+ compounds 
is expected to be significantly larger than those of HIA- compounds. 
 
4.1.2.2 Molecular descriptors 
 The molecular descriptors used in this work are selected from those commonly 
used in the literature (Todeschini et al. 2000). There are a total of 159 descriptors, 
given in Table 4.1, which can be divided into five classes based on their properties. 
These classes are simple molecular properties, molecular connectivity and shape, 
electrotopological state, quantum chemical properties, and geometrical properties. 
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Table 4.1 Molecular descriptors and their classes used for human intestinal 
absorption property predictiona. 






18 Molecular weight, Number of ring structures, number of rotatable 





28 Molecular connectivity indices, Valence molecular connectivity 









13 Atomic charge on the most positively charged H atom, Largest 
negative charge on a non-H atom, Polarizability index, Hydrogen 
bond acceptor basicity (covalent HBAB), Hydrogen bond donor 
acidity (covalent HBDA), Molecular dipole moment, Absolute 
hardness, Softness, Ionization potential, Electron affinity, Chemical 





16 Molecular size vectors (distance of the longest separated atom pairs, 
combined distance of the longest separated three atoms, combined 
distance of the longest separated four atoms), Molecular van der 
Waals volume, Solvent accessible surface area, Molecular surface 
area, van der Waals surface area, Polar molecular surface area, Sum 
of solvent accessible surface areas of positively charged atoms, Sum 
of solvent accessible surface areas of negatively charged atoms, Sum 
of charge weighted solvent accessible surface areas of positively 
charged atoms, Sum of charge weighted solvent accessible surface 
areas of negatively charged atoms, Sum of van der Waals surface 
areas of positively charged atoms, Sum of van der Waals surface 
areas of negatively charged atoms, Sum of charge weighted van der 
Waals surface areas of positively charged atoms, Sum of charge 
weighted van der Waals surface areas of negatively charged atoms 
a The total number of descriptors is 159. 
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 There are 18 descriptors in the class of simple molecular properties, 28 
descriptors in the class of molecular connectivity and shape, 84 descriptors in the 
class of electrotopological state, 13 descriptors in the class of quantum chemical 
properties, and 16 descriptors in the class of geometrical properties. These descriptors 
are computed using our own designed molecular descriptor computing program. 
 
4.1.2.3 Computation procedure 
 The computation procedure used in this work is outlined as follows: The SVM 
classification system was trained by using a Gaussian kernel function. The training 
was conducted by sequential variation of the parameter σ in the special region against 
the whole training set. The prediction accuracy of this SVM system during the 
training process was evaluated by means of 5-fold cross-validation. In the first step, 
for a fixed σ, the SVM classifier is trained by using the complete set of descriptors. 
The second step is to compute the ranking criterion score DJ(i) for each descriptor in 
the current set by using equation (2.8). All of the computed DJ(i) values are 
subsequently ranked in descending order. The third step is to remove the m 
descriptors with smallest criterion scores. In this work, m was chosen to be 5, similar 
to that used in earlier studies (Yu et al. 2003). In the fourth step, the SVM 
classification system is retrained by using the remaining set of descriptors, and the 
corresponding prediction accuracy is computed by means of 5-fold cross-validation. 
The first to fourth steps are then repeated for other values of σ. After the completion 
of these procedures, the set of descriptors and parameter σ that give the best 
prediction accuracy are selected. 
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4.1.3 Results and discussion 
4.1.3.1 Effect of feature selection on classification accuracy 
 The prediction accuracies of SVM classification systems using the RFE 
method (termed as SVM+RFE) and those without using RFE (termed as SVM) were 
evaluated by means of 5-fold cross-validation method. The computed sensitivity (SE) 
and specificity (SP) for each fold and the average accuracies of HIA+ and HIA- 
compounds as well as the overall prediction accuracy (Q) and Matthews correlation 
coefficient (MCC) are given in Table 4.2.  
 
Table 4.2 SVM and SVM+RFE prediction accuracy of human intestinal absorption 
(HIA+) and nonabsorption (HIA-) of compounds by using 5-fold cross-validation. 
HIA+ HIA- Method Cross-




1 22 5 81.5 7 5 58.3 74.4 0.40 
2 18 3 85.7 8 3 72.7 81.3 0.58 
3 37 3 92.5 7 5 58.3 84.6 0.54 
4 16 4 80.0 7 8 46.7 65.7 0.28 
5 18 5 78.3 12 3 80.0 79.0 0.57 
SVM 
Average   83.4   63.2 77.0 0.48 
1 22 5 81.5 10 2 83.3 82.1 0.61 
2 20 1 95.2 11 0 100.0 96.9 0.93 
3 35 5 87.5 8 4 66.7 82.7 0.53 
4 18 2 90.0 10 5 66.7 80.0 0.59 
5 22 1 95.7 13 2 86.7 92.1 0.83 
RFE  + 
SVM 
Average   90.0   80.7 86.7 0.70 
 
 The average accuracy for the SVM prediction of HIA+ and HIA- compounds 
is 83.4% and 63.2% respectively. By using RFE, the total number of descriptors is 
 
CHAPTER 4: ABSORPTION 81
significantly reduced from 159 to 27. The average accuracies for the prediction of 
HIA are substantially improved by using the reduced set of descriptors. These are 
90.0% and 80.7% for HIA+ and HIA- compounds respectively. Our study seems to 
suggest that RFE is useful for removing redundant descriptors, which helps to 
increase the computational efficiency of statistical learning system. RFE is also 
capable of improving the accuracy of SVM classification of HIA behavior of 
compounds. 
 
4.1.3.2 Comparison with other classification studies 
 The effect of feature selection on classification performance can be further 
evaluated by comparison with other classification studies of the same systems that use 
preselected descriptors. Direct comparison between our results and those from other 
studies may not be appropriate because of differences in the use of dataset, descriptors, 
evaluation, and classification methods. Nonetheless, a tentative comparison may 
provide some crude estimate regarding the approximate level of accuracy of our 
method with respect to those obtained by other studies that used more selective 
descriptors. 
 The reported accuracies of HIA+ predictions are 77%-87% by using 
partitioned total surface models (Bergstrom et al. 2003), 80% by using neural network 
methods together with 2D topological descriptors (Niwa 2003), and 97% by using 
structure activity relationship (SAR) models together with physicochemical and 
structural descriptors (Zmuidinavicius et al. 2003). The reported accuracy for HIA- 
prediction is 85% by using SAR models (Zmuidinavicius et al. 2003). Our prediction 
accuracy of 90.0% for HIA+ and 80.7% for HIA- by using SVM+RFE is thus 
comparable to the results from these methods that use selective sets of descriptors.  
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4.1.3.3 RFE selected molecular descriptors 
 Table 4.3 gives the descriptor classes of the RFE-method-selected descriptors. 
These descriptors along with their descriptor types are given in Table 4.4. It is found 
that hydrogen bonding and size are the dominant factors involved in the 
characterization of HIA property. This finding is consistent with the Lipinski’s rule of 
five (Lipinski et al. 1997). In addition, hydrophobic and electrostatic interactions are 
also found to be important. 
 
Table 4.3 Descriptor classes selected by the RFE method. 
Descriptor class Number of descriptors in 
descriptor class 
Percentage in each class (%) 
Electrostatic 4 14.8 
Hydrogen bond acceptors 3 11.1 
Hydrogen bond donors 6 22.2 
Hydrophobic 6 22.2 
Size 8 29.6 
 
Table 4.4 Molecular descriptors in the reduced set selected by the RFE method 
No Descriptors Description Type 
1 S(1) Atom-type H Estate sum for -OH Electrotopological state 
2 S(5) Atom-type H Estate sum for > NH Electrotopological state 
3 S(10) Atom-type H Estate sum for :CH: (sp2, 
aromatic) 
Electrotopological state 
4 S(13) Atom-type H Estate sum for CH n 
(unsaturated) 
Electrotopological state 
5 S(16) Atom-type Estate sum for -CH 3 Electrotopological state 
6 S(20) Atom-type Estate sum for =CH- Electrotopological state 
7 S(25) Atom-type Estate sum for =C< Electrotopological state 
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8 S(26) Atom-type Estate sum for : C:- Electrotopological state 
9 S(31) Atom-type Estate sum for >NH Electrotopological state 
10 S(34)  Atom-type H Estate sum for =N-  Electrotopological state 
11 S(35) Atom-type Estate sum for :N: Electrotopological state 
12 S(39)  Atom-type H Estate sum for –OH  Electrotopological state 
13 S(40)  Atom-type H Estate sum for =O  Electrotopological state 
14 2χ Simple molecular connectivity Chi 
indices for path order 02  
Connectivity and shape 
 
15 3χC Simple molecular connectivity Chi 
indices for cluster  
Connectivity and shape 
 
16 5χCH Simple molecular connectivity Chi 
indices for cycle of 5 atoms 
Connectivity and shape 
 
17 6χCH Simple molecular connectivity Chi 
indices for cycle of 6 atoms 
Connectivity and shape 
 
18 3χvC Valence molecular connectivity Chi 
indices for cluster 
Connectivity and shape 
 
19 5χvCH valence molecular connectivity Chi 
indices for cycle of 5 atoms 
Connectivity and shape 
 
20 6χvCH valence molecular connectivity Chi 
indices for cycle of 6 atoms 
Connectivity and shape 
 
21 πi Polarizability index Quantum chemical properties 
22 εa  Hydrogen bond donor acidity (covalent 
HBDA)  
Quantum chemical properties 
23 A  Electron affinity  Quantum chemical properties 
24 dis3  Length vectors (longest distance, longest 
third atom, 4th atom)  
Geometrical properties  
25 Sanc Sum of solvent accessible surface areas of 
negatively charged atoms 
Geometrical properties 
26 Sancw Sum of charge weighted solvent 
accessible surface areas of negatively 
Geometrical properties 
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charged atoms 
27 Ndonr Number of H-bond donors Simple molecular properties 
 
 The RFE selected descriptors describe polar properties, molecular size, cluster 
connectivity, and various +N–, –OH, and =O electrotopological properties, which are 
likely to be important for describing passive transport across membranes. These 
descriptors are primarily uncorrelated to each other. The majority of the descriptors 
removed by the RFE method, particularly those of electrotopological state, 
geometrical, and quantum chemical properties, were found to have at least a 
correlation coefficient of 0.7 to some of the descriptors selected. The rest of the RFE 
removed descriptors are mostly simple molecular properties (such as molecular 
weight, the number of specific types of atoms, and the number of rings), geometrical 
properties (such as molecular volume and surface areas), and connectivity properties 
(such as index for clusters and paths). These descriptors are not selected because they 
may not contain as much information as the current descriptor subset for describing 
the penetration of a compound through the intestinal membrane. For instance, 
Lipinski’s rule of five (Lipinski et al. 1997) states that molecular weight is important 
for the prediction of drug absorption through the intestine. One reason why molecular 
weight was not selected by the RFE method in this study may be because it does not 
contain as much information as the current descriptor subset for describing the 
penetration of a compound through the intestinal membrane. Thus descriptors such as 
molecular connectivity and length vectors, which encode the shape and size of a 
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4.1.4 Conclusion 
 Statistical-learning methods have been developed for facilitating the prediction 
of pharmacokinetic and toxicological properties of compounds. These methods 
employ a variety of molecular descriptors to characterize structural and 
physicochemical properties of molecules. Some of these descriptors are specifically 
designed for the study of a particular type of properties or compounds, and their use 
for other properties or compounds might generate noise and affect the prediction 
accuracy of a statistical learning system. In this work, a feature selection method, RFE, 
is used to automatically select molecular descriptors for SVM prediction of HIA. RFE 
significantly reduces the number of descriptors need to develop a qSPkR model for 
HIA, thereby increasing the computational speed for their classification. The SVM 
prediction accuracies of HIA are substantially increased by RFE. These prediction 
accuracies are comparable to those of earlier studies derived from a selective set of 
descriptors. Our study suggests that molecular feature selection is useful for 
improving the speed and, in some cases, the accuracy of statistical learning methods 
for the prediction of pharmacokinetic and toxicological properties of chemical agents.  
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4.2 P-glycoprotein (P-gp) substrates 
4.2.1 Introduction 
 P-gp, encoded by the highly conserved multidrug resistant (MDR) genes, is an 
ATP-dependent drug efflux pump which can transport a diverse range of structurally 
and functionally unrelated substrates across the plasma membrane (van Veen et al. 
1998; Schmitt et al. 2002). Over expression of this protein may result in multidrug 
resistance and is a major cause of the failure of cancer chemotherapy (Gottesman et al. 
1996; Ambudkar et al. 1999) and diminished efficacy of antibiotics and antiviral 
compounds (Kim et al. 1998; Delph 2000). Two approaches have been explored to 
circumvent MDR. One is the design of P-gp inhibitors (Klopman et al. 1997; Bakken 
et al. 2000) and another is to identify and eliminate drug candidates that are substrates 
of P-gp in early stage of drug discovery (Bain et al. 1997; Litman et al. 1997; Seelig 
1998; Penzotti et al. 2002). Methods that facilitate the identification of P-gp substrates 
and inhibitors in a cost efficient and fast-speed manner are therefore useful for 
facilitating drug discovery. 
 Efforts have been directed at the development of computational methods for 
P-gp substrate prediction (Bain et al. 1997; Litman et al. 1997; Seelig 1998; Penzotti 
et al. 2002). Molecular mechanism of P-gp mediated transport is not well understood 
and the high-resolution structure of P-gp is unavailable (van Veen et al. 1998; Schmitt 
et al. 2002). Thus prediction methods are primarily based on statistical models 
derived from identification of structure-activity relationships (Bain et al. 1997; 
Litman et al. 1997), structural recognition elements (Seelig 1998), and multiple 
pharmacophores (Penzotti et al. 2002). In particular, the multiple-pharmacophore 
model showed promising capability of P-gp substrate prediction for a large variety of 
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compounds that conform to the known pharmacophores (Penzotti et al. 2002), 
achieving a prediction accuracy of 63 % for a set of 195 compounds. Not all of the 
pharmaceutically important substrates, agonists and antagonists have available 
pharmacophore models. Therefore methods that extend the prediction range beyond 
those compounds covered by known pharmacophore models are desired.  
 This work explored the use of SVM as a potential tool for the prediction of P-
gp substrates. Known P-gp substrates and non-substrates were used for training and 
testing a SVM classification system for recognition of physicochemical features of P-
gp substrates. Through this learning-by-examples process, the trained SVM system 
can then be used for classifying a chemical compound as either a substrate or a non-
substrate of P-gp. The classification accuracy of this system was evaluated by using 
two methods, an independent set of compounds and 5-fold cross-validation, and it is 
compared to the 5-fold cross-validation prediction accuracies derived from three other 
machine learning methods using the same sets of data and molecular descriptors, so as 
to objectively examine whether SVM is useful for P-gp substrate prediction. 
 
4.2.2 Methods 
4.2.2.1 Selection of substrates and non-substrates of P-gp 
 P-gp substrates were collected from the literature (Seelig 1998; Penzotti et al. 
2002). Non-substrates of P-gp are those specifically described as not transportable by 
P-gp. A total of 116 substrates and 85 non-substrates of P-gp were collected. These 
compounds were further separated into training and testing sets by two different 
methods. The first method is an independent validation set to evaluate the 
classification accuracy. The second method is 5-fold cross-validation. 
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 In the first method, these compounds were separated into three sets: training, 
testing and independent validation set. The training set is used by SVM to develop a 
statistical model. The testing set is used by SVM to optimize the parameters of SVM 
classification algorithm and the independent validation set is used for assessing the 
classification accuracy of the model. These compounds were divided into the three 
sets by using the removal-until-done method (section 2.2.2.3). 
 
4.2.2.2 Molecular descriptors 
 This study used the same set of 159 molecular descriptors as the HIA study 
(section 4.1.2.2). Redundant and un-related descriptors are further reduced by using 
RFE method with the same computation procedure as the HIA study (section 4.1.2.3). 
 
4.2.2.3 Other statistical classification systems 
 To objectively examine whether SVM is useful for P-gp substrate prediction, 
prediction accuracies of the trained SVM system were compared with those derived 
from three other classification methods by using 5-fold cross-validation. These 
methods are k nearest neighbour (kNN), probabilistic neural network (PNN) and C4.5 
decision tree (DT).  
 
4.2.3 Results and discussion 
 SVM prediction of both substrates and non-substrates of P-gp was evaluated 
by means of independent validation set and 5-fold cross-validation. The results of 
these two methods are given in Table 4.5 and Table 4.6 respectively. The accuracy for 
the prediction of P-gp substrate using 5-fold cross-validation is 81.2% and that by 
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using independent validation set is 84.2% respective. Thus both methods appear to 
give consistent assessment about the prediction accuracy. This suggests that the 
trained SVM system is unlikely to overfit. 
 
Table 4.5 SVM prediction accuracy for the substrates and non-substrates of P-gp by 
using independent validation sets.  
Testing set Independent validation set 
Substrates Nonsubstrates Substrates Nonsubstrates 
Training set 
TP FN TN FP TP FN SE (%) TN FP SP (%) 
74 68 22 0 12 0 16 3 84.2 4 2 66.7 
 
Table 4.6 SVM prediction accuracy of the substrates and non-substrates of P-
glycoprotein by using 5-fold cross-validation. 
Substrates Non-substrates Cross-
validation TP FN SE (%) TN FP SP (%) 
Q (%) 
1 17 7 70.8 12 4 75.0 72.5 
2 15 2 88.2 11 5 68.8 78.8 
3 30 8 78.9 13 1 92.9 82.7 
4 15 4 78.9 15 3 83.3 81.1 
5 16 2 88.9 16 5 76.2 82.1 
Average   81.2   79.2 79.4 
Standard error   7.5   9.2 4.2 
 
 A direct comparison with results from previous study is inappropriate because 
of differences in the use of dataset, molecular descriptors and classification methods. 
A tentative comparison suggests that our prediction accuracy for P-gp substrates is 
substantially improved with respect to the value of 63% derived from the ensemble 
pharmacophore model (Penzotti et al. 2002). 
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 The prediction accuracy for non-substrates of P-gp is 79.2% using 5-fold 
cross-validation and 66.7% using independent validation set. The substantially lower 
accuracy derived from the independent validation set likely arises because of the 
small number of P-gp non-substrates in the set. Another factor is the inadequate 
sampling of the chemical space covered by non-substrates of P-gp. It is likely that the 
85 non-substrates collected in this work only represent a portion of all possible classes 
of non-substrates of P-gp. Protein non-substrates are rarely described in the literature, 
thus additional efforts are needed to enable the collection of this information. 
 SVM classification results were further compared to those from other machine 
learning methods like kNN, PNN, and C4.5 DT to determine whether it is possible to 
use a simpler model for the prediction of P-gp substrates and non-substrates. The 
same sets of data and descriptors are used in these computations. The results are 
shown in Table 4.7 and it is found that the accuracy from SVM classification system 
is slightly better than those from other classification methods. This suggests that the 
SVM classification system developed in this study is not more flexible than is 
necessary and thus is unlikely to have overfitting problems. 
 
Table 4.7 Comparison of the prediction accuracy of the substrates and non-substrates 
of P-glycoprotein from different classification methods by using 5-fold cross-
validation. 
Method SE (%) SP (%) Q (%) 
kNN 79.2 61.6 70.8 
PNN 77.3 71.4 74.4 
C4.5 DT 74.6 69.9 71.5 
SVM 81.2 79.2 79.4 
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 SVM typically uses a portion of the training set as support vectors for 
classification. In contrast, kNN and PNN use the whole training set for classification. 
Our own studies suggest that the number of support vectors of SVM is in the range of 
40-70% of the training set. Thus the classification speed of SVM is usually 30-60% 
faster than that of kNN and PNN. On the other hand, the classification speed of SVM 
is slower than that of decision tree methods which conduct tests on descriptors to 
reach a decision leaf. 
 In the independent validation set, there are three and two incorrectly classified 
substrates and non-substrates of P-gp respectively, which are shown in Figure 4.1. 
The three P-gp substrates are catharantine, depredil and yohimbine, and the two non-
substrates of P-gp are NSC364080 and NSC630357.  
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 Table 4.8 gives the molecular descriptors selected from the feature selection 
method RFE. Those from the class of topological descriptor constitute the largest 
percentage of the descriptors selected. This is consistent with the findings from the 
classification of MDR compounds, many of which are P-gp substrates, by using 
structure-based descriptors and linear discriminant analysis, which showed that 60% 
of the molecular descriptors important for MDR are topological in nature (Bakken et 
al. 2000). A QSAR study of MDR compounds also identified several pharmacophores, 
e.g., a generic form of C-C-X-C-C with X=N, NH, or O (preferably a tertiary 
nitrogen), as a key structural element for MDR (Klopman et al. 1997). These 
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pharmacophores are primarily determined by electrotopological features and bond 
connectivity. In addition to the large percentage of electrotopological descriptors, 
RFE method also selected three molecular connectivity descriptors, which seems to 
correlate with the features of the pharmacophores identified from the QSAR study of 
MDR compounds. 
 
Table 4.8 Molecular descriptors selected from the feature selection method for 
classification of P-gp substrates and non-substrates. 
No Descriptors Description Class 
1 Ncocl Count of Cl atoms Simple molecular properties 
2 Ndonr Number of H-bond donors Simple molecular properties 
3 5χCH Simple molecular connectivity Chi 
indices for cycle of 5 atoms 
Connectivity and shape 
4 3χvP Valence molecular connectivity Chi 
indices for path order 3 
Connectivity and shape 
5 5χvCH valence molecular connectivity Chi 
indices for cycle of 5 atoms 
Connectivity and shape 
6 Scar Sum of Estate indices of carbon atoms Geometrical properties 
7 dis2 Length vector (longest third atom) Geometrical properties 
8 Sapcw Sum of charge weighted solvent 
accessible surface areas of positively 
charged atoms 
Geometrical properties 
9 S(1) Atom-type H Estate sum for -OH Electrotopological state 
10 S(9) Atom-type H Estate sum for =CH- (sp2) Electrotopological state 
11 S(12) Atom-type H Estate sum for CHn 
(Saturated) 
Electrotopological state 
12 S(13) Atom-type H Estate sum for CH n 
(unsaturated) 
Electrotopological state 
13 S(16) Atom-type Estate sum for -CH 3 Electrotopological state 
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14 S(18) Atom-type Estate sum for >CH 2 Electrotopological state 
15 S(20) Atom-type Estate sum for =CH- Electrotopological state 
16 S(21) Atom-type Estate sum for : CH : 
(aromatic) 
Electrotopological state 
17 S(25) Atom-type Estate sum for =C< Electrotopological state 
18 S(36) Atom-type Estate sum for >N- Electrotopological state 
19 πi Polarizability index Quantum chemical properties 
20 q+ Atomic charge on the most positively 
charged H atom 
Quantum chemical properties 
21 μ Molecular dipole moment Quantum chemical properties 
22 ω Electrophilicity index Quantum chemical properties 
 
 The rest of the RFE selected descriptors are from the quantum chemical class 
and simple molecular property class. The selected quantum chemical descriptors 
determine polarizability, molecular dipole moment, electrophilicity, and the atomic 
charge of the positively charged hydrogen atoms in a molecule. The selected simple 
molecular property descriptors give the number of hydrogen bond donors and that of 
Cl atoms. With the exception of the last descriptor, the MolSurf counterparts of these 
quantum chemical and simple molecular property descriptors have used for the 
prediction of P-gp-interacting drugs by means of multivariate statistics 
method (Österberg et al. 2000). Based on structural comparison, it has been found that 
the number of electron donors and hydrogen bond acceptor groups are important 
elements for P-gp substrate recognition (Seelig 1998). An analysis of multiple 
pharmacophores of P-gp substrates has identified hydrophobe, hydrogen bond donor 
and acceptor as important elements for P-gp substrates (Penzotti et al. 2002). Thus 
these studies consistently suggested the importance of the selected quantum chemical 
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features and hydrogen-bond property for prediction of P-gp substrates and non-
substrates. 
 The other RFE selected descriptor, the count of Cl atoms, has not been 
specifically used in other P-gp substrate studies. One possible reason is that the 
molecules used in those studies do not contain a Cl atom, thus it is unnecessary to 
introduce this descriptor in those studies. In this work, the descriptor for hydrogen 
bond acceptor was not selected by RFE, which has been found to be an important 
element for P-gp substrates in other studies (Seelig 1998; Penzotti et al. 2002). One 
likely reason for the exclusion of this descriptor is that it has a high level of 
redundancy with the relevant features covered by the quantum chemical descriptors 
such as electrophilicity, polarizability and molecular dipole moment when they are 
combined with the hydrogen bond donor descriptor. 
 
4.2.4 Conclusion 
 SVM is a potentially useful computational method for facilitating the 
prediction of P-gp substrates. The SVM model developed in this work gave a 
prediction accuracy for P-gp substrates that is substantially improved against that 
obtained from the multiple-pharmacophore model. The prediction accuracy for 
nonsubstrates of P-gp is slightly better than those obtained from other statistical 
classification methods, including kNN, PNN, and C4.5 decision tree, that use the 
same sets of data and molecular descriptors. Prediction accuracy may be further 
improved by consideration of factors such as hydrogen bonding, active transport, and 
relationship with pharmacodynamic properties. 
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Chapter 5 
Prediction of Drug Distribution 
 
 This chapter describes the prediction of a few important distribution processes, 
such as blood-brain barrier penetration, human serum albumin binding and milk-
plasma ratio by using GRNN. The prediction accuracies of the GRNN-developed 
models were compared with those of QSPkR models developed by using MLR and 
MLFN. A new method for interpreting GRNN-developed QSPkR models, which 
enables relevant physicochemical and structural properties of a compound to be 
identified, is also introduced. 
 
5.1 Introduction 
 Optimization of pharmacokinetic as well as the pharmacodynamic properties 
of a drug candidate is an important consideration in drug design process (Eddershaw 
et al. 2000; van de Waterbeemd et al. 2003). One important aspect of 
pharmacokinetic properties of a drug candidate is its distribution in the human body. 
A drug is required to achieve sufficient concentration at target site while possibly 
limiting its distribution elsewhere so as to produce desired therapeutic action with 
minimum side effects (Butina et al. 2002). Traditionally, the distribution properties of 
a drug candidate are obtained via in vivo and in vitro studies, which tend to be time-
consuming and costly. Therefore, QSPkR modeling has recently been explored for 
predicting the distribution properties of drug candidates (Ekins et al. 2000c) in an 
effort to eliminate undesirable compounds in a fast and cost-effective manner.  
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 The most common modeling methods for obtaining QSPkR models are linear 
methods such as multiple linear regression (MLR) (Geladi et al. 1986). These 
methods can be easily used and the derived models can be easily interpreted. However 
multiple mechanisms may be involved in determining a particular pharmacokinetic 
property. A variety of factors may interact in complex ways to affect the 
pharmacokinetic property of a compound. Therefore methods based only on linear 
relationships may not always be the most efficient approach for constructing a QSPkR 
model. Thus non-linear methods such as multi-layer feedforward neural networks 
(MLFN) (Wythoff 1993) and general regression neural network (GRNN) (Specht 
1991) have increasingly been used for construction of QSPkR models.  
 GRNN has been explored for QSPkR modeling of human intestinal 
absorption (Niwa 2003) as well as for developing QSAR and QSPR of chemical 
compounds (Mosier et al. 2002). The prediction capability of GRNN has been found 
to be comparable to those of conventional non-linear methods such as MLFN but the 
former requires fewer descriptors (Mosier et al. 2002). Thus GRNN is expected to be 
equally useful for developing QSPkR models of other pharmacokinetic properties. 
This work is intended to test this feasibility by applying GRNN for developing 
QSPkR models of three distribution properties, blood-brain barrier (BBB) penetration, 
binding to human serum albumin (HSA) and milk-plasma (M/P) distribution. The 
performances of the GRNN-developed models were compared with those developed 
by using MLR and MLFN to determine whether GRNN produces more predictive 
QSPkR models.  
 The BBB exists at the choroids plexus and at the tissue capillary membranes 
between the blood and brain fluid, and BBB penetration is necessary for central 
nervous system (CNS) drugs (Hardman et al. 2002). Examples of these drugs are 
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antipsychotics, antiepileptics and antidepressants. For drugs not directed at targets in 
the brain, BBB penetration is undesirable because of potential CNS-related side 
effects. For example, the first generation antihistamines are known to penetrate the 
BBB leading to drowsiness (Meltzer 1990). The second generation antihistamines 
have a significantly reduced BBB penetration capability and are thus less likely to 
cause drowsiness (Kaliner 1992). One method for assessing the effects of a compound 
in the brain is to determine its concentration in the brain. This concentration can be 
calculated from the brain-blood (BB) ratio which is the concentration of this 
compound in the brain divided by that in the blood. Thus the BB ratio is an important 
pharmacokinetic property and a number of QSPkR models of BB ratio have been 
developed (Young et al. 1988; van de Waterbeemd et al. 1992; Abraham et al. 1994; 
Lombardo et al. 1996; Norinder et al. 1998; Clark 1999; Kelder et al. 1999; Luco 
1999; Feher et al. 2000; Kaznessis et al. 2001; Keserü et al. 2001; Liu et al. 2001; 
Platts et al. 2001; Iyer et al. 2002; Hou et al. 2003), the majority of which were 
developed by using MLR and the computed r2 values are in the range between 0.723-
0.941. 
 Most drugs bind to serum proteins and such binding regulates drug 
distribution and subsequently its effect (Colmenarejo 2003). Albumin is the most 
abundant of all serum proteins and is the most common drug-binding protein in the 
circulatory system. Because of the important role of albumin-binding in regulation of 
drug distribution, QSPkR models for predicting the extent of albumin-binding have 
been developed (Gobburu et al. 1995; Colmenarejo et al. 2001; Kratochwil et al. 2002; 
Hall et al. 2003; Turner et al. 2003b), the majority of which were developed by using 
MLR and a congeneric series of compounds. In a study of a diverse set of 94 drugs 
and drug-like compounds, two QSPkR models developed by using MLR gave 
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computed r2 values of 0.88 and 0.82 respectively on a separate testing 
set (Colmenarejo et al. 2001). 
 Breast milk is the best form of nutrition available to a newborn infant. Certain 
drugs administered to a nursing mother may be distributed into breast milk and thus 
transferred into the infant. The concentration of drug present in the breast milk can be 
used as an indicator of breast feed risk. The ratio of drug concentration in milk and 
plasma (M/P ratio) is the most widely used quantity for describing drug concentration 
in breast milk (Begg et al. 1993). However, the M/P ratio is seldom determined 
during clinical trials or after the drug has entered the market. In addition, M/P ratios 
were often obtained from studies involving a small number of women. This may lead 
to significant variations in the reported M/P ratio for a drug and makes it difficult for 
clinicians to advise women on the safety of breast-feeding. Methods for estimating the 
M/P ratios of drugs have been developed by using various modeling methods (Wilson 
1981; Meskin et al. 1985; Fleishaker et al. 1987; Atkinson et al. 1990; Agatonovic-
Kustrin et al. 2000; Agatonovic-Kustrin et al. 2002). In a recent study (Agatonovic-
Kustrin et al. 2002), MLFN was used to train and test on 123 diverse compounds. The 




5.2.1 MLFN algorithm 
 The algorithm of MLFN has been extensively described in 
literatures (Wythoff 1993; Erb 1995; Hudson et al. 1995). Thus only a brief 
description is given here. MLFN is composed of an input layer, a variable number of 
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hidden layers and an output layer. The input and output layers contain neurons 
representing the descriptors and response value respectively. In a fully connected 
MLFN, each neuron in the input layer sends its value to all neurons in the first hidden 
layer. Each neuron in the hidden layers receives inputs from all neurons in the 
previous layer and computes a weighted sum of the inputs. The neuron output is 
determined by passing the weighted sum through a transfer function, which is usually 
a linear or sigmoidal function. The single neuron in the output layer determines the 
predicted response value by computing a weighted sum of the outputs of all neurons 
in the last hidden layer. Weights for the connections between neurons in adjacent 
layers are initially randomly assigned. These weights are then refined via a backward 
propagation of error process during training of the MLFN. In this study, MLFN were 
performed using the YMLL library (section 3.2) and had a single hidden layer with 
ten neurons. 
 
5.2.2 Molecular descriptors 
 A total of 1497 1D, 2D and 3D molecular descriptors were computed by using 
DRAGON (Todeschini et al. 2003). These descriptors, which can be divided into 18 
classes, include 47 constitutional descriptors, 70 geometrical descriptors, 266 
topological descriptors, 150 RDF descriptors (Hemmer et al. 1999), 21 molecular 
walk counts (Rücker et al. 1993), 160 3D-MoRSE descriptors (Schuur et al. 1996), 64 
BCUT descriptors (Pearlman et al. 1999), 99 WHIM descriptors (Bravi et al. 1997), 
21 Galvez topological charge indices (Galvez et al. 1994), 197 GETAWAY 
descriptors (Consonni et al. 2002), 96 2D autocorrelations, 121 functional groups, 14 
charge descriptors, 120 atom-centred descriptors, 4 aromaticity indices (Randic 1975), 
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 The BBB penetration dataset contains 175 compounds with experimental log 
BB values collected from various literature sources (Luco 1999; Kaznessis et al. 2001; 
Platts et al. 2001; Hou et al. 2003). Twelve compounds were identified as outliers by 
previous studies (Abraham et al. 1994; Lombardo et al. 1996; Clark 1999; Luco 1999; 
Kaznessis et al. 2001; Liu et al. 2001; Platts et al. 2001) and were removed from the 
dataset. The DRAGON software was unable to compute the descriptors of four 
compounds, argon, krypton, neon and xenon, and thus these compounds were also 
removed from the dataset. The final dataset of 159 compounds were divided into a 
training set of 129 compounds and a validation set of 30 compounds. 
 The HSA binding dataset was composed of 94 compounds with HSA binding 
constants, log Khsa, and was obtained from Colmenarejo et al (Colmenarejo et al. 
2001). One compound, ebselen, was removed from the original dataset as its 
descriptors cannot be computed by the DRAGON software. These compounds were 
divided into a training set and a validation set of 75 and 18 compounds respectively. 
 The M/P distribution dataset consists of 123 compounds used in the 
Agatonovic-Kustrin’s study (Agatonovic-Kustrin et al. 2002). An erroneous 
compound, norfluexetine, was identified and removed from the original dataset. The 
remaining compounds were split into a training set and validation set of 102 and 20 
compounds respectively. 
 Kennard and Stone algorithm (section 2.2.2.2), which has been found to be 
useful for constructing representative training and validation sets from a dataset (Wu 
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et al. 1996; Zuegge et al. 2002; Rajer-Kanduc et al. 2003), was used in this work. In 
computing the Euclidean distance for the algorithm, principal component analysis 
(PCA) was used to select principal components (PC) whose eigenvalues were larger 
than one. The Euclidean distance was then calculated from the retained PCs. The 
selection process continues until approximately 80% ∼ 85% of the compounds were 
selected for the training set. The remaining 15% ∼ 20% of the compounds in the 
dataset were used as the validation set. 
 
5.2.4 Descriptor selection 
 The first step involves the removal of all irrelevant descriptors such as 
constant descriptors and near-constant descriptors that have the same value for more 
than 80% of the compounds. All the remaining descriptors were autoscaled using 
equation (2.3). Genetic algorithm (section 2.3.3.2) was then used to further remove 
descriptors of low information content. In the mutation process of the genetic 
algorithm, descriptors may be randomly added to or deleted from a descriptor subset, 
subjected to an overall minimum and maximum of 3 and 10 descriptors respectively 
for each descriptor subset. At the end of the genetic algorithm-based descriptor 
selection process, the highest ranked subset was retained. As genetic algorithm is a 
heuristic method, the selection of relevant descriptor subset was repeated 10 times to 
improve the chances of finding the optimum descriptor subset. The best descriptor 
subset from these 10 runs was used to construct the QSPkR model.  
 In the descriptor selection process, the original training set was divided by 
using Kennard and Stone algorithm into a modeling training set and a modeling 
testing set by a 4:1 ratio. The modeling training set was used for constructing the 
QSPkR models in the genetic algorithm. The testing set was used to evaluate the 
 
CHAPTER 5: DISTRIBUTION 103
trained systems so that no overtrained systems are selected. The following cost 
function (Wessel et al. 1998; Mosier et al. 2002) was used as the fitness function 
during genetic algorithm optimization: 
 0.4train train testCost MSE MSE MSE= + × −     (5.1) 
where MSEtrain and MSEtest are the mean square error of the modeling training set and 
testing set respectively and were calculated using the equation (2.35). 
 
5.2.5 Model validation 
 Y-randomization was used to determine the probability of chance correlation 
during descriptor selection (Manly 1997; Leardia et al. 1998). The distribution 
properties of all the compounds in the modeling training set were first randomly 
rearranged. Descriptor selection using genetic algorithm was then used to find the 
optimum descriptor subset for the scrambled data and the cost of this descriptor subset 
was measured. The scrambling of the distribution properties and descriptor selection 
was repeated for 30 times. If the cost of all of the scrambled QSPkR models were 
significantly worse than the cost of the original QSPkR model, it can be concluded 
that the original QSPkR model was relevant and unlikely to arise as a result of chance 
correlation. 
 The validation set, not used in the derivation of the QSPkR models, was used 
to estimate the prediction capability of the final QSPkR models. Leave-one-out (LOO) 
and 10-fold cross-validation were not used for this purpose in this work because there 
are reports of the lack of correlation between cross-validation methods and the 
prediction capability of a QSAR model (Golbraikh et al. 2002; Kozak et al. 2003; 
Reunanen 2003; Olsson et al. 2004). In addition, cross-validation methods have a 
tendency to underestimate the prediction capability of a QSAR model, especially if 
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important molecular features are present in only a minority of the compounds in the 
training set (Mosier et al. 2002; Hawkins et al. 2004). Thus a model having low cross-
validation results can still be quite predictive (Mosier et al. 2002). 
 
5.2.6 Interpretation of GRNN-developed models 
 In multi-sigma GRNN-developed models, the contribution of each descriptor 
on the distribution property of a compound can be estimated from its σ value. Those 
descriptors with smaller σ values give higher contributions. From equation (2.27), it 
can be seen that the change in the distribution property is proportional to 1/σ2. A 
functional dependence study was also done using the procedures described in section 
2.5.3.  
 
5.3 Results and discussion 
5.3.1 BBB penetration 
 A seven-descriptor subset was selected by the descriptor selection algorithm as 
the optimum set for GRNN model of BBB penetration, which is given in Table 5.1. 
Absolute pairwise correlation between the seven descriptors ranged from 0.032 to 
0.561 with an absolute mean correlation of 0.287. For both MLR and MLFN, a nine-
descriptor subset was obtained by the descriptor selection algorithm. The minimum 
costs of 30 scrambled QSPkR models developed using GRNN, MLR and MLFN were 
0.375 (Mean: 0.430, SD: 0.033), 0.300 (Mean: 0.356, SD: 0.027) and 0.338 (Mean: 
0.391, SD: 0.021) respectively. These were significantly larger than the cost of the 
original GRNN-, MLR- and MLFN-developed models, which were 0.042, 0.180 and 
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0.109 respectively. Thus y-randomization showed that the original QSPkR models 
were relevant and unlikely to arise from chance correlation. The prediction results of 
the QSPkR models, given in Table 5.2, show that the QSPkR model developed using 
GRNN was the best model. 
 
Table 5.1 Descriptors selected for BBB GRNN model. 
Range Descriptor Type Sigma 
Min Max 
Explanation 
Ms Constitutional 0.22 1.50 6.94 Mean electrotopological state 
RBN Constitutional 0.48 0 21 Number of rotatable bonds 




0.68 0.00 2.54 Geary autocorrelation - lag 5 / weighted 
by atomic Sanderson electronegativities
SPAM Geometrical 0.32 0.30 0.72 Average span R 
E1p WHIM 0.68 0.20 0.89 1st component accessibility directional 
WHIM index / weighted by atomic 
polarizabilities 
R2v GETAWAY 0.66 0.10 1.14 R autocorrelation of lag 2 / weighted by 
atomic van der Waals volumes 
 
Table 5.2 Predictive capabilities of BBB QSPkR models on independent validation 
set. 
Method r2 Rs a MSE 
GRNN 0.701 0.825 0.130 
MLR 0.649 0.782 0.154 
MLFN 0.662 0.802 0.147 
a Spearman rho coefficient 
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 The ranking of the descriptors in the GRNN-developed model, which is 
determined by the individual sigma values, is in the following decreasing order: Ms, 
SPAM, RBN, R2v, GATS5e, E1p and piPC08. The frequency at which individual 
descriptors were selected during the ten genetic algorithm descriptor selection runs 
can be used to determine the relevance of the descriptors for the QSPkR model. 
During the ten genetic algorithm descriptor selections, Ms, RBN and SPAM were 
selected in 50%, 40% and 30% of the GRNN models respectively. Although R2v, 
GATS5e and E1p were not selected by the other nine GRNN models, other similar 
GETAWAY, 2D autocorrelations and WHIM descriptors which are correlated with 
R2v, GATS5e and E1p respectively were selected in five, three and two other GRNN 
models respectively. Only piPC08 had no similar descriptors in other models. Thus 
the majority of the descriptors in the GRNN model were selected more than once by 
the genetic algorithm descriptor selection method and hence these descriptors were 
likely to be important for the prediction of BBB penetration. The artificial testing sets 
prediction results for the first 4 principal components (PCs) of these seven descriptors 
are shown in Figure 5.1. Plots for the fifth to seventh PCs are not shown as they 
explained less than 17% of the total variance of the descriptors and thus likely to 
contain noise rather than useful information. 
 Explained variations of the descriptors showed that the first PC was primarily 
determined by SPAM, with some contributions from R2v, piPC08, Ms and GATS5e. 
SPAM is used to describe long chain molecules and is determined by the size and 
flexibility of a molecule. R2v encodes both molecular structure and van der Waals 
volume of a molecule. piPC08 belongs to the molecular path count type of descriptors, 
which are a useful measure of molecular size and complexity (Todeschini et al. 2000). 
Ms is an electrotopological state descriptor that encodes the electronic and topological 
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information of a molecule. GATS5e encodes both molecular structure and the group 
electronegativity of molecular substituents. The presence of these five descriptors in  











the first PC suggests that the first PC is a measure of molecular size. The artificial 
testing sets show that BBB penetration generally increases with decreasing molecular 
size (Figure 5.1a). This is consistent with the findings that small molecular size is 
necessary for good BBB penetration (Pardridge 1998). On the other hand, this figure 
also suggests that large molecules have better BBB penetration than molecules of 
intermediate size. This finding is consistent with the results from other studies which 
 
CHAPTER 5: DISTRIBUTION 108
showed that increasing molecular volume seems to be correlated with increasing BBB 
penetration (Kaznessis et al. 2001; Platts et al. 2001).  
 E1p was the main contributor to the second PC and encodes information about 
the size, shape, symmetry, atom distribution and polarizability of a molecule (Bravi et 
al. 1997). As E1p encodes multiple characteristics of a molecule, it is not possible to 
clearly determine a relationship between a specific characteristic of a molecule and its 
BBB penetration. However, studies had consistently found the importance of 
size (Pardridge 1998; Kaznessis et al. 2001; Platts et al. 2001), shape (Ooms et al. 
2002; Lobell et al. 2003a) and polarizability (Platts et al. 2001; Abraham 2004) of a 
molecule in determining the log BB of a molecule. 
 The third PC was formed mainly by RBN, and to a lesser extent, by piPC08. 
RBN is related to the flexibility of a molecule. The complex role of molecular 
flexibility in membrane permeation has been found by two studies. One found a 
positive correlation between flexibility and permeation (Iyer et al. 2002) while the 
other found a negative correlation (Veber et al. 2002). This seems to suggest that 
flexibility is an important factor in BBB penetration but its precise effects are 
dependent on the presence of other molecular characteristics. Using the artificial 
testing sets, it was found that compounds with 5 or 6 rotatable bonds had the lowest 
log BB values (Figure 5.1c).  
 The fourth PC was determined primarily by GATS5e and partially by Ms. As 
molecular size was described by the first PC, the fourth PC probably represented the 
electronegativity of a molecule. Electronegativity affects pKa of a compound and thus 
influences molecular charge at physiological pH. This is consistent with findings 
implicating molecular charge in the extent of BBB penetration (Lobell et al. 2003a). 
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5.3.2 HSA binding 
 Table 5.3 shows the optimum descriptor subset of the GRNN model of HSA 
binding. The descriptor subset contained only six descriptors compared to the 10-
descriptor subset of MLR and eight-descriptor subset of MLFN. The absolute 
minimum, maximum and mean of the pairwise correlation between the six descriptors 
of the GRNN model are 0.012, 0.291 and 0.117 respectively. All of the scrambled 
QSPkR models produced during y-randomization had significantly larger costs than 
that of the corresponding original QSPkR models. The minimum cost of 30 scrambled 
QSPkR models for GRNN, MLR and MLFN were 0.234 (Mean: 0.344, SD: 0.048), 
1.374 (Mean: 1.681, SD: 0.151) and 0.258 (Mean: 0.300, SD: 0.023) respectively and 
the cost for the corresponding original QSPkR models were 0.029, 0.053 and 0.050 
respectively. Hence it is unlikely that the original QSPkR models were a result of 
chance correlation. Results of the validation set, given in Table 5.4, shows that the 
GRNN-developed model had a better prediction capability than that of the models 
developed by using MLR or MLFN. 
 Among the six descriptors, only Mor20p and GATS8e were selected in some 
of the other nine GRNN models. However, when similar and correlated descriptors 
were considered, Mor20p, GATS8e, C-040 and H-050 were present in 50%, 50%, 
40% and 40% of the GRNN models respectively. Only RDF040m and SRW07 were 
not selected in other nine GRNN models. The plots of log Khsa against the first four 
PCs, obtained using the artificial testing sets, are shown in Figure 5.2. The last two 
PC accounted for less than 21% of the total variance of the descriptors and are not 
shown. 
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Table 5.3 Descriptors selected for HSA GRNN model. 
Range Descriptor Type Sigma 
Min Max 
Explanation 
SRW07 Molecular walk 
counts 
1.389 0 518 Self-returning walk count of order 07 
GATS8e 2D 
autocorrelations 
0.500 0.00 4.26 Geary autocorrelation - lag 8 / weighted 
by atomic Sanderson electronegativities
RDF040m RDF 1.297 0.24 23.51 Radial Distribution Function - 4.0 / 
weighted by atomic masses 




0.902 0 4 R-C(=X)-X / R-C#X / X-=C=X 
H-050 Atom-centred 
fragments 
0.568 0 7 H attached to heteroatom 
 
Table 5.4 Predictive capabilities of HSA QSPkR models on independent validation 
set. 
Method r2 Rs a MSE 
GRNN 0.851 0.825 0.041 
MLR 0.770 0.822 0.079 
MLFN 0.749 0.851 0.089 
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 The first PC was determined mainly by H-050 and to a lesser extent by C-040. 
H-050 is related to hydrogen bond donating ability of a molecule while C-040 
encodes information on hydrogen bond acceptors. Results from the artificial testing 
set suggest that binding affinity to HSA generally decreases with increasing hydrogen 
bonding ability of a molecule (Figure 5.2a). This is consistent with the findings of a 
HSA QSPkR model of beta-lactams (Hall et al. 2003).  
 Mor20p was the main contributor to the second PC. It is a representation of 
the 3D structure of a molecule and encodes information about the polarizability of a 
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molecule. Hence, in addition to hydrogen bonding, the binding affinity to HSA may 
also be affected by the polarizability of a molecule. 
 The third PC was primarily contributed by SRW07 and RDF040m. SRW07 is 
related to molecular branching and size and in general to the molecular complexity of 
e group electronegativity of molecular substituents. 
ts 
the graph. RDF040m provides information about interatomic distances in the entire 
molecule and also other useful information such as bond distances, ring types, planar 
and non-planar systems, atom types and molecular weight. Thus, the third PC 
probably is a measure of the shape of a molecule. Shape of a molecule has also been 
identified as an important descriptor in other HSA binding studies (Colmenarejo et al. 
2001; Kratochwil et al. 2002). 
 Most of the variances in GATS8e were explained by the fourth PC. GATS8e 
contains information about th
Various QSAR models have identified charge distribution in a molecule (Kratochwil 
et al. 2002), electrostatic interactions (Colmenarejo 2003), and presence and electron 
accessibility of certain molecular substituents (Colmenarejo 2003) as important 
elements for HSA binding. Thus these studies consistently suggested the importance 
of electronic descriptors such as electronegativity in the prediction of HSA binding. 
 The ranking of the descriptors in the GRNN-developed model, in decreasing 
order, is GATS8e, H-050, C-040, Mor20p, RDF040m and SRW07. This sugges
electronic properties are more important factors in determining the binding affinity to 
HSA than the shape of the molecule. This is consistent with findings that HSA can 
bind to a large variety of compounds with different shapes and sizes (Colmenarejo 
2003). Lipophilic descriptors such as log P, which had been identified as an important 
factor for HSA binding in a number of studies (Colmenarejo et al. 2001; Kratochwil 
et al. 2002; Colmenarejo 2003), were absent from the current GRNN-developed 
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model. It is possible that descriptors such as log P do not contain as much information 
as the current descriptor subset for describing molecule-protein 
interactions (Agatonovic-Kustrin et al. 2002). Thus descriptors such as Mor20p and 
RDF040m which encode multiple characteristics of a molecule and have some degree 
of correlation with lipophilicity were included instead. 
 
5.3.3 Milk-Plasma Distribution 
 Genetic algorithm descriptor selection found an optimum descriptor subset of 
d  of the M/P distribution, which is given in Table 
.5. Th
seven escriptors for GRNN model
5 ese seven descriptors had an absolute minimum, maximum and mean pairwise 
correlation of 0.030, 0.476 and 0.169 respectively. A 10- and an eight-descriptor 
subset were found for MLR and MLFN respectively. The minimum cost of 30 
scrambled QSPkR models for GRNN, MLR and MLFN were 1.582 (Mean: 2.080, SD: 
0.407), 1.372 (Mean: 1.659, SD: 0.160) and 1.209 (Mean: 1.659, SD: 0.140) 
respectively. These were significantly larger than the cost of the corresponding 
original QSPkR models, which were 0.358, 0.985 and 0.412 respectively. Hence y-
randomization showed that the original QSPkR models were relevant and unlikely to 
be a result of chance correlation. Table 5.6 shows the testing results of the QSPkR 
models by using the independent validation set. Among the three modeling methods, 
GRNN was the only one that produced a model with reasonable predictive ability. 
Both models developed by MLR and MLFN had computed r2 values of less than 0.5. 
This suggests that GRNN is more suitable than either MLR or MLFN for developing 
QSPkR models of M/P distribution. 
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Table 5.5 Descriptors selected for M/P GRNN model. 
Range Descriptor Type Sigma 
Min Max 
Explanation 
TIE Topological 0.750 4.54 495.50 E-state topological parameter 
GATS3e 2D 
autocorrelations 
0.650 0.46 1.79 Geary autocorrelation - lag 3 / weighted 
by atomic Sanderson electronegativities
HOMT Aromaticity 
indices 
0.220 -28.20 20.43 HOMA total 
Mor23m 3D-MoRSE 1.661 -0.94 1.36 3D-MoRSE - signal 23 / weighted by 
atomic masses 
Mor06p 3D-MoRSE 1.120 -2.39 2.80 3D-MoRSE - signal 06 / weighted by 
atomic polarizabilities 
HATS5e GETAWAY 0.138 0.00 1.12 Leverage-weighted autocorrelation of 
lag 5 / weighted by atomic Sanderson 
electronegativities 
R4u GETAWAY 0.650 0.33 2.99 R autocorrelation of lag 4 / unweighted 
 
Table 5.6 Predictive capabilities of M/P QSPkR models on independent validation 
set. 
Method r2 Rs a MSE 
GRNN 0.677 0.769 0.206 
MLR 0.224 0.460 0.647 
MLFN 0.201 0.408 0.587 
 
 The descriptors TIE, GATS3e, HOMT, Mor23m, Mor06p, HATS5e, and R4u, 
or their similar and correlated counterparts were selected in 20%, 50%, 60%, 30%, 
40%, 30% and 20% of the GRNN models respectively. Seven PCs are generated by 
the PCA of the descriptor subset of the GRNN-developed model. Only the first 5 PCs 
were significant. The plots of M/P ratios against these PCs, obtained from the 
artificial testing sets, are given in Figure 5.3. The sixth and seventh PCs were 
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responsible for less than 12% of the total variance and thus are not shown. The shapes 
of the plots are more complicated than those in Figure 5.1 and Figure 5.2, suggesting 
the tr drugs  pl  i multiple 
sm
 




















 The first PC was contributed by Mor23m, R4u and TIE. Mor23m is a 
representation of the three-dimensional structure of a molecule and encodes 
information about atomic masses in a molecule. R4u and TIE encode the 3D and 2D 
structure of a molecule respectively. GATS3e, Mor06p and HATS5e were grouped 
together in the second PC. Both GATS3e and HATS5e encode molecular structure 
and the group electronegativity of molecular substituents. Mor06p is a representation 
of the three-dimensional structure of a molecule and encodes information about the 
polarizability of a molecule. The third PC
TIE. HOMT encodes information about the  
molecule and was involved in the fourth PC
mainly by Mor06p.  
 The information encoded by the curren
grouped into electronic factors such as 
properties and molecular charge and steric
hese factors have also been found by other studies to be important for the prediction 
f M/P ratios (Atkinson et al. 1990; Begg et al. 1992; Agatonovic-Kustrin et al. 2000; 
gatonovic-Kustrin et al. 2002). The sigma values of the descriptors suggest 
 was determined primarily by HATS5e and 
degree of electron delocalization in the
 with R4u. The fifth PC was contributed 
t descriptor subset can be broadly 
π electrons distribution, charge-transfer 





CHAPTER 5: DISTRIBUTION 117
electronic properties w re more important than steric factors in determining M/P 
ratios. 
 
5.3.4 General considerations 
 In the present study, the prediction capabilities of the GRNN-, MLR- MLFN-
developed models were assessed by using independent validation sets. It is important 
that the results for the independent validation sets truly reflect the generalization 
bility of the QSPkR models. It has been suggested that both training and validation 
d overlapping among the chemical descriptors, while Parzen’s 
e
a
sets should be diverse and the validation sets should be representative of the training 
sets (Rajer-Kanduc et al. 2003; Schultz et al. 2003). The diversity index (DI) of the 
training and validation sets used in the present study are 0.321 and 0.405, 0.135 and 
0.341, and 0.220 and 0.309 for BBB penetration, HSA binding and M/P distribution 
respectively. This suggests that the training and validation sets used in this work are 
sufficiently diverse. The representativity index (RI) between each of the training sets 
and its corresponding validation sets are 0.752, 0.590, and 0.645 for BBB penetration, 
HSA binding and M/P distribution respectively. These RI values suggest that the 
validation sets are representative of the training sets. 
 The GRNN models developed in this study may not be the optimum because 
of the correlations an
nonparametric estimator (Equation (2.18)) normally requires that these descriptors are 
statistically independent. However, various studies have shown that descriptor 
correlation does not drastically affect the predictive ability of a GRNN model (Currit 
2002; Mosier et al. 2002; Mosier et al. 2003; Niwa 2003). In one study, good 
predictive results were obtained even with pairwise correlation between descriptors of 
up to 0.94 (Currit 2002). The maximum pairwise correlation between descriptors for 
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the BBB penetration, HSA binding and milk-plasma distribution study is 0.561, 0.291 
and 0.476 respectively. Thus intercorrelation among the descriptors is not expected to 
gnificantly affect the predictive ability of the GRNN models generated in this study. 
However, intercorrelation among the descriptors may increase the complexity of the 
GRNN models by obscuring models consisting of fewer or more interpretable 
descriptors (Mosier et al. 2003). This problem can be partially alleviated by using PCs 
instead of individual descriptors for the explanation of the QSPkR model. The 
grouping of similar descriptors in a single PC enables the explanation of the GRNN 
models to be made in terms of simple molecular characteristics instead of the more 
abstract molecular descriptors. 
 The CPU time needed for developing GRNN models is faster than that of 
MLFN but slower than that of MLR. During the prediction process, GRNN-developed 
models require substantially higher memory and CPU time than models developed by 
using MLR and MLFN, especially when large training sets are involved. This is 
because GRNN uses every compound in the training set to facilitate the prediction of 
the property of new compounds. Such a problem can be alleviated by the use of 
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5.4 Conclusion 
us unlikely to overfit. Most of the non-linear methods 
 Future development of 
tors that can be easily translated back to the molecular structure will further 
enhance the interpretability of GRNN developed models. 
 
 Results from this work suggest that GRNN is a potentially useful method for 
developing QSPkR models from a diverse set of drug data. QSPkR models developed 
using GRNN for three drug distribution properties – BBB penetration, HSA binding, 
and M/P distribution – were tested and compared with those developed by using a 
linear method, MLR, and a non-linear method, MLFN. All the GRNN-developed 
models showed better prediction capability than the corresponding MLR- or MLFN-
developed models. This suggests that the GRNN-developed models are not more 
flexible than is necessary and th
including neural networks are incapable of providing explicit relationships between 
the predicted properties and the molecular features of the compounds. The use of 
multi-sigma GRNN models and PCA may be helpful for partially solving this 
problem. The individual values for each descriptor provide a useful hint about its 
contribution to the distribution properties. PCA, when coupled with specially 
designed artificial testing sets, may provide a rough guide for the influence of 
molecular characteristics on drug distribution properties.
descrip
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Chapter 6 
P ction of Drug Metabolism and Elimination, Part I: 
 
 The use of consensus SVM model strategy to improve the prediction 
accuracies of substrates and inhibitors of three cytochrome P450 isoenzymes, 3A4, 
2D6 and 2C9 is presented in this chapter. Physicochemical and structural properties 
of compounds that are important for the identification of substrates and inhibitors 





 Drug metabolism is a process whereby a drug is modified by a metabolizing 
enzyme, and these processes play important roles in pharmacokinetics and therapeutic 
actions of drugs (van de Waterbeemd et al. 2003). For instance, lipophilic drugs need 
to be metabolized to hydrophilic metabolites so that they can be readily 
excreted (Smith et al. 1997a). Although the primary site of drug metabolism is in the 
liver, metabolism can also occur in the intestines, blood and other tissues. 
Profiles of drug metabolism has increasingly become an important 
consideration in early stages of drug development because of the profound effect of 
metabolism on such important drug properties as metabolic stability, drug-drug 
interactions and drug toxicity (Li 2001; van de Waterbeemd et al. 2003). Lower 
metabolic stability of a drug generally reduces its efficacy as it becomes more 
difficult to reach an adequate therapeutic concentration at a target site. Whereas 
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higher metabolic stability of a drug may lead to harmful effect because of the 
prolonged half-life (Keseru 2001). A significant portion of adverse drug reactions has 
inhibition or induction of its metabolic enzyme by 
another drug (Ekins et al. 2001; Molnar et al. 2002). Drug metabolism is also known 
to produce metabolites more toxic than their parent compound (Li et al. 1995). 
There are mainly two phases in drug metabolism processes. The first involves 
phase I enzymes responsible for drug oxidation, reduction or hydrolysis. The second 
involves phase II enzymes responsible for drug conjugation of the phase I metabolite 
with a water-solubilizing endogenous moiety (Long et al. 2003). The cytochrome 
P450 isoenzymes are responsible for most of the phase I metabolism processes (Smith 
et al. 1997a; de Groot et al. 2002), with CYP3A4, CYP2D6 and CYP2C9 mediating 
ly 70% of all phase I metabolism (Lewis et al. 2002). CYP3A4 
 substrates 
contain
been attributed to drug-drug interactions that involve the interference of the normal 
metabolism of a drug due to the 
the metabolism of near
is responsible for the metabolism of over 50% of drugs (Smith et al. 1997a; Smith et 
al. 1997b; Zuegge et al. 2002) and its ability to metabolize a wide variety of drugs of 
varying molecular weight and physicochemical properties is attributed to its relatively 
large active site that facilitates weak hydrophobic interactions with its 
substrates (Smith et al. 1997a; Smith et al. 1997b; Long et al. 2003). CYP2D6 is a 
polymorphic enzyme primarily responsible for the metabolism of
ing a basic nitrogen (Langowski et al. 2002), which includes antiarrhythmics, 
antidepressants and beta-blockers (Susnow et al. 2003). Its metabolism activity is in 
many cases facilitated by an ion pair interaction between an aspartic acid residue at 
the active site and a protonated nitrogen atom of the substrate (Langowski et al. 2002). 
CYP2C9 is primarily involved in the metabolism of many polar drugs that are ionized 
at physiological pH, such as ibuprofen, naproxen, diclofenac and 
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sulphaphenazole (Smith et al. 1997b; Ekins et al. 2000a). Most of the substrates of 
CYP2C9 contain an aromatic group, and drug-enzyme interaction has been attributed 
to the π-π interactions between the aromatic groups of the substrate and specific 
residue at the binding site (Langowski et al. 2002) and hydrogen bonding (de Groot et 
al. 2002). Therefore, prediction of inhibitors, substrates and inducers of these P450 
isoenzymes is important for analysis of drug metabolism and for developing efficient 
tools for screening drugs of appropriate metabolism profiles.  
 Several computer prediction systems have been developed by using statistical 
learning methods for identification of inhibitors of specific P450 isoenzymes. Zuegge 
et al (Zuegge et al. 2002) developed a filter for predicting CYP3A4 inhibition by 
using a linear partial least square-based approach, which gives an accuracy of 93% for 
29 inhibitors and 86% for 21 non-inhibitors. Another filter for prediction of CYP3A4 
inhibition was developed by Molnar and Keseru (Molnar et al. 2002) by using neural 
networks, which gives an accuracy of 91.7% for 36 inhibitors and 88.9% for 36 non-
inhibitors respectively. A consensus filter for predicting CYP2D6 inhibitors was 
developed by Susnow and Dixon (Susnow et al. 2003) using recursive partitioning, 
which gives an accuracy of 100% for 10 inhibitors and 76% for 41 non-inhibitors. 
Ekin et al (Ekins et al. 2003) also used recursive partitioning to develop filters for 
predicting CYP3A4 and CYP2D6 inhibitors, which gives a Spearman’s ρ value of 
0.48 and 0.61 for a test set of 98 compounds respectively. The success of these 
methods raises an interest in the exploration of other statistical learning methods that 
have been used in a variety of drug studies (Trotter et al. 2001; Doniger et al. 2002; 
Cai et al. 2003). 
The aim of this work is to explore the use of support vector machine (SVM) 
for facilitating the prediction of substrates and non-substrates, and inhibitors and non-
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inhibitors of P450 isoenzymes. A genetic algorithm-based descriptor selection 
method (Gao et al. 2002; Frohlich et al. 2003) is used to select relevant molecular 
descriptors for SVM classification of the substrates and inhibitors of P450 isoenzymes. 
Because of the high number of redundant and overlapping descriptors, many sets of 
descriptors, which describe similar overall physicochemical properties but are derived 
from slightly different algorithms and parameters, can be selected by this genetic 
algorithm (GA) with different random seed. Consensus modeling strategy has been 
trodu
 
in ced for developing prediction systems based on multiple descriptor 
sets (Gramatica et al. 2004). In this work, this strategy was applied to the 
development of consensus SVM (CSVM) classification systems for the prediction of 
inhibitors and substrates of P450 isoenzymes by using multiple descriptor sets 
generated from GA of different seeds. 
 Our method was first applied to the prediction of the inhibitors of CYP3A4 
and CYP2D6 by using a substantially higher number of inhibitors and non-inhibitors 
than those in earlier studies (Molnar et al. 2002; Zuegge et al. 2002; Susnow et al. 
2003), which serves as a test of the capability of our method. It was then used for the 
prediction of the inhibitors of CYP2C9 and substrates of CYP3A4, CYP2D6 and 
CYP2C9. The relevance of the selected descriptors by the CSVM methods to drug 




Inhibitors and substrates of CYP3A4, CYP2D6 and CYP2C9 P450 
isoenzymes were collected from various sources (Lacy et al. 2002; Rendic 2002; 
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Flockhart 2003; MICROMEDEX 2003a). In order to ensure that interlaboratory 
variations in experimental protocols do not significantly affect the quality of the data 
sets, the most common range of Ki values for the compounds investigated in more 
than one sources was used to select compounds as inhibitors or substrates (Susnow et 
al. 2003). The generated datasets are composed of 241 inhibitors and 368 substrates 
for CYP3A4, 180 inhibitors and 198 substrates for CYP2D6, and 167 inhibitors and 
144 substrates for CYP2C9. Non-inhibitors and non-substrates are seldom described 
in the literature and few of these compounds are specified in a known chemical 
database. For instance, a comprehensive search of the literature sources (Lacy et al. 
2002; Rendic 2002; Flockhart 2003; MICROMEDEX 2003a) identified only seven 
non-inhibitors and six non-substrates for CYP3A4, nine non-inhibitors and eight non-
substrates for CYP2D6, and eight non-inhibitors and seven non-substrates for 
k, this method was used to generate 
on-inhibitors or non-substrates of the P450 isoenzymes. From this procedure, 461 
non-inhibitors and 334 non-substrates for CYP3A4, 522 non-inhibitors and 504 non-
substrates for CYP2D6, and 535 non-inhibitors and 558 non-substrates for CYP2C9 
e ubstrates and inhibitors of an isoenzyme were denoted as belonging 
the 
CYP2C9. In an earlier study of the prediction of CYP3A4 inhibitors (Molnar et al. 
2002), non-inhibitors of the enzyme were selected from those well-studied 
compounds that are known inhibitors/substrates/agonists of proteins other than that 
enzyme and there is no report that any of these is an inhibitor of that enzyme. Such a 
method is based on the assumption that, as they have been well studied, if these 
compounds have not been reported to be inhibitors or substrates of a specific enzyme, 
it is highly likely that they are not. In this wor
n
were g nerated. S
to positive class (D+) and non-substrates and non-inhibitors of the isoenzyme 
were denoted as belonging to the negative class (D-) of the isoenzyme. 
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 Representative training and validation sets were constructed from the datasets 
by using the removal-until-done method (section 2.2.2.3). The number of compounds 
in the training and validation sets for the inhibitors or substrates of each of these 
enzymes are given in Table 6.1. 
 
Table 6.1 Number of compounds in the training, independent validation, modeling 
P450 isoenzymes. 
training set testing set 
training and modeling testing sets for the inhibitors/substrates of different cytochrome 
Training set Validation set Modeling Modeling Dataset CYP 
D+a D-b D+a D-b D+a D-b D+a D-b
3A4 216 386 25 75 196 306 20 80 
2D6 160 442 20 80 143 359 17 83 
Inhibitors / 
non-inhibitors 
2C9 149 453 18 82 134 368 15 85 
3A4 312 290 56 44 256 246 56 44 
2D6 169 433 29 71 149 353 20 80 
Substrates / 
non-substrates 
2C9 130 472 14 86 121 381 9 91 
a Inhibitors or substrates 
 
 Prediction accuracy of statistical learning systems is known to be strongly 
affected by the diversity of samples used in the training set (Rajer-Kanduc et al. 2003; 
Schultz et al. 2003). Independent validation sets have frequently been used for 
evaluating the predictive performance of these classification systems, and these need 
also to be diverse and representative of the samples studied in order to accurately 
assess the capabilities of the prediction systems (Rajer-Kanduc et al. 2003; Schultz et 
al. 2003). The diversity index (DI) of the six training sets and six validation sets are in 
the range between 0.001 and 0.005 and between 0.002 and 0.020 respectively. The 
low DI value of the D+ compounds and D- compounds for all of th
b Non-inhibitors or non-substrates 
e training and 
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validation sets suggest that these datasets are sufficiently diverse. The representativity 
index (RI) value between each of the training sets and its corresponding validation set 
is in the range between 0.446 and 0.511, which suggests that these validation sets are 
representative of their corresponding training sets and these validation sets are 
itable for assessing the systems developed in this work. 
6 olecul uct scr
 This study used the same set of 1497 DRAGON descriptors as the 
distribution study (section 5.2.2). Moreover, an additional set of 105 
electrotopo e descriptors  et . 1999) and 5 linear solvation energy 
relationship desc rs (Platts et al. 1999) were com d usin ur n 
developed code. Our code has bee sted a nu r o pounds used in earlier 
s re t cur pu  desc tors
 
.2.3 Descriptor selection 
su
 
.2.2 M ar str ures and de iptors 
 molecular 
logical stat (Kier  al
ripto pute by g o ow
n te on mbe f com
tudies to ensu he ac acy of the com ted rip . 
6
 A GA (section 2.3.3.2) was used to remove descriptors irrelevant to the 
prediction of CYP450 inhibitors and substrates. The retained descriptors from this 
process were used for representing the compounds studied in this work. All of the 
descriptors in the training set were first normalized in the range of -1 to 1 by using 
equation (2.4) before applying the GA-based descriptor selection method. At the end 
of the GA-based descriptor selection process, the highest ranked descriptor subset was 
used to construct the final SVM classification system.  
 In the descriptor selection process, ranking of the different descriptor subsets 
can be determined by using either 10-fold cross-validation, 5-fold cross-validation or 
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a modeling testing set. Our analysis of the 30 P450 isoenzyme SVM classification 
systems derived from each of these cross-validation methods showed that the 
modeling testing method gives the best performance, and thus this validation method 
was used in all of the descriptor selection processes in this study. The modeling 
testing set was derived by dividing the original training set into a modeling training 
t and modeling testing set of 502 and 100 compounds respectively by using the 
removal-until-done method (section 2.2.2.3). The modeling training and modeling 
testing sets for the inhibitors or substrate of each of these enzymes are given in Table 
6.1 above. The modeling training set was used for constructing the SVM classification 
systems in the GA. Matthews correlation coefficient (MCC) (equation (2.33)) was 
used as the fitness function for GA optimization. 
 
Two types of CSVM methods were used. The first is a ‘positive majority’ 
consensus SVM classification system (PM-CSVM), which classifies a compound as 
D+ if the majority of its SVM classification systems classify the compound as 
D+ (Eriksson et al. 2003). A PM-CSVM requires an odd number of SVM 
classification systems to prevent ambiguity in its prediction. The second is a ‘positive 
probability’ consensus SVM classification system (PP-CSVM), which explicitly 
computes the probability for a compound to be D+ using the following 
formulas (McDowell et al. 2002): 
se
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where Pr( | )i iS P
+  is the posterior probability that a compound is D+ given the 
classification result from SVM classification system i and iα+  and iα− is the sensitivity 
i D+
D- respectively. In the absence of the knowledge about the ratio of D+ to D- 
tentatively set at 0.5. Sensitivity and specificity of SVM classification system i were 
all optimized SVM classification systems for consensus modeling. The first method is 
(SE) and specificity (SP) of SVM classification system i respectively. Equation (6.1) 
or (6.2) was used when SVM classification system  classifies the compound as  or 
compounds in the population, the prior probability of a compound to be D+ is 
estimated by using the validation method of the descriptor selection process. 
 There are two methods for using GA-based descriptor selection process to find 
to perform a single run of GA-based descriptor selection and record all the SVM 
ification systems in the final population that have a certain level of accuracy. The 
orm multiple runs of GA-based descriptor selection using 
selection process was repeated for 101 times, 
producing a pool of SVM classification systems. SVM classification systems were 
randomly selected, with replacement, from the pool of SVM classification systems to 
m nine classes of CSVMs, each containing 11, 21, 31, 41, 51, 61, 71, 81 or 91 
SVM classification systems. This random selection of SVM classification systems 
class
second method is to perf
different random seeds and select the best SVM classification system from each run 
for consensus modeling. The current study uses the second method to obtain SVM 
classification systems for consensus modeling because our analysis of the two 
methods showed that the top few SVM classification systems from the first method 
tends to be similar to one another whereas SVM classification systems from the 
second method tends to be more diverse.   
 To determine an appropriate number of SVM classification systems for the 
CSVM methods, the descriptor 
for
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from the pool of SVM classification systems and construction of CSVMs were 
repeated 1000 times. Our analysis of these nine CSVMs classes showed that the best 
accuracies for the two types of CSVM methods were obtained when at least 81 SVM 
off at higher number of SVM classification systems. Thus, 81 SVM classification 
are used for developing CSVMs for all the datasets in this work. 
 
classification systems were used to develop CSVMs, and the accuracies roughly level 
systems appear to be the optimum number of systems for constructing CSVMs, which 
.3 R6 esults 
 The SVM classification system with the best cross-validation accuracies was 
selected from the 81 SVM classification systems as the “best-trained” single SVM 
classification system. This selection method has been used by other studies that used 
GA as the descriptor selection method (Sutherland et al. 2003b). A PM-CSVM and a 
PP-CSVM were constructed by using the 81 SVM classification systems. The 
prediction accuracies of these three systems were determined by using the 
independent validation set, which are given in Table 6.2.  
 
 
CHAPTER 6: METABOLISM AND ELIMINATION, PART I 130
Table 6.2 Accuracies of the “best-trained” single SVM classification systems, PM-
inhibitors by using the independent validation sets. 
CSVM and PP-CSVM for the prediction of CYP3A4 and CYP2D6 inhibitors/non-
CYP Classification system TP FN TN FP SE SP Q MCC 
“Best-trained” single SVM 
classification system 
20 5 72 3 80.0 96.0 92.0 0.782 3A4 
PM-CSVM 21 4 75 0 84.0 100.0 96.0 0.893 
PP-CSVM 23 2 73 2 92.0 97.3 96.0 0.893 
ed” single SVM 
classification system 
15 5 77 3 75 96.3 92.0 0.742 “Best-train2D6 
PM-CSVM 16 4 78 2 80.0 97.5 94.0 0.807 
PP-CSVM 18 2 76 4 90.0 95.0 94.0 0.821 
  
 It is found that both CSVM methods give better accuracies than that of the 
“best-trained” single SVM classification system. Moreover, PP-CSVM gives similar 
sensitivities and slightly better specificities, while PM-CSVM gives slightly lower 
sensitivities and slightly better specificities than those of earlier classification systems 
r prediction of inhibitors of CYP3A4 (Molnar et al. 2002; Zuegge et al. 2002) and 
CYP2D6 (Susnow et al. 2003). Thus PP-CSVM appears to be more useful than PM-
CSVM for predicting inhibitors and substrates of P450 isoenzymes. 
 The accuracies of PP-CSVM for the prediction of inhibitors of CYP2C9 and 
substrates of CYP3A4, CYP2D6 and CYP2C9 are given in Table 6.3. The prediction 
accuracies of these CSVMs are at a similar level as those of the inhibitors of CYP3A4 
and CYP2D6, which suggest that these CSVM methods, particularly PP-CSVM, are 
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Table 6.3 Accuracies of PP-CSVM for the prediction of CYP2C9 inhibitors/non-
inhibitors and CYP3A4, CYP2D6, and CYP2C9 substrates/non-substrates by using 
the independent validation sets. 
Dataset FN  %)  (%) MCYP TP TN FP SE (%) SP ( Q  CC 
Inhibitors / non-
inhibitors 
2C9 16 2 79 3 88.9 96.3 95.0 0.835 
3A4 55 1 40 4 98.2 90.9 95.0 0.899 
2D6 28 tes 
2C9 
1  96 4 5.0 0.
Substrates / non-
a
12 2 85 1 85.7 98.8 97.0 0.872 




 ence between the sp icities of th cu  C s h  
stems from earlier studies may be due to the difference in the number 
 
hich uses a more 
.4 iscussion 
Overall pr s 
The differ ecif e rrent SVM and t ose of
classification sy
and diversity of D- compounds used for training the classification systems. In our 
work, the number of D- compounds in the training set ranges from 290 to 472, 
whereas earlier classification systems were developed by using 41 to 145 D- 
compounds. Statistical learning methods require a large number of compounds for 
development of classification systems. In addition, diversity of the training sets has 
been shown to affect the applicability domain of qSPkR models (Dimitrov et al. 2005).
Therefore it is not surprising that the methods of the current work, w
diverse and larger number of D- compounds, give higher specificities than those of 
earlier studies. Another possible reason for the improved specificities is the use of 
SVM, which has been found to be consistently superior to other classification 
methods in most classification problems (Burbidge et al. 2001; Czerminski et al. 2001; 
Meyer et al. 2003).  
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 For all of the datasets, with the exception of the CYP3A4 substrates/non-
substrates dataset, the number of D- compounds is always higher than the number of 
D+ s to predict 
unknown compounds as D-, resulting in higher number of false negatives. However, 
previous studies suggest that SVM are n sig ntly cted unb d 
d ai et al 3; sm n 2 ), eci han 0 
compounds of each class in ing set (Han et al.
in this work contains at least 130 compounds of each class in the training set and thus 
n set is not expected to significantly affect the predictive ability of 
the SVM classification systems. 
 compounds. This may create a bias of the SVM classification system
ot nifica  affe  by alance
atasets (C . 200 Les an 004 esp ally if there are more t 80-10
 the train  2004). All of the datasets used 
the u balanced data
 
6.4.2 Evaluation of prediction performance 
 The results of our SVM systems were compared with those of several 
statistical learning methods including multiple linear regression (MLR), partial least 
squares (PLS), logistic regression (LR), C4.5 decision tree (DT) and k nearest 
neighbour (kNN). GA was used to determine the optimum descriptor subsets for each 
of these classification methods by using 30 different random seeds, from which 30 
separate classification models were generated for each method. The prediction 
accuracies of these classification models were determined by using the independent 
validation set. Table 6.4 gives the results for CYP3A4 substrates/non-substrates. The 
accuracies for the other P450 isoenzymes datasets are similar and thus are not given 
here. It was found that the SVM classification systems give the highest prediction 
accuracies than those of other methods. 
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T .4 Average accuracies of different statistical learning classification systems 
validation sets. 
a a a a
able 6
for the prediction of CYP3A4 substrates/non-substrates by using independent 
Classification method SE (%) SP (%) Q (%) MCC
MLR 86.1 (3.9) 71.4 (4.4) 79.6 (2.9) 0.586 (0.060) 
LR 83.8 (3.9) 71.0 (5.1) 78.1 (3.0) 0.555 (0.063) 
PLS 79.9 (5.8) 72.5 (5.2) 76.7 (3.7) 0.528 (0.073) 
C4.5 DT 75.5 (6.8) 66.4 (6.7) 71.5 (4.3) 0.423 (0.087) 
kNN 92.4 (2.0) 82.6 (3.4) 88.1 (1.7) 0.759 (0.034)  
SVM 98.0 (1.4) 85.3 (3.1) 92.4 (1.2) 0.849 (0.024) 
a
 
 To determine whether t
 Numbers in parenthesis are the standard deviations. 
he selected descriptors of the SVM classification 
stems include those irrelevant for the prediction of the inhibitors or substrates of the 
respective enzymes, 10 groups of classification systems were generated by using the 
GA-based descriptor selection method. These groups are SVM100, SVM200, SVM300, 
400 500 600 700 800 900 1000
tain irrelevant descriptors. Similar 
sy
SVM , SVM , SVM , SVM , SVM , SVM , and SVM , in which the 
subscript denotes the number of descriptors used. Each group contains 30 SVM 
classification systems. The prediction accuracies of these SVM classification systems 
were determined by using the independent validation sets. Table 6.5 gives the results 
for the CYP3A4 substrates/non-substrates, which shows that prediction accuracies 
begin to decrease when more than 400 descriptors are used in a SVM classification 
system. This suggests that the maximum number of relevant descriptors for the 
CYP3A4 substrates/non-substrates dataset is around 400. Because the original 81 
SVM classification systems for the CYP3A4 substrates/non-substrates dataset contain 
214 to 402 descriptors, our results seem to suggest that the original 81 SVM 
classification systems are unlikely to con
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conclusions are also made for the rest of the P450 isoenzymes datasets based on our 
computational studies. 
 
Table 6.5 Average accurac  grou M cla  sy  
prediction of CYP3A4 substrates/non-substrates by using independent validation sets. 
umber of 
tors 
SE (% SP Q
ies of 10 ps of SV ssification stems for the
N
descrip
)a (%)a  (%)a MCCa
100 93.0 (3 80.4 87 0.1)  (4.4) .5 (2.7) .747 (0.054) 
200 96.7 (2 83.0 90 0
92.6 (1.9) 0.853 (0.037) 
400 98.0 (1.3) 82.4 (3.4) 91.1 (1.6) 0.825 (0.032) 
611 
900 99.9 (0.3) 45.7 (2.4) 76.1 (1.0) 0.565 (0.017) 
.0)  (3.3) .7 (1.9) .814 (0.039) 
300 98.0 (1.6) 85.6 (3.6) 
500 98.2 (1.0) 80.9 (3.1) 90.6 (1.4) 0.815 (0.028) 
600 98.6 (0.8) 74.5 (3.3) 88.0 (1.5) 0.769 (0.028) 
700 99.3 (0.9) 66.4 (5.4) 84.8 (2.3) 0.715 (0.040) 
800 100.0 (0.0) 51.5 (3.1) 78.7 (1.4) 0. (0.024) 
1000 100.0 (0.0) 37.3 (3.2) 72.4 (1.4) 0.500 (0.026) 
a Numbers in parenthesis are the standard deviations. 
 
 It has been shown that chance correlations may occur during descriptor 
selection especially if the number of descriptors available for selection is 
large (Topliss et al. 1979; Jouan-Rimbaud et al. 1996). Y-randomization (section 
2.5.2) has been frequently used to determine the probability of chance correlation 
during descriptor selection processes (Manly 1997; Leardia et al. 1998). In this work, 
y-randomization was repeated for 81 times. The average Matthews correlation 
coefficient of these scrambled SVM classification systems derived by using the 
independent validation sets were found to be in the range between 0.189 and 0.288, 
which are significantly lower than those of the original SVM classification systems, 
which are in the range between 0.783 and 0.852. This suggests that the original SVM 
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classification systems are relevant and unlikely to arise as a result of chance 
correlation. 
 A frequently used method for checking whether a prediction system is 
vali thods ose det  by us ependent ation 
sets 2004). Because descriptor selection was performed by using the 
modeling testing sets as the cross-validation method, an overfitted classification 
system ch higher o  
sets th r the inde alidatio s show  6.6, the prediction 
accuracies of the SVM  based o deling t  and n 
indepe t validatio e simila uggests SVM n 
systems in this work are unlikely to overfit. 
 
overfitted is to compare the prediction accuracies determined by using cross-
dation me
 (Hawkins 
with th ermined ing ind valid
 is expected to have mu  prediction accuracy for the m deling testing
an fo pendent v n sets. A n in Table
 systems n the mo esting sets those based o
nden n sets ar r. This s  that the  classificatio
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Table 6.6 Comparison of the average accuracies of SVM classification systems for 
testing sets a
the prediction of inhibitors/substrates of different P450 isoenzymes by using modeling 
nd independent validation sets. 

































































(7.3) (1.4) (0.8) (0.028) (5.4) (1.6) (1.7) (0.054) 
2D6 84.6 98.9 96.0 
Substrates / non-
substrates 



























a Numbers in parenthesis are the standard deviations. 
 
6.4.3 The selected descriptors 
 The majority of the selected descriptors in our SVM classification systems are 
composite descriptors, which can be divided into three groups: 3D-MoRSE, RDF and 
Randic molecular profiles. 3D-MoRSE descriptors, which are representations of the 
3D structure of a molecule and encode features such as molecular weight, van der 
Waals volume, electronegativities and polarizabilities, have been used for the 
classification of dopamine D1 and D2 agonists and modeling the binding of steroids 
to corticosteroid binding globulin (Schuur et al. 1996). RDF descriptors provide 
information about bond lengths, ring types, planar and nonplanar systems, atom types, 
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and molecular weight and have been used for pharmacokinetic studies (Wegner et al. 
2004). Randic molecular profiles measure interactions between atoms in a molecule 
and encode information on molecular shape, which is an important factor in ligand-
enzyme interactions. Bec  sh and mical complementarily between a ligand 
a  ar o for d me ng, no ri ha  
t ses of 3D d to h ro fo on h h  
electronegativities, polarizabilities and shape of a molecule, are frequently selected by 
the descriptor selection process. 
 Because composite d to nc ul p oc c  
s ts he ec it ffic ex fr he sc  
i n about whic c o r characteristics are imp   
inhibitors and substrates of these P450 isoenzym ss, it is possible to r 
some information from non-composite descriptors. As many descriptors are 
overlapping and some o  ed t, it is mor ro  t u  
nd discuss their contribution to the 
inhibitor/substrates predictions at the class level. Table 6.7 gives the classes of non-
s  our computations. It is found that shape is the 
omina
ause ape  che
nd an enzyme
hree clas
















escrip rs e ode m tiple hysic hemi al and
tructural aspec
nformatio










es. Nonethele  infe
f them are r undan e app priate o gro p them
into classes of descriptors of similar properties a
compo ite descriptors selected by
d nt factor involved in ligand-P450 isoenzyme interaction. This is not surprising 
because shape complementarity is important for ligand-protein interactions. In 
addition to the shape descriptors, electrostatic and hydrophobic interactions are found 
to be the dominant forces involved in ligand-P450 isoenzyme interaction. Descriptors 
that describe hydrogen bonding, also appear to be important for the ligand-P450 
isoenzyme interactions, which is consistent with the findings that hydrogen bonds are 
involved in the ligand-P450 isoenzyme interactions (de Groot et al. 2002). 
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Table 6.7 Important descriptor classes selected for the prediction of 













inhibitors/substrates of different P450 isoenzymes. 
(%) (%) 
3A4 20.4 3.6 3.3 8.8 56.8 7.1 
2D6 20.5 2.4 2.5 10.0 57.1 7.5 non-inhibitors 
2C9 20.1 2.0 2.9 8.8 59.0 7.2 
3A4 21.0 
Inhibitors / 
2.8 1.9 9.5 57.2 7.5 Substrates / 
2D6 18.9 3.1 3.5 8.5 59.7 6.3 non-substrates 
2C9 19.1 3.5 3.0 9.4 58.2 6.8 
 
selected descriptors, S, nHAcc, nHDon, MLOGP, MW, and SPH. These descriptors 
bond acceptor, hydrogen bond donor and hydrophobicity, and size and shape of the 
MLOGP is the Moriguchi Log P (Moriguchi et al. 1992), MW is the molecular weight 
compounds of all the various datasets are given in 
 It is also possible to roughly distinguish between D+ and D- compounds and 
to roughly distinguish between inhibitors and substrates from the values of six 
are representative of the four dominant interaction forces, electrostatic, hydrogen 
compounds respectively. S is the combined dipolarity/polarizability, nHAcc and 
nHDon, are the number of acceptor and donor atoms for hydrogen bonds respectively, 
and SPH is the spherosity. The average values of these four descriptors for D+ and D- 
are generally larger in size, less spherical in shape, more hydrophobic and have more 
hydrogen bonding sites than non-substrates. Inhibitors of CYP3A4 are generally less 
donors and acceptors. Substrates of CYP2D6 are generally smaller in size, more 
hydrophobic than non-substrates and contain one hydrogen bond donor. There are 
Table 6.8. Substrates of CYP3A4 
hydrophobic than substrates but are larger in size and contained more hydrogen bond 
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only minor differences between inhibitors and substrates of CYP2D6, which suggest 
that there is c r o ra C  
Substrates of CYP2C9 g ally ar  hydrophobic than inhibitors of CYP2C9 
but are smaller in size and have lesser hydrogen bonding capacity. 
 







he inhibit rs and subst tes of YP2D6.
Table 6.8 D
D+ and D- c
eren
pou
 the of d tors im
A valueDataset CYP scriptoDe r 
D+ D- 
S 2.56 4)  (1.1  (1.2 2.36 2) 
n c 6.47 5)  (2.6
nHDon 2.27 (2.44) 1.23 (1.40) 
MLogP 1.83 (2.02) 1.96 (2.06) 
MW 417 (185) 313 (116) 
3A4 
HAc  (4.0 4.59 4) 
SPH 0.77 (0.13) 0.77 (0.13) 
S 2.17 (1.00) 2.52 (1.20) 
nHAcc 4.57 (2.70) 5.47 (3.48) 
nHDon 1.57 (1.81) 1.59 (1.92) 
2D6 
SPH 0.78 (0.13) 0.77 (0.13) 
S 2.56 (1.21) 2.39 (1.15) 
MLogP 2.54 (1.76) 1.70 (2.09) 
MW 355 (125) 346 (159) 
nHAcc 5.31 (2.65) 5.21 (3.50) 
nHDon 1.49 (1.52) 1.62 (1.99) 
2C9 
SPH 0.76 (0.13) 0.78 (0.13) 
S 2.56 (1.15) 2.29 (1.17) 
MLogP 1.78 (2.11) 1.96 (2.02) 








nHDon 1.72 (1.99) 1.44 (1.75) 
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MLogP 2.20 (1.99) 1.60 (2.06) 
MW 379 (157) 315 (137) 
SPH 0.76 (0.13) 0.78 (0.13)  
S 2.19 (1.08) 2.53 (1.18) 
nHAcc 4.10 (2.13) 5.68 (3.58) 
nHDon 1.15 (1.22) 1.76 (2.07) 
M 319.6 (9 166) 
2D6 
SPH 0.7 4) 0.77 3) 
MLogP 2.51 (1.74) 1.68 (2.11) 
W 9.8) 360 (
8 (0.1  (0.1
S 2.52 (1.26) 2.41 (1.14) 
nHAcc 4.69 (2.52) 5.38 (3.48) 
nHDon 1.03 (1.14) 1.73 (2.01) 
MLogP 2.05 (2.04) 1.88 (2.05) 
MW 326 (112) 354 (160) 
2C9 
SPH 0.75 (0.14) 0.78 (0.13) 
a Numbers in parenthesis are the standard deviations. 
 
 CYP3A4 has a relatively large active site that facilitates weak hydrophobic 
interactions with its substrates (Smi . 1997a; Sm 1997b al. 
2003). A pharmacophoric model of the substrates suggests that there are four 
important features: two hydrogen bond acceptor, one hydrogen bond donor and one 
hydrophobic region  et al. 1999b). Some of the descriptor classes frequently 
selected by the SVM classification systems for the prediction of substrates and non-
substrates of CYP3A4 are related to rophobicity gen bo ity 
of the molecule. Examples of descr  in these class  ARR, the 
aromatic ratio, aaCH and aasC, which are electrotopological descriptors for carbons in 
arom differences in the distribution of 
intermolecular forces between inhibitors and substrates of CYP3A4 suggest that the 
th et al ith et al. ; Long et 
(Ekins
 the hyd  and hydro nding abil
iptors es include which is 
atic rings, nHAcc and nHDon. The 
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inhibitors have less electrostatic an ophobic int nd m en 
bonding at the binding site than the substrates. 
 The pharmacophoric model for substrates of CYP2D6 consists of a basic 
nitrogen atom and a flat hydrophobic region (Ekins et  
2002). Some of the frequently se
systems for predicting substrates and non-substrates of CYP2D6 matc el. 
Examples of descriptors in these c s include MA ch is al 
electrotopological positive variation topological descriptor and is related to the 
electrophilicity of the molecule, nN, which is the number of nitrogen atoms, and BLI, 
which is the Kier benzene-likeness These descr es are ed 
by the SVM classification systems for predicting inhibitors and non-inhibitors of 
CYP2D6. However, differences in the distribution of intermolecular for en 
inhibitors of CYP2D6 suggest that the inhibitors may have increased electrostatic and 
ydrophobic interactions at the active site. This is consistent with the findings from 
harma
d hydr eractions a ore hydrog
 al. 2001; Langowski et al.
lected descriptor classes by SVM classification 
h this mod
lasse XDP, whi the maxim
index. iptor class also select
ces betwe
h
p cophoric studies of inhibitors of CYP2D6 which suggests that the inhibitors 
have an additional region in which functional groups with lone pairs enhance 
inhibitory potency and a region for hydrophobic groups (Ekins et al. 2001). 
 Descriptors encoding aromaticity, polarity and hydrogen bond donors are 
frequently selected by SVM classification systems for predicting substrates and non-
substrates of CYP2C9. These include aasC, which is the electrotopological state atom 
index for aromatic carbons, MAXDN, which is the maximal electrotopological 
negative variation topological descriptor and is related to the nucleophilicity of the 
molecule, and nHDon. These selected descriptors are consistent with the findings that 
the substrates of CYP2C9 are primarily polar compounds that contains an aromatic 
group and that drug-CYP2C9 interaction is mediated by both hydrogen bonding (de 
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Groot et al. 2002) and π-π interactions at the binding site (Langowski et al. 2002). 
The differences in the distribution of intermolecular forces between inhibitors and 
6.4.4 Potential training errors and misclassified compounds 
 In this work, non-inhibitors and non-substrates were selected from those 
without a report identifying them as an inhibitor or a substrate. There is also a certain 
level of overlapping between non-inhibitors of different CYP subtypes, between non-
and substrates of a particular CYP subtype. A potential problem with this method is 
that a small number of true inhibitors or substrates may be selected as non-inhibitors 
or non-substrates (false negatives). The extent of training errors caused by false 
negatives can be roughly estimated by using experimentally confirmed non-
confirmed non-inhibitors/non-substrates. In the CYP3A4 substrate/non-substrate 
validation set, only irbesartan is a known non-substrate (MICROMEDEX 2003a). In 
the CYP2C9 inhibitor/non-inhibitor validation set, only reboxetine is experimentally 
determined to be a non-inhibitor (MICROMEDEX 2003a). In the CYP2D6 
substrate/non-substrate validation set, only nilvadipine is a known non-
substrate (MICROMEDEX 2003a). In the CYP2D6 inhibitor/non-inhibitor validation 
set, only gatifloxacin is a known non-inhibitor (MICROMEDEX 2003a). All of these 
compounds, except irbesartan, were correctly predicted by the CSVMs to be non-
inhibitors/non-substrates. These results, together with the reported high accuracies of 
the SVM classification systems for other systems (Sorich et al. 2003; Xue et al. 
substrates of CYP2C9 suggest that the inhibitors have fewer hydrogen bonds but 
increased electrostatic interactions at the active site than the substrates. 
 
inhibitors and non-substrates of a specific CYP subtype, and between non-inhibitors 
inhibitors/non-substrates. However, there is only a limited number of experimentally 
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2004c), suggest that by using SVM (Vapnik 1995), the training errors caused by false 
negatives can be kept at a minimum. 
 Table 6.9 gives the list of compounds misclassified by more than 50% of the 
SVM classification systems for each dataset. A possible reason for the 
isclassification of some of these compounds is that some descriptor subsets may be 
inadequate to properly describe these compounds. Examples of these compounds are 
carbamazepine, chlorphenamine, cinnarizine, doxepin, methadone, olanzapine and 
zuclopenthixol, which contain two aromatic rings separated by an atom and irbesartan 
and lorsartan, which contain a highly polar tetrazole ring. Among the misclassified 
non-inhibitors or non-substrates, only irbesartan is a known non-
substrate (MICROMEDEX 2003a). Oxomemazine is a known inducer and 
flurithromycin is a known inhibitor of CYP3A4 (Rendic 2002). Thus it may be 
possible that both oxomemazine and flurithromycin are actually false negatives as 
more than 60% of the CYP3A4 inhibitors in the dataset are both CYP3A4 inhibitors 
and substrates. Similarly, doxepin, which is a known CYP2D6 substrate (Rendic 
2002), may also be a false negative as nearly 50% of the CYP2D6 substrates are both 
CYP2D6 substrates and inhibitors. 
m
 
6.4.5 Comparison of the two CSVM systems 
 The results from our studies show that PP-CSVM gives slightly better 
accuracies than PM-CSVM. This is because individual SVM classification systems in 
PP-CSVM are ranked according to their accuracies and SVM classification systems 
with better accuracies have more influence on the final classification of a compound.  
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Table 6.9 List of misclassified compounds in this worka. 
Dataset CYP Misclassified compounds 









Inhibitors / non-inhibitors 
Sulconazole (D+) 
2C9 Stiripentol (D+) 
Isoconazole (D-) 
Sulconazole (D+) 














2C9 Cinnarizine (D+) 
Losartan (D+) 
Methadone (D+) 
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This is different from PM-CSVM where all individual SVM classification systems, 
r ccuracies, co ute e  final classification of a 
compound. Thus it is expected that PP-CSV ing the contribution from 
SVM classification systems with lower accu  better or at least equal 
accuracies as PM-CSVM. 
 There are two potential problems wit he first is that the prior 
probability, which was tentatively set at 0.5, m s be the most appropriate 
value for representing the ratio of D+ to D- nds in the population. This 
problem can be partially solved by using a large number of individual SVM 
classification systems to construct a CSVM so luence of prior probability 
on the final classification result is reduced. In this study,  
c ere obtained n whe ility was varied from 
0.05 to 0.95 when 81 SVM classification syste t the CSVM. The 
second problem is the difficulty in determining itivities and specificities 
of the individual SVM classification systems, which are required by equations (6.1) 
and (6.2). In the present study, sensitivities an  of the SVM classification 
systems were estimated by using the modeling testing set and have a mean absolute 
difference of 2.0% and 3.4% respectivel  derived by using the 
independent validation set. If sensitivities a f the individual SVM 
classification systems derived from the independent validation set are used in PP-
CSVM, the resultant CSVMs are f  to gi her accuracies, suggesting 
a possible need for a more accurate estim erformance of some SVM 
classification systems. 






 that the inf
we have found that the same
lassification results w  eve n the prior probab
ms used to construc
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ate of the p
 
 
CHAPTER 6: METABOLISM AND ELIMINATION, PART I 146
6.5 Conclusion 
 Results from this work are consistent with earlier studies which suggest that 
consensus classification systems give better predictive performance than single 
classification systems. All of the PP-CSVMs for predicting inhibitors/substrates of the 
three P450 isoenzymes, CYP3A4, CYP2D6 and CYP2C9, show high prediction 
accuracies, with improved specificities compared to earlier studies. A potential 
problem of this work is that the selection criteria for non-inhibitors and non-substrates 
may result in a small number of false negatives. However, the use of SVM in this 
work can help to achieve a balance between training errors and prediction accuracies. 
The accuracies of the SVM classification systems may also be improved by the 
addition of a correction factor to the SVM decision function. The present CSVMs are 
only suitable for distinguishing between inhibitors and non-inhibitors or substrates 
and non-substrates. With the availability of more detailed experimental data, it is 
possible to use multi-class SVM (Angulo et al. 2003) for classification of non-
inhibitors, weak inhibitors and strong inhibitors or SVM regression (Smola et al.) for 
quantitative prediction of the Ki values of inhibitors. Our computational results 
suggest PP-CSVM is better than PM-CSVM for constructing CSVMs for classifying 
inhibitors and substrates of various P450 isoenzymes. Thus CSVMs, particularly PP-
CSVM, are potentially useful for developing filters for prediction of inhibitors and 
substrates of P450 isoenzymes. 
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Chapter 7 
Prediction of Drug Metabolism and Elimination, Part II: 
rug elimination and can be used to determine the 
dosing rate and steady-state concentration of a drug (Toutain et al. 2004). Thus it is 
important to predict the CLtot value of drug leads during drug discovery so that 
compounds with acceptable metabolic stability can be identified and those with poor 
bioavailability can be eliminated.  
Regression Methods 
 
 This chapter describes three machine learning approaches for the prediction 
of total clearance. Several different sets of descriptors are compared for their 
usefulness in modeling total clearance. Important physicochemical and structural 
properties of a compound are also identified by using the new method that is 
introduced in Chapter 5. 
 
7.1 Introduction 
 Drug clearance is measured by a quantity, total clearance (CLtot), which is a 
proportionality constant describing the relationship between a substance’s rate of 
transfer, in amount per unit time, and its concentration, in an appropriate reference 
fluid (Wilkinson 1981). Drug clearance occurs by perfusion of blood to the organs of 
extraction, which are generally the liver and the kidney (Smith et al. 2001b). The 
CLtot value of a drug is an important pharmacokinetic parameter because it is directly 
related to bioavailability and d
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 Traditionally, the CLtot value of a drug candidate is obtained via in vivo and in 
vitro studies (Naritomi et al. 2001; Zuegge et al. 2001; Wajima et al. 2003a; Wajima 
 explored for predicting the CLtot value of drug 
candidates (Karalis et al. 2002; Karalis et al. 2003; Turner et al. 2003b; Ng et al. 2004; 
Turner et al. 2004b) in an effort to eliminate undesirable compounds in a fast and 
cost-effective manner. An initial partial least squares (PLS) study conducted by 
Karalis et al (Karalis et al. 2002) using 272 structurally unrelated compounds failed to 
find any correlation between CLtot and a large variety of molecular descriptors used in 
that study. Karalis et al (Karalis et al. 2003) then developed a partial least square 
(PLS) model and non-linear regression model for CLtot by using 23 cephalosporins. 
The r2 and q2 values of the PLS-developed model are 0.775 and 0.731, while the r2 





N) and PLS. The kNN-developed QSPkR model 
gives a q2 value of 0.77 for a training set of 38 antimicrobial compounds and a r2 
et al. 2003b), which tends to be time-consuming and costly. Therefore, QSPkR 
modeling has recently been
value of the non-linea
m e mechanisms may be involved in CLtot and thus linear methods may not 
always be suitable for constructing QSPkR models for CLtot. Another study for the 
prediction of CLtot was done by Turner et al (Turner et al. 2003b) who used artificial 
neural network (ANN), which gives a r  value of 0.982 for a training set of 16 
cephalosporins and a r  value of 0.998 for a validation set of 4 cephalosporins. 
Subsequently, Turner et al (Turner et al. 2004b) used a larger training set of 56 
compounds to develop an ANN-based QSPkR model, which gives a r  value of 0.731 
for a validation set of 6 compounds. These results suggest that non-linear methods 
may be useful for developing models for CLtot prediction of structurally unrelated 
compounds. Two QSPkR models for CLtot were developed by Ng et al (Ng et al. 2004) 
by using k nearest neighbour (kN
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value of 0.94 for a validation set of 6 antimicrobial compounds. There are 68% of the 
44 compounds having predicted CLtot within twofold of actual values. For the PLS-
developed QSPkR model, there are only 50% of the 44 compounds having predicted 
CLtot within twofold of actual values and the q2 value of this model is 0.09 for the 
training set and its r2 value is 0.35 for the validation set. These results are consistent 
with the study of Turner (Turner et al. 2004b) and further confirm the usefulness of 
non-linear methods for developing QSPkR models for predicting CLtot. All of the 
previous QSPkR models for predicting CLtot have primarily been developed and 
tested by using a relatively small number of compounds (<70), which is significantly 
smaller in number and diversity than the number of compounds with known CLtot data. 
Thus it is of interest to evaluate the prediction capabilities of QSPkR models that are 
developed by using much larger and more diverse datasets.    
 This work is intended to evaluate the capability of several statistical learning 
methods for predicting CLtot by using 503 compounds found from a comprehensive 
literature search, which is substantially larger in number and more diverse in structure 
than those used in earlier studies. The methods used include general regression neural 
network (GRNN), support vector regression (SVR) and kNN. Different descriptor sets, 
which encode different combination of the structural and physiochemical properties of 
a compound, were also compared for their usefulness for constructing QSPkR models 
to predict CLtot. Consensus modeling strategy has been introduced for developing 
prediction systems based on multiple models (Mosier et al. 2003; Asikainen et al. 
2004). In this work, this strategy was also applied to the development of consensus 
QSPkR (cQSPkR) models for the prediction of CLtot by using QSPkR models 
generated from different statistical learning methods. 
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7.2 Method 
 Compounds with known human CL
7.2.1 Dataset 
g
s which do not permit 
to describe the structural and 
hysico-chemical properties of the compounds. The first set (DS-MIXED) contains a 
tot values were selected from several 
sources including Micromedex (MICROMEDEX 2003b), a classic pharmacology 
textbook (Hardman et al. 2002) and a number of publications (Ito et al. 1998; Obach 
1999; Naritomi et al. 2001; Turner et al. 2003b; Wajima et al. 2003a; N  et al. 2004; 
Turner et al. 2004b). In order to ensure that experimental variations in determining 
CLtot do not significantly affect the quality of our data sets, only CLtot values obtained 
from healthy adult males and from intravenous administration were used for 
constructing the dataset. In addition, a number of compounds were excluded because 
they are known to possess certain molecular characteristic
reliable calculations of the molecular descriptors used in this study (Karalis et al. 
2002). Examples of these compounds are quaternary ammonium compounds, 
molecules with complex chemical structures like amphotericin-B, aminoglycosides, 
vancomycin, and compounds containing one or more metal atoms. A total of 503 
compounds were selected from this process and these were used as the dataset for this 
work. The CLtot value for each of these compounds was log-transformed (logCLtot) to 
normalize the data and to reduce unequal error variances (Neter et al. 1996). 
Representative training set and validation set were constructed from our dataset by 
using the removal-until-done method (section 2.2.2.3). 
 
7.2.2 Molecular structures and descriptors 
 Six different sets of descriptors were used 
p
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number of commonly used descriptors, including 21 constitutional descriptors, six 
geometrical descriptors, 72 topological descriptors and 108 electrotopological state 
descriptors (Kier et al. 1999). The second set (DS-3DMoRSE) includes 224 3D-
tot of the compounds, so as to 
prove computation speed, performance and interpretability of predictive models. 
elevant descriptors such as constant 
MoRSE descriptors (Schuur et al. 1996), which are representations of the 3D structure 
of a molecule and encode features such as molecular weight, van der Waals volume, 
electronegativities and polarizabilities. The third set (DS-ATS) is composed of 209 
Moreau-Broto topological autocorrelation (ATS) descriptors (Moreau et al. 1980), 
which describes how molecular properties such as polarizability, charge, 
electronegativity, are distributed along the topological structure. The fourth set (DS-
GETAWAY) consists of 340 GETAWAY descriptors (Consonni et al. 2002), which 
encodes both molecular structure and chemical information such as atomic mass, 
polarizability, van der Waals volume and electronegativity. The fifth set (DS-RDF) 
contains 203 RDF descriptors (Hemmer et al. 1999), which provides information 
about interatomic distances in the entire molecule and also other useful information 
such as bond distances, ring types, planar and non-planar systems, atom types and 
molecular weight. The last set (DS-WHIM) includes 126 WHIM descriptors (Bravi et 
al. 1997), which encodes information about the size, shape, symmetry, atom 
distribution and polarizability of a molecule. All of the descriptors were computed 
from the 3D structure of each compound using MODEL (Li et al. 2005b). 
 Objective feature selection is applied to all of the six sets of descriptors to 
remove descriptors irrelevant or redundant to the CL
im
The first step involves the removal of all irr
descriptors. Redundant descriptors were then eliminated by removing one of the two 
descriptors with pairwise correlation coefficient of greater than 0.90 (Wessel et al. 
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1998; Mosier et al. 2002). The final number of descriptors for each descriptor set is 
84, 109, 142, 155, 111 and 44 for DS-MIXED, DS-3DMoRSE, DS-ATS, DS-
GETAWAY, DS-RDF, and DS-WHIM, respectively. All of the remaining descriptors 
in each descriptor set were autoscaled to a mean value of zero and a variance of one 
(equation (2.3)) to ensure that all descriptors have equal potential to affect the QSPkR 
model (Livingstone 1995b). 
 
7.2.3 Optimization of the parameters of GRNN, SVR and kNN 
 Optimization of the parameters for GRNN, SVR and kNN was conducted by 
scanning the parameter value through a range from 1 to 30. The predictive capability 
of the QSPkR model developed from a particular parameter value can be determined 
by using cross-validation methods, such as 5-fold cross-validation, 10-fold cross-
validation and modeling testing set. Our cytochrome P450 study has shown that the 
use of a modeling testing set gives the best performance for assessing the predictive 
capability of a model (section 6.2.3). Thus this validation method was used to select 
the optimum parameter for each statistical learning method in this study. The 
following function was used to measure the predictive capability of a QSPkR 
model (Wessel et al. 1998; Mosier et al. 2002): 
 F train train testMAE MAE MAE= + −      (7.1) 
  
where MAEtrain and MAEtest are the mean absolute error of the modeling training set 
and modeling testing set respectively. The modeling testing set was derived by 
dividing the original training set into a modeling training set and modeling testing set 
of 303 and 95 compounds respectively by using the removal-until-done method 
(section 2.2.2.3). 
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7.2.4 cQSPkR method 
 In this work, consensus QSPkR (cQSPkR) models were developed by 
combining QSPkR models generated from different statistical learning methods. 
cQSPkR models compute the predicted CLtot of a compound by averaging the 
predicted CLtot of that compound from the different QSPkR models (Sutherland et al. 
2003b). 
 
7.2.5 Evaluation of QSPkR models 
 The validation set, not used in the derivation of the QSPkR models, was used 
to estimate the prediction capability of the QSPkR models. The fold-error for each 
compound and the percentage of compounds in the validation set where the fold-error 
is less than two or three were calculated. The predictive capability of the QSPkR 
models can be measured by the Spearman rank correlation coefficient (Rs) and 
average-fold error (Obach et al. 1997). Rs is used to assess the ability of the QSPkR 
models to rank compounds based on their CLtot. The average-fold error is the 
geometric mean of the ratio of predicted and actual values, and QSPkR models that 
predicts CLtot perfectly gives a value of 1 and a model with an average-fold error of 
less than 2 is considered to be a successful one (Obach et al. 1997). The predicted 
gCLtot values of the compounds were colo nverted back to CLtot prior to the calculation 
of fold-errors and average-fold errors. A functional dependence study was also done 
using the procedures described in section 2.5.3. 
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7.3 Results and discussion 
7.3.1 Dataset analysis 
 The diversity index (DI) of the training set and validation set used in this study 
and those of several reference datasets are given in Table 7.1.  
 
Table 7.1 Diversity indices of the datasets used in this and other studies. 




Training set 398 0.067 Datasets used in 
this work Validation set 105 0.068 
Satellite structures (Oprea et al. 2001) 8 0.076 
FDA approved drugs 1121 0.069 
Highly diverse 
datasets 
NCI Diversity set (NCI/NIH) 1804 0.124 
Penicillins 59 0.452 
Cephalosporins 73 0.568 datasets 
Fluoroquinolones 39 0.579 




Benzodiazepine receptor ligands (Sutherland 
et al. 2003a) 
405 0.314 
 
Dihydrofolate reductase (DHFR) 




Cyclooxygenase 2 (COX2) 
inhibitors (Sutherland et al. 2003a)
467 0.584 
 
 It is found that the DI values of the training set and validation set is very small, 
as low as 0.067, which is at the level of those of highly diverse datasets. For 
comparison, the DI values of datasets containing congeneric compounds are typically 
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greater than 0.452, and those of the compounds used in QSAR and QSPR studies are 
typically in the range of 0.274 to 0.584. This suggests that the training set and 
validation set are sufficiently diverse. The representativity index (RI) value between 
sessing the predictive 
apability of the QSPkR models developed in this work. 
y 
using the dataset of 503 compounds to identify outliers and clusters. Two principal 
c s ed which is able to explain 73.2  the total variance 
in the descriptors. Com are able to explain 
the variance respectively. Figure 7.1 shows a score plot of the compounds in the 
training set and validation set by using the first two PCs. Score plots are useful for 
c he dis f compounds in the chemical space between two datasets 
and to identify clusters of compounds and single comp ds that be 
outliers (Wold et al.  et al. 2006). There are no distinct clusters in 
the training set and validation set. The validation set is evenly distributed throughout 
the score space of entativ s of the ion 
set. Four compounds, alendronic acid, clodronic acid, foscarnet and zoledronic acid, 
were found to be ty of compound  are loca  the 
bottom right of the ds that are farther away from the 
majority of compounds are cefoperazone, cefpiramide and tezosentan, which are 
ace, and carbimide and borocaptate, which are 
the training set and validation set is 0.881, which suggests that the validation set is 
representative of the training set and thus is suitable for as
c
 Principal component analysis (PCA) (Wold et al.  pe1987) was rformed b
omponents (PC ) were deriv % of
ponents one and two 60.9% and 12.3% of 
omparing t tribution o
oun may 
 1987; Doddareddy
 the training set, confirming the repres enes validat
farther away from the majori
 score space. Other compoun
s and ted at
located at the left of the score sp
located at the right and top right of the score space respectively. There seems to be no 
evidence to suggest that these compounds are outliers. Thus they are retained in the 
training set and validation set. 
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 may partially neglect some important features.  
7.3.2 Analysis of descriptor sets 
 The computed Rs values and average-fold errors of the QSPkR models 
developed by using different descriptor sets are shown in Table 7.2. Comparison of 
the QSPkR models based on the six descriptor sets shows that models based on the 
DS-MIXED descriptor set generally give higher Rs values and lower average-fold 
errors than those based on other descriptors sets. This suggests that models based on 
the DS-MIXED descriptor set are more useful and it may be advantageous to use a 
variety of descriptors for prediction of pharmacokinetic properties than to use a 
specialized descriptor set which
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 The descriptors in the six descriptor sets were combined to form a new 
descriptor set (DS-ALL). The G-ALL, S-ALL and K-ALL models developed by using 
DS-ALL have higher predictive capabilities compared to models developed by using 
individual descriptor sets. This suggests that all of the three statistical learning 
methods are able to extract useful information from the different descriptor sets and to 
effectively combine them to develop more predictive QSPkR models. 
 
Table 7.2 Average-fold errors of QSPkR models developed by using different 








G-MIXED DS-MIXED 2 0.636 1.73 
G-3DMoRSE DS-3DMoRSE 3 0.540 1.75 
G-ATS DS-ATS 3 0.448 1.86 
G-GETAWAY DS-GETAWAY 3 0.520 1.80 
G-RDF DS-RDF 3 0.558 1.80 
G-WHIM DS-WHIM 2 0.302 1.96 
GRNN 
G-ALL DS-ALL 7 0.633 1.63 
IXED 3 0.558 1.73 S-MIXED DS-MSVR 
S-3DMoRS 3DMoRSE 4 0.518 1.81 
S-GETAWAY DS-GETAWAY 8 0.564 1.78 
S-RDF DS-RDF 4 0.607 1.76 
S-WHIM DS-WHIM 5 0.346 1.95 
S-ALL DS-ALL 13 0.643 1.66 
K-MIXED DS-MIXED 2 0.523 2.00 
E DS-
S-ATS DS-ATS 7 0.548 1.74 
K-3DMoRSE DS-3DMoRSE 2 0.360 2.23 
kNN 
K-ATS DS-ATS 3 0.406 2.03 
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K-GETAWAY DS-GETAWAY 2 0.522 2.00 
K-RDF DS-RDF 3 0.447 1.98 
P-MIXED DS-MIXED 17 0.528 1.89 
K-WHIM DS-WHIM 3 0.392 2.01 
K-ALL DS-ALL 2 0.513 1.90 
P-3DMoRSE DS-3DMoRSE 8 0.377 2.26 
P-ATS DS-ATS 7 0.562 
PLS 
2.09 
P-GETAWAY DS-GETAWAY 10 0.474 1.92 
0.282 2.10 
P-ALL DS-ALL 5 0.559 1.96 
P-RDF DS-RDF 6 0.468 1.99 
P-WHIM DS-WHIM 28 
a The average-fold errors were assessed by using the validation set. 
 
7.3.3 Predicti  o  cQSPk  models
 Table 7.2 above shows the predictive capabilities o  QSPkR dels 
developed by using GRNN, SVR a  PLS was used as a reference QSPkR 
method for comparison of the predictive capabilities of the different models. The 
results for the corresponding PLS-developed QSPkR odels o given able 
7 ll of the G d SV ed QSPkR models have average-fold errors 
less than 2 while kNN-developed models have average-fold errors near 2, which are 
similar to those of PLS-developed models. GRNN- and SVR-developed QSPkR 
models were also found to generally give higher R  values than the corresponding 
kNN- and PLS-developed models. This suggests that both GRNN and SVR are more 
useful than either kNN or PLS for developing QSPkR models ug clea  and 
b RNN- an velo  are not m  flexibl  is necessary and 
thus unlikely to overfit.  
ve capability f QSPkR and R  
f the  mo
nd kNN.
 m are als  in T
.2. A RNN- an R-develop
s
 of dr rance
oth G d SVR-de ped models ore e than
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 To assess the performa e stati cal lear ethods Ltot 
prediction of a iverse s mpounds, it is useful to examine whether the 
predictive capability of these methods is at a similar level as those derived from the 
use of a significantly smaller set of com s. It is noted that, a direct com
with results fro tu opriate cause o ifferenc  the 
dataset, molecular descriptors, and computing algorithms used. Although desirable, it 
is impossible t s ison g resu ectly fr ther 
studies without f ormation about the algorithms of molecular descriptors and 
modeling methods used in each study. Nonetheless, a tentative comparison may 
f the QSPkR models studied in this work. 
ALL, K-ALL and P-
LL m
ay not be the most efficient approach for 
constructing a QSPkR model for predicting CLtot. Thus non-linear methods, such as 
nce of the thre sti ning m  for C
more d et of co
pound parison 
m previous s dies is inappr be f the d es in
o conduct a eparate compar usin lts dir om o
ull inf
provide some crude estimate regarding the approximate level of predictive capability 
o
 Table 7.3 gives the prediction results of the G-ALL, S-
A odels from this work along with those derived from previous studies. The 
percentage of compounds in the validation set with predicted CLtot within two-fold 
error of actual values of G-ALL and S-ALL models are comparable and in some cases 
slightly better than those of earlier studies that were tested by using a much smaller 
number of compounds. Diversity of the training sets has been shown to affect the 
applicability domain of QSPkR models (Dimitrov et al. 2005). Thus the results 
suggest that using a more diverse and larger number of compounds and applying 
statistical learning methods, particularly GRNN and SVR, are useful for prediction of 
CLtot. A possible reason for the better performance of GRNN and SVR is that 
multiple mechanisms are involved in determining CLtot. A variety of factors may 
interact in complex ways to affect the CLtot of a compound. Therefore methods based 
only on linear relationships, such as PLS, m
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GRNN and SVR, which do not require prior knowledge about the molecular 
mechanism or structure-activity relationship of a particular drug property may be 
more suitable.  
 
Table 7.3 Number of compounds with the predicted CLtot within two-fold error of 
Model Number of 
compounds 
Number (percentage) of compounds 
with fold-errors < 2 
the actual CLtot from this work and other studies. 
G-ALL (this work) 105 73 (69.5%) 
S-ALL (this work) 105 78 (74.3%) 
 (Wajim
 44 (64.7%) 
PLS (Ng et al. 2004) 44 22 (50.0%) 
K-ALL (this work) 105 65 (61.9%) 
P-ALL (this work) 105 63 (60.0%) 
Multiple linear regression 68
a et al. 2003a) 
kNN (Ng et al. 2004) 44 30 (68.2%) 
Parallel tube (Obach 1999) 29 16 (55.2%) 
 
 Plots of the predicted CLtot against the actual values for the G-ALL and S-
ALL models are shown in Figure 7.2. These plots show that both models tend to 
under-predict the CLtot value of compounds rather than over-predicting the CLtot. 
Under-prediction of CLtot is more desirable than over-prediction of CLtot during drug 
development because over-prediction results in more frequent dosing of a drug 
candidate during clinical trials which may lead to higher rates of adverse drug 
reactions. For compounds with fold-errors greater than 2, the G-ALL model 
underpredicted 22 and overpredicted 10 of these compounds respectively. The 
corresponding values for the S-ALL model are 18 and 11 respectively.  
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Figure 7.2 (a) Plot of predicted CLtot vs actual CLtot for the G-ALL model. (b) Plot of 
a 




L and S-ALL 
 
 
The dotted line represents line of unity. The area between the two solid lines and between the 
two dotted-dash lines represents an area between two-fold and three-fold error respectively. 
Compounds in validation set with fold-error greater than 3 for both G-AL
models are identified. 
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Figure 7.3 Chemical structures of compounds in validation set with fold-errors 
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 There are 7 compounds having fold-errors greater than 3 for both models and 
their chemical structures are shown in Figure 7.3. A possible reason for the high fold-
errors of some of these compounds is that the descriptors used in this study may be 
inadequate to properly describe these compounds. Examples of these compounds are 
chlorphenamine and fendiline, which contain two aromatic ted by an atom, 
allopurinol, whi  a complex two ring system with m heteroatoms, 
carbidopa, which has a hydrazine group that is a highly reactive reducing agent, and 
raltitrexed, which has two carboxylic acid groups that makes it highly charged at 
physiological pH. Our previous studies (sections 4.2.3, 6.4.4, and 8.1.3.3) have 
suggested that c containing these structural fea e adequately 
represented by c ailable descriptors. Thus by us tly available 
algorithm, these compounds are misrepresented and incorrectly positioned in the 
chemical space, leading to inaccurate prediction of their CLtot values. 
 A cQSPkR model was developed by using G-ALL and S-ALL models. The K-
ALL model was not used because its prediction capability is significantly lower than 
those of the G-ALL and S-ALL models and hence m the prediction 
capability of the cQSPkR model. The cQSPkR model has an average-fold error of 
1.61. Thus the cQSPkR model had slightly better prediction capability than either the 
G-ALL or S-ALL model. The relatively small average-fold error suggests that the 
model is useful for the prediction of CLtot. The cQSPkR model correctly predicted 77 
(73.3%) compounds in validation set to be within two-fold error of actual CLtot. For 
compounds with fold-errors greater than 2, the cQSPkR model under-predicted 19 and 
over-predicted 9 of these compound ly. None of the under-predicted or 
proved over that of the G-ALL and S-ALL models which have two and four 
rings separa
c sh contain ultiple 
ompounds tures may not b
urrently av ing the curren
ay reduce 
s respective
over-predicted compounds have fold-errors greater than 4.5. This is significantly 
im
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c nds with fold-errors greater than 4.5 respectively. The cQSPkR model gives 
an R
ompou
7.3.4 Functional dependence analysis 
 Multiple elimination processes are involved in drug clearances. Thus it is 
difficult to determine which molecular characteristics are important in affecting CL . 
Nonetheless, it is possible to infer some information from a functional dependence 
study of the QSPkR models. It is noted that the results of a functional dependence 
study may vary with respect to different QSPkR models. Thus the following 
interpretation of the descriptors must be taken in light of the absolute predictive 
ability of the QSPkR models. Figure 7.4 shows the prediction results of the first seven 
PCs of the G-MIXED model by using artificial testing sets. The first seven PCs are 
able to explain approximately 60% of the total variance of the descriptors. Plots of 
logCL  against the PCs for the S-MIXED model are similar and thus are not given 
here. The DS-MIXED descriptor set was used to determine the relationship between a 
specific molecular characteristic and CL  because models developed by using this 
descriptor set have higher predictive capabilities than those developed by using other 
descriptor sets. In addition, it is relatively easier to assign the descriptors in the DS-
MIXED descriptor set to specific molecular characteristics. Table 7.4 gives the list of 
the dominant descriptors and the corresponding molecular characteristic in different 
PCs. 
 
s value of 0.652 which suggests that the model may be useful for ranking 
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Table 7.4 The dominant descriptors and the corresponding molecular characteristic 
PC Dominant Descriptors Corresponding Molecular 
in different principal components. 
Characteristic 
First 3D-Wiener index (Basak et al. 1999) 
Valence molecular connectivity Chi index for 
Molecular shape 
path order 2 (Kier et al. 1999) 
Second 2
aromatic) (Kier et al. 1999) 
Fifth Atom-type Estate sum for =S=< (Kier et al. 1999) Charge and molecular solvation 
capability 
Atom-type Estate sum for :CH: (sp , 
Atom-type Estate sum for :C:-  (Kier et al. 1999) 
AlogP- (Viswanadhan et al. 1993) 
Lipophilicity  
Third Kier flexibility index (Kier 1990) Flexibility 
Fourth Average molecular weight 
Gravitational 3D index (Wessel et al. 1998) 
Molecular size 
Solvation molecular connectivity Chi index for 
path order 2 (Todeschini et al. 2000) 
Mean topological charge index for path order 
1 (Galvez et al. 1994) 
Sixth Number of H-bond acceptors Hydrogen bond accepting 
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Figure 7.4 Plots of log CLtot against the various PCs for G-ALL model. Increasing 
values of PC1 denotes increasing sphericity of a compound. Increasing values of PC2 
den decreasing lip ound. Increasi tes 
decreasing flexibility of a compound. Increasing values of PC
molecular size of a compound. Increasing values of PC6 denote ydrogen 
b accept easing values of PC7 denotes increasing 






















otes ophilicity of a comp ng values of PC3 deno
4 denotes increasing 
s increasing h








scriptors shows that the first PC is 
riptors. These include 3D-Wiener index, 
phericity of a structure, and 2χv, which is th
alence molecular connectivity Chi index for path order 2 and encodes the relative 
egree of branching in a compound (Kier et al. 1986). Prediction results by using the 
rtificial testing set show that CLtot generally decreases with increasing value of the 
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molecules with fewer side chain branching tend to have higher CLtot than that of 
aspherical molecules with multiple branches. 
 Electrotopological state descriptors like Estate_aaCH and Estate_aasC, which 
describe electrotopological properties of carbons in aromatic rings, and 
AlogP (Viswanadhan et al. 1993), which measures the partition coefficient of a 
compound, are the main contributor to the second PC. Thus it is likely that the second 
PC is a measure of the lipophilicity of a compound. Results of the artificial testing set 
suggest CLtot increases with increasing lipophilicity of a compound. 
 The third PC is determined primarily by KierFlexibilityIndex, which is related 
to the flexibility of a molecule. The complex role of molecular flexibility in 
membrane permeation has been found by two studies. One found a positive 
correlation between flexibility and permeation (Iyer et al. 2002) while the other found 
a negative correlation (Veber et al. 2002). Using the artificial testing set, it was found 
that compounds with low or high flexibility have higher CLtot than those with 
moderate flexibility. This may partially explain the apparent contradiction between 
the two earlier studies. 
The fourth PC is formed mainly by AMW, which is the average molecular 
electrotopological descriptor for sulfur atoms, 2χs, which is the solvation molecular 
 
weight, and Gravitational3DIndex. These are related to the volume of a molecule and 
the distribution of atomic masses within the molecular space. The contribution of 
these two descriptors to the fourth PC suggests that the fourth PC is a measure of 
molecular size. The artificial testing sets show that CLtot generally increases with 
decreasing molecular size. This is consistent with the findings that small molecular 
size is necessary for good membrane penetration (Pardridge 1998). 
 The main contributors to the fifth PC are Estate_ddssS, which is the 
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connectivity Chi index for path order 2, and Mean1Gc, which is the mean topological 
charge index for path order 1. It is difficult to attribute these descriptors to a single 
pectively. Figure 
.4f an
nge in CLtot per unit change in the PC values can provide a 
molecular characteristic. Nonetheless, studies have consistently shown that charge 
and molecular solvation are important in determining the metabolism (Smith et al. 
1997b; de Groot et al. 2002) and renal clearance (Turner et al. 2004b; Venturoli et al. 
2005) of a molecule. 
 The sixth and seventh PCs are determined primarily by descriptors encoding 
the hydrogen bond acceptor and donor properties of a compound res
7 d Figure 7.4g shows that CLtot increases with increasing hydrogen bonding 
capability of a compound. Studies have found that binding affinity to human serum 
albumin generally decreases with increasing hydrogen bonding capability of these 
compounds (Hall et al. 2003; Yap et al. 2005b). Many compounds bind to serum 
albumin and the albumin-bound fraction is not available for hepatic metabolism or 
renal clearance (Colmenarejo 2003). Thus factors which decrease serum albumin 
binding are expected to increase the CLtot of a compound. 
 The rate of cha
useful hint about the contribution of a molecular characteristic to the clearance of a 
compound. The plots in Figure 7.4 show the effect of changing the value of each PC 
on the clearance of a compound in the following order: PC5 > PC4 > PC3 > PC6 > 
PC1 ≈ PC2 > PC7. Thus charge, molecular solvation, molecular size and flexibility 
are the most important molecular properties which influence clearance of a compound. 
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7.4 Conclusion 
with those developed by using a linear method, PLS. All of the 
e such type of feature bias. 
h
 Our study suggests that both GRNN and SVR are potentially useful for 
developing QSPkR models to predict drug clearance from a large diverse set of 
compound data. QSPkR models developed by using GRNN, SVR and KNN were 
tested and compared 
GRNN- and SVR-developed models show better prediction capability than the 
corresponding KNN- or PLS-developed models. The predictive capabilities of the 
QSPkR models developed in this study are comparable to those of previous studies 
and can be further improved by using consensus modeling methods. 
 A collection of constitutional, geometrical, topological and electrotopological 
descriptors seems to be more useful for modeling drug clearance than specialized 
descriptor sets such as 3DMoRSE, ATS, GETAWAY, RDF and WHIM. An 
individual descriptor set tends to partially neglect some important features and thus 
the use of all the available descriptors may help to alleviat
The three statistical learning met ods used in this work appears to be capable of 
combining the information encoded in the different descriptor sets effectively to 
develop more predictive QSPkR models. 
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Chapter 8 
T ity Prediction oxic
 
 This chapter describes two important drug toxicities: genotoxicity (section 8.1) 
and torsade de pointes (section 8.2). The classification accuracies of the qSPkR 
models for prediction of genotoxic potential and torsade-causing potential of 
compounds developed by using SVM and other classification methods are presented. 
The possible reasons for misclassification of some compounds are also discussed. 
 
8.1.1 Introduction 
cological tests and clinical safety 
uated by the drug regulatory authorities for 
drug safety assessment. Because of the high cost of conducting toxicity tests and 
clinical trials, effort has been directed at developing low-cost and efficient tools for 
predicting ADRs aimed at eliminating unsafe drug candidates in the early stages of 
drug development (Kennedy 1997; van de Waterbeemd et al. 2003). 
 Genotoxicity is one of the ADRs closely evaluated in drug discovery and 
approval processes. The molecular mechanisms of genotoxicity include DNA 
intercalation by aromatic ring of a drug, DNA methylation, DNA adduct formation 
8.1 Genotoxicity 
 Adverse drug reactions (ADRs) are responsible for the failure of a substantial 
percentage of investigational drugs and the withdrawal of marketed drugs (Johnson et 
al. 2000; van de Waterbeemd et al. 2003). Up to one-third of all drug failures are due 
to ADRs (Kennedy 1997). A variety of toxi
evaluations need to be conducted and eval
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and strand break, and unscheduled DNA synthesis (Bolzan et al. 2002). Some 
genotoxic (GT+) compounds require metabolic activation and their GT+ effect are 
 (Snyder et al. 2004). These events subsequently result in 
hromosomal aberrations, micronuclei, sister chromatid exchanges, and cell death 
ude 
eductive Estimation on Risk from Existing Knowledge (DEREK), Multiple 
Computer Automated Structure Evaluation (MCASE) and Toxicity Prediction by 
puter Assisted Technology (TOPKAT). Specific details about these 
t es can be found in the review by Greene (Greene 2002). qSPkR 
pounds based on 
mediated via N-dialkylation
c
which contribute to drug ADR (Bolzan et al. 2002). 
 Tools for fast and efficient prediction of drug GT+ potential, particularly those 
based on computational methods, are being developed (Kramer 1998; Schwetz et al. 
1998). For instance, expert systems that use structural alerts for predicting GT+ as 




models have been developed for predicting GT+ potential of several groups of related 
chemicals (Marchant 1996; Cash 2001). However the qSPkR models of a majority of 
chemical groups are yet to be determined which hinders the practical application of 
this method. 
 Statistical learning methods have recently been explored as a new approach 
for genotoxicity prediction without the restriction on the features of structures or types 
of molecules (He et al. 2003; Mattioni et al. 2003; Mosier et al. 2003). Instead of 
focusing on specific structural feature or a particular group of related molecules, these 
methods classify molecules into GT+ and non-genotoxic (GT-) com
their general structural and physicochemical properties regardless of their structural 
and chemical types. Therefore, in principle, these methods are expected to be 
applicable to a diverse set of molecules. However, the performance of these methods 
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can be practically limited by the quality of molecular descriptors, diversity of training 
and testing data, and the efficiency of statistical learning algorithm. 
 So far, three statistical learning methods, linear discriminant analysis (LDA), k 
nearest neighbour (kNN), and probabilistic neural network (PNN), have been used 
and achieved a prediction accuracy of up to 73.8% for GT+ and 92.8% for GT- 
ompou
 GT- compounds. These methods include SVM, PNN, kNN and C4.5 
c nds respectively (He et al. 2003; Mattioni et al. 2003; Mosier et al. 2003). 
However, these methods have been developed and tested by using no more than 394 
GT+ and GT- compounds (Snyder et al. 2004), which is significantly smaller in 
number and diversity than the 860 known GT+ and GT- compounds found from our 
recent literature search. Therefore, there is a need to examine if a similar level of 
accuracy can be achieved for the more diverse set of molecules. It is also of interest to 
determine if the GT+ accuracy can be further improved by a training set composed of 
a more diverse set of GT+ compounds. Moreover, other statistical learning methods 
such as support vector machine (SVM) and C4.5 decision tree (DT) have shown 
promising potential, and it is useful to evaluate these methods. 
 This work is intended to evaluate several statistical learning methods by using 
860 GT+ and
DT. Recursive feature elimination (RFE) is used in this work for selecting the 
molecular descriptors relevant to the classification of GT+ and GT- compounds. To 
adequately assess the prediction accuracy of the methods used in this work, two 
different evaluation methods are used. One is 5-fold cross-validation, and the other is 
the use of an external independent validation set. 
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8.1.2 Methods 
8.1.2.1 Selection of GT+ and GT- compounds 
 A total of 860 GT+ and GT- compounds with known genotoxicity test results 
are selected from several sources including the 1999-2002 Physician’s Desk 
Reference, National Toxicology Program, and a number of publications (Snyder et al. 
2001; He et al. 2003; Mattioni et al. 2003; Mosier et al. 2003; Snyder et al. 2004). 
Genotoxicity tests for generating these data include the pre-ICH four standard 
batteries (Ames test, in vitro cytogenetics, in vivo cytogenetics, mouse lymphoma 
assay) and the Salt-Overly-Sensitive (SOS) chromotest (which is a rapid alternative 
genotoxicity test based on the detection of the DNA damage through the SOS 
pathway)  (Quillardet et al. 1993; Vasilieva 2002). Compounds with genotoxicity test 
results are divided into GT+ and GT- groups according to whether these genotoxicity 
test results showed at least one positive finding. Under this definition, there are a total 
of 229 GT+ compounds and 631 GT- compounds. 
 These compounds are further separated into training and testing sets by either 
5-fold cross-validation or removal-until-done method (section 2.2.2.3) depending on 
the evaluation method used. For evaluation by an independent validation set, these 
compounds are divided into training, testing, and independent validation set. The 
generated training, testing and independent evaluation set contains 577 (166 GT+, 
411 GT-), 160 (36 GT+, 124 GT-) and 123 (27 GT+, 96 GT-) compounds respectively. 
 
.1.2.2 Molecular descriptors 
 In this work, a set of 199 molecular descriptors, which include 143 topological, 
31 quantum chemical, and 25 geometrical descriptors, are computed using our own 
8
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design d molecule ar descriptor computing program. The remaining redundant and un-
related descriptors are further reduced by using RFE method. The computation 
procedure for RFE is the same as that in the human intestinal absorption study 
(section 4.1.2.3). 
 
 Prediction results of SVM without RFE and SVM with RFE (SVM+RFE) by 
using 5-fold cross-validation are given in Table 8.1. The accuracies of SVM+RFE are 
75.5% for GT+ compounds and 90.6% for GT- compounds, which are slightly better 
than the values of 69.4% for GT+ compounds and 88.2% for GT- compounds derived 
from SVM without RFE. The GT+ prediction accuracy is noticeably improved, which 
indicates the usefulness of RFE in selecting the proper set of descriptors for the 
prediction of GT+ and GT- compounds. The use of these RFE-selected descriptors 
also slightly improves the prediction accuracy of the other three statistical methods. 
The GT+ accuracies are improved from 70.4% to 74.1% for PNN and from 44.4% to 
55.6% for DT respectively, and that of kNN remains roughly unchanged. The GT- 
accuracy of kNN is improved from 82.2% to 86.5%, and those of PNN and C4.5 DT 
are roughly unchanged. These results showed that descriptor selection by using RFE 
plays the important role in improving the prediction capability for the above methods 
in general. Similar prediction accuracies are also found from two additional 5-fold 
ed by using training-testing sets separately generated 
om d
8.1.3 Results and discussion 
8.1.3.1 Overall prediction accuracies 
cross-validation studies conduct
fr ifferent random number seed parameters. 
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Table 8.1 SVM and SVM+RFE prediction accuracy of the GT+ and GT- compounds 
Genotoxicity Non-genotoxicity  
by using 5-fold cross-validation. 
Method Cross -
validation TP FN SE (%) TN FP SP (%) 
Q (%) MCC 
1 32 17 65.3 109 11 90.8 83.4 0.59 SVM 
2 30 10 75.0 115 14 89.1 85.8 0.62 
3 32 13 71.1 119 21 85.0 81.6 0.53 
62.7 106 11 90.6 82.1 0.56 
5 32 12 72.7 107 18 85.6 82.2 0.56 
9.4   88.2 83.0 0.57 
4 32 19 
average   6
SD   4.6   2.5 1.5 0.03 
SE   1.9   1.0 0.6 0.01 
1 35 14 71.4 111 9 92.5 86.4 0.66 
a
b
2 32 8 80.0 118 11 91.5 88.8 0.69 
3 35 10 77.8 123 17 87.9 85.4 0.62 
4 35 16 68.6 109 8 93.2 85.7 0.65 
5 35 9 79.5 110 15 88.0 85.8 0.65 
average   75.5   90.6 86.4 0.66 




b   1.9   0.9 0.5 0.01 
a standard deviation 
b standard error 
 
 Table 8.2 gives the GT+ and GT- prediction accuracies derived from the four 
methods SVM, PNN, kNN and C4.5 DT by using the independent validation set and 
the RFE-selected molecular descriptors. The GT+ accuracies are in the range of 
55.6%-77.8% and the GT- accuracies are in the range of 75.0%-92.7%. Similar level 
of accuracies are obtained for SVM, PNN and kNN, with SVM giving the highest 
alue of 77.8% and 92.7% for GT+ and GT- compounds respectively. C4.5 DT 
appears to give substantially lower accuracies, which is concordant with other 
v
 
CHAPTER 8: TOXICITY 177
experimental comparison results (Brown et al. 2000; Huang et al. 2002). A possible 
reason for this lower accuracy is that C4.5 D on o he 
optimum set of descriptors, which m be the m ef approach for every 
problem. It has been pointed out that filter me y 
not be as efficient as wrapper methods, such as RFE, for determining the subset of 
descriptors relevant to a p u rob (Sa t a 00
 
Table 8.2 Co n of he edic accuracies of G nd G compounds 
derived from different machine learning methods by using the independent validation 
set in this work.
Method Para TP FN T FP SE ( ) P (%) Q 
T uses informati gain t find t
ay not ost fective 
thods, such as information gain, ma
artic lar p lem eys e l. 2 4). 
mpariso  t pr tion T+ a T- 
 
meter N % S (%) 
C4.5 DT - 15 12 72 24 55.6 75.0 70.7 
PNN σ=0.2 20 7 77 19 74.1 80.2 78.9 
k-NN k=3 19 8 83 13 70.4 86.5 82.9 
SVM σ=3 21 6 89 7 77.8 92.7 89.4 
 
8.1.3.2 Relev ures to genotoxicity study 
 Apart from the quality of datasets used, selection of descriptors relevant to 
genotoxicity study is important for optimizing the prediction system by reducing the 
tical learning process. A total of 39 molecular descriptors are selected 
by the RFE method, as given in Table 8.3. Most of these are found to be relevant to 
the assessment of genotoxicity potential of molecules. For instance, an important 
characteristics of some GT+ compounds is their ability to intercalate DNA (He et al. 
2003). The selected electrotopological state descriptors S(10) and S(14) describe 
atom-type H estate sum for :CH: sp2 aromatic structures and atom-type H estate sum 
for CH  aromatic structures respectively. 
 
ance of selected feat
noise in a statis
n
 
CHAPTER 8: TOXICITY 178
Table 8.3 Molecular descriptors selected from the RFE method for SVM 
Descriptors Description Class 
classification of GT+ and GT- compounds. 
Nrot Number of rotatable bonds Simple molecular properties 
ndonr Number of H-bond donors Simple molecular properties 
cluster 
3χC Simple molecular connectivity Chi indices for Connectivity and shape 
path/cluster 
ctivity and shape 
lar conn ty indi
/cluste
Conn nd sha
-type stat m f NH Electrotopological stat
-type stat m H Electro gical stat
-type  E e  fo :CH: 
aromatic) 
Electro gical stat
S(13) Atom-type H Estate sum for CHn (unsaturated) Electrotopological state 
ctrotopological state 
6) 
S(26) Atom-type Estate sum for : C:- Electrotopological state 
S(27) Atom-type Estate sum for : C :: Electrotopological state 
Tradi PetitJohn R2 Index Electrotopological state 
Tpeti PetitJohn I2 Index Electrotopological state 
Quantum chemical properties 
μ cp Chemical potential Quantum chemical properties 
4χ Simple molecular connectivity Chi indices for ConnePC
3χvC Valence molecular connectivity Chi indices for 
cluster 
Connectivity and shape 
4χvPC Valence molecu ectivi  Chi ces for 
path r 
ectivity a pe 
S(2) Atom  H E e su or =  e 
S(4) Atom  H E e su for -N  2 topolo e 
S(10) Atom  H stat sum r (sp2, topolo e 
S(14) Atom-type H Estate sum for CH n (aromatic) Ele
S(1 Atom-type Estate sum for -CH 3 Electrotopological state 
S(25) Atom-type Estate sum for =C< Electrotopological state 
S(30) Atom-type Estate sum for =NH Electrotopological state 
S(34) Atom-type Estate sum for =N- Electrotopological state 
S(35) Atom-type Estate sum for :N: Electrotopological state 
S(41) Atom-type Estate sum for -O- Electrotopological state 
Μ Molecular dipole moment 
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χ en Electronegativity index Quantum chemical properties 
ω Electrophilicity in dex Quantum ch roperties 
x toms  
toms  
rties 
Q H, Min, gative charge on H atoms Quantum chemical properties 
c rties 
Rnc tive charge Quantum chemical properties 
ty 
Gloty lar globularity Geometrical properties 
l 




Hiwpa ic moment Geometrical properties 
emical p
Q H, Ma Most positive charge on H a Quantum chemical properties
Q N, Max Most positive charge on N a Quantum chemical properties
Q O, Max Most positive charge on O atoms 
Most ne
Quantum chemical prope
Rp Relative positive charge 
Relative nega
Quantum chemical prope
Rug Molecular rugosity 
Molecu
Geometrical properties 
Shp Hydrophilic region 
Hydrophobic
Geometrical properties 
Capty Capacity factor Geometrical properties 
Hiwp Hydrophilic integy moment Geometrical properties 




 Many G ally valent 
bond to DNA  substantial po lected 
descriptors are from the class of electrotopological state that describe characteristics 
of specific types of functiona
substantial num e quantum che rmine 
m lar dipo tential, electron ilicity, 
relative positive the atomic charge on H, N and O atoms in a 
molecule. These properties are important for describing features of chemical reactions 
involved in the m  
 The size, shape, and polar property of a molecule have also been found to play 
a e in geneti d by GT+ compounds (H e 
T+ compounds are known to structur modify or form a co
via chemical reactions. A rtion of the RFE se
l groups involved in DNA modification. There are also a 
ber of descriptors from th mical class that dete
olecu le moment, chemical po egativity, electroph
 and negative charge, and 
odification of DNA.
 rol c damages cause e et al. 2003). Eight of th
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selected descri descriptors (Cruciani e 
molecular rugosity, molecular globularity, capacity factor, hydrophilic and 
hydrophobic region, hydrophilic integy moment, hydrophobic moment and 
amphiphilic mo arily describe the size, sha
p  of a m  descriptors, l 
descriptors extr uted 3D molecular f d 
s ically for  pharmacodynamics l. 
2000; Cruciani et al. 2000b). It is thus not surprising that the VolSurf descriptors 
rela e mo e, and polar property are selected. 
 Molecul is another feature kno nt for 
discriminating b GT+ compounds from their stance, 
4 -3-nitro  GT+ compound, while its analog 4-amino-3-
nitro-2,6-dimethylaniline is GT- (Chung et al. 1997). Four molecular connectivity 
3χC, 4χPC, 3χvC, and 4χvPC, are selected by RFE in this work. These 
connectivity chi indices for path/cluster, valence molecular connectivity chi indices 
respectively. 
similar level as those derived by the use of a 
gnific
ptors are VolSurf et al. 2000b). These ar
ment. These descriptors prim pe, and polar 
roperty olecule. In general VolSurf which are one-dimensiona
acted from the comp ield maps, were develope
pecif pharmacokinetics and  applications (Crivori et a
ted to th lecular size, shap
ar connectivity wn to be importa
etween some GT- analogs. For in
-amino -2,5-dimethylaniline is a
descriptors, 
descriptors are simple molecular connectivity chi indices for cluster, simple molecular 
for cluster, and valence molecular connectivity Chi indices for path/cluster 
 
8.1.3.3 Performance evaluation 
 To assess the performance of the statistical learning methods for genotoxicity 
prediction of the more diverse set of molecules, it is useful to examine whether the 
accuracy from these methods is at a 
si antly smaller set of molecules. It is noted that, a direct comparison with results 
from previous studies is inappropriate because of the differences in the dataset and 
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molecular descriptors used. Table 8.4 gives the prediction results of the four statistical 
methods from this work along with those derived from previous studies.  
 
Table 8.4 Overview of the prediction accuracies of GT+ and GT- compounds from 
a
Study Method Number of 
compounds 
SE (%) SP (%) Q (%) 













 (Snyder et al. 2004) DEREK 394 51.9 75.1 73.6 
Philip D. Mosier k-NN 140 66.7 
 ( r et al. 2003) 
Linnan He 
 (He et al. 2003)  
Consensus model 




73.8 84.3 81.2 
Brian E. Matt ni 
 (Mattioni et al. 2003) 
k- N 334 69.3 74.1 72.2 
























a Prediction accuracies of this work listed here are based on independent evaluation sets, 
which are similar to those based on 5-fold cross-validation. Since different groups used 
acies given in this table only reflect the relative 
y
b Best performance characteristics of the three programs were selected. 
different sets of descriptors, the accur
efficienc  of each method. 
 
 The GT+ accuracies of these four methods are comparable and in some cases 
slightly better than those of earlier studies derived from kNN (Mattioni et al. 2003; 
Mosier et al. 2003) and the consensus model developed with kNN, LDA, and 
PNN (He et al. 2003). The GT- accuracies of these four methods are comparable to 
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those of earlier studies (He et al. 2003; Mattioni et al. 2003; Mosier et al. 2003; 
Snyder et al. 2004). The results from all of these statistical learning methods are 
bstantially better than those obtained by DEREK, TOPKAT, MCASE 
the applicability domain of odels et ). he  
suggest that the better prediction performance of the qSPkR models developed in this 
work is likely due to the use of a more diverse and larger number of compounds and 
the capability of statistical ethods for classification of a mo  
o n tha uctural alert-based approaches. 
  study suggests that statistical learning methods, particularly SVM, 
k NN, are us icity asses pounds. 
The prediction accuracy of these methods is at a similar level as those of earlier 
studies that were tested by using a much smaller number of molecules. Another 
advantage of these me is that they do not require know o r 
m ture activity relationship (SAR) of a particular drug property. 
Moreover, the classification speed of these methods is generally fast. For instance, the 
number of compounds which can be classified per second by using SVM, kNN, PNN 
and C4.5 DT method is approximately 4000, 3000, 2000 and 62000 respectively on a 
 
training set. Thus the classification speed of SVM is usually 25-55% faster than that 
of kNN and PNN. On the other hand, the classification speed of SVM is slower than 
that of C4.5 DT which uses a set of rules to reach a decision leaf. 
su
programs (Snyder et al. 2004). Diversity of the training sets has been shown to affect 
 QSPkR m (Dimitrov al. 2005  Thus t  results
learning m re diverse range
f molecules tha t of str
Overall, our
NN and P eful for genotox sment of a broad range of com
thods ledge about the m lecula
echanism or struc
P4 3.6Ghz machine. SVM typically uses a portion of the training set as support 
vectors for classification. In contrast, kNN and PNN use the whole training set for 
classification. The number of support vectors of SVM is in the range of 45-75% of the
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 There are six GT+ and seven GT- compounds in the independent validation 
set that were misclassified by SVM, which are shown in Figure 8.1 and Figure 8.2 
respectively.  
 
Figure 8.1 Six structures of misclassified GT+ compounds in the independent 
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Figure 8.2 Seven structures of misclassified GT- compounds in the independent 
number of these compounds are shown in the figure. 
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 The six misclassified GT+ compounds are mebendazole, clomiphene, 
lansoprazole, clarithromycin, imipramine and ampicillin. From the study of Snyder et. 
al (Snyder et al. 2004), ampicillin, imipramine and lansoprazole were also 
misclassified by MCASE, DEREK and TOPKAT. Clomiphene was misclassified by 
MCASE and TOPKAT, but correctly classified by DEREK which alerts the 
halogen r et al. 2004). Mebendazole was misclassified by 
DEREK but predicted as equivocal genotoxicity by TOPKAT and by MCASE as 
GT+ with 57% probability (Snyder et al. 2004). To the best of our knowledge, there 
is no computational study on clarithromycin, which has been found to be GT+ in the 
in vitro cytogenetics tests (Snyder et al. 2001) but GT- in other assays such as 
bacterial mutation (Ames), mouse lymphoma assay (MLA), and in vivo cytogenetics. 
 ased expert system ation 
model (Greene 2002). MCASE performs a quantitative prediction by generating each 
test molecule into 2-10 atoms fragments by consideration of their physicochemical 
properties (Greene 2002). TOPKAT uses electrotopological states as well as shape, 
symmetry, molecular weight and logP as descriptors in a QSAR model for 
prediction (Greene 2002). Although each of these methods is able to correctly predict 
one of th  misclassified by our method, there are also GT+ 
com (Snyder et al. 2004), correctly 
predicted by our method but misclassified by each of these methods. While all of the 
methods misclassified some of the GT+ compounds due to the general inadequacy for 
fully representing all of the properties of these molecules, each method appears to be 
more useful to specific types of compounds than other methods. For instance, 
clomiphene is correctly predicted by DEREK because of the use of knowledge-based 
alert for halogenated alkene stru assified by our method because 
ated alkene structure (Snyde
DEREK is a knowledge-b  of qualitative estim
e six GT+ compounds
pounds, such as naloxone and pentobarbital 
cture, while it is miscl
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of the lack of a descriptor to properly represent halogen atoms. Thus the use of 
multiple methods may be useful to cover a more diverse set of compounds. 
 The seven misclassified GT- compounds are dansyltryptamine, ketotifen, 2-
chloro-4-(4-methoxyphenyl)-3-phenylquinoline, ceftibuten, 5-chloro-1,3-dihydro-
1,3,3 trimethylspiro, candesartan, and indinavir. Both candesartan and indinavir were 
correctly classified by MCASE, DEREK and TOPKAT (Snyder et al. 2004). 
Ketotifen was correctly classified by MCASE and DEREK, but misclassified by 
TOPKAT (Snyder et al. 2004). Ceftibuten was correctly classified by MCASE and 
TOPKAT, but misclassified by DEREK (Snyder et al. 2004). The first two 
compounds contain aromatic amines, the third contains an α,β-unsaturated ketone 
group, the fourth is composed of an α,β-unsaturated amide group, These chemical 
groups can be easily distinguished from the structural alerts of genotoxicity (Ashby 
1985) used in MCASE, DEREK and TOPKAT, but they are not properly described by 
the commonly used molecular descriptors. This is perhaps the reason why our method 
failed to correctly classify these four compounds. Dansyltryptamine, 2-chloro-4-(4-
methoxyphenyl)-3-phenylquinoline and 5-chloro-1,3-dihydro-1,3,3 trimethylspiro 
were correctly predicted by using LDA, kNN, PNN and their consensus model in an 
earlier study (He et al. 2003). These are polycyclic aromatic compounds that contain 
either chlorine atom or aromatic amine and a N-dimethyl group. One possible reason 
for the correct prediction of these compounds in that study (He et al. 2003) is that it 
focused on polycyclic aromatic compounds only and thus was easier to select all of 
the relevant features without the concern of introducing noise for other types of 
chemical groups. In contrast, our study includes a diverse set of compounds, and our 
feature selection method can only pick up those descriptors that are both relevant to 
the polycyclic aromatic compounds and without significant noise to other types of 
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compounds. It is also noted that there are polycyclic aromatic compounds, such as 9-
aminophenanthrene and ethyl 5-hydroxy-2-methylindole-3-carb-oxylate that were 
correctly predicted by our method and misclassified in the earlier study (He et al. 
2003). This seems to suggest that the currently available descriptors may not be fully 
representative of the polycyclic aromatic compounds. 
 In general, the main reason for the SVM misclassification of these GT+ and 
GT- compounds is that none of the current descriptors adequately represents the 
compounds containing multi-rings with various heteroatoms such as nitrogen, oxygen, 
sulphur, fluorine and chlorine. Current topological descriptors are capable of 
representing molecular shape, connectivity, and some level of molecular 
flexibility (Basak et al. 1999; Luco 1999; Wegner et al. 2004). However, because of 
the limited coverage of the number of bond links in a heteroatom loop, these 
descriptors are not yet capable of describing the special features of a complex multi-
ring structure that contains multiple heteroatoms. Another reason for the 
misclassification of some of these compounds is that none of the current descriptors 
can be used to fully represent molecules containing a long flexible chain. Therefore, 
there is a need to explore different combination of descriptors and to select more 
optimum set of descriptors by using more refined feature selection algorithms and 
parameters. However, indiscriminate use of many existing topological descriptors, 
which are overlapping and redundant to each others, may introduce noise as well as 
extending the coverage of some aspects of these special features. Thus, it may be 
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8.1.4 Conclusion 
 This study shows that statistical learning methods, particularly SVM, kNN, 
and PNN, are useful for facilitating the prediction of GT+ potential of a diverse set of 
molecules without requiring the intrinsic mechanism knowledge of chemical 
compounds. The prediction accuracy of these methods may be further improved by 
troduin cing molecular descriptors that can better represent complex ring structures 
and flexible long chains and by selection of descriptors most relevant to genotoxicity 
prediction by means of more refined feature selection methods and parameters. 
Current efforts are directed at the improvement of the efficiency and speed of feature 
selection methods (Furlanello et al. 2003), which can further help to optimally select 
molecular descriptors and enable the development of more accurate and efficient 
computational tools for genotoxicity prediction. Moreover, recent works on the 
introduction of weighting function into SVM descriptors (Chapelle et al. 2002) may 
also be helpful in developing SVM into a practical tool for the prediction of 
toxicological properties of compounds. 
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8.2 Torsade de Pointes 
l. 2000; Devillers 2000). 
So far, attention has not been sufficiently paid to the development of methods 
for prediction of serious ADRs that occur less frequently. While these ADRs are 
tolerated to a certain extent for the approval of drugs used in serious diseases urgently 
needing effective or more treatment options such as AIDS and cancer (Somers et al. 
1990), they are nonetheless important safety issues for the approval of drugs intended 
for minor illnesses with availability of alternative treatment options. Examples of 
these illnesses are rhinitis, cough, pain, inflammation and hypertension. Therefore, 
there is a need to develop computational methods for facilitating the prediction of the 
ADRs of these drugs. 
8.2.1 Introduction 
 In an effort to improve the efficiency of drug discovery, computational tools 
for ADR prediction have been developed, aimed at facilitating the elimination of 
ADR causing compounds in early stages of drug development (Kennedy 1997; van de 
Waterbeemd et al. 2003). Mechanism-based knowledge systems (Sanderson et al. 
1991; Smithing et al. 1992) and statistical models describing the correlation between 
specific ADR and structure-derived physicochemical features (Klopman 1992; Prival 
2001) have been developed. Moreover, ligand-protein docking methods have also 
been explored for the prediction of ADR by screening ADR-inducing drug-protein 
interactions (Chen et al. 2001; Rockey et al. 2002). These methods have shown 
promising potential in the prediction of such ADRs as carcinogenicity, mutagenicity, 
teratogenicity, irritation, sensitization, immunotoxicity and neurotoxicity (Cronin et al. 
1994; Kulkarni et al. 1999; Benigni et a
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 One such ADR is torsade de pointes (TdP), which is an atypical rapid 
ventricular tachycardia with periodic waxing and waning of amplitude of the QRS 
plexes about the 
larly human ether-a-
 HERG K+ channel (Muzikant et al. 2002). Thus, it is desirable 
complexes on the electrocardiogram as well as rotation of the com
isoelectric line (Saunders 2000). TdP may be self-limited or may progress to 
ventricular fibrillation (Saunders 2000). This ADR is uncommon (Darpo 2001) and 
thus difficult to detect during clinical trials. There are cases of TdP-causing drugs 
which were initially approved and later withdrawn after post-marketing surveillance 
revealed their TdP-causing potential (De Ponti et al. 2002; Layton et al. 2003). 
 Not all mechanisms of TdP are completely understood (Moss 1999). TdP is 
frequently associated with QT prolongation, which is the lengthening of the time 
between the start of ventricular depolarization and the end of ventricular 
repolarization. This arises from the disruption of the balance between inward and 
outward currents during the cardiac action potential repolarization phase (Malik et al. 
2001). Drugs that induce QT prolongation usually cause disruption of the outward 
potassium currents by blocking potassium ion channels, particu
gogo related gene (HERG) K+ channel (Vandenberg et al. 2001). This correlation 
between QT prolongation and blockade of relevant channels had been exploited in the 
development of computational methods for the prediction of the QT prolongation risk 
of drugs using artificial neural network (Roche et al. 2002) and pharmacophore 
models (Cavalli et al. 2002).  
 There is no definitive correlation between QT prolongation and TdP (Malik et 
al. 2001; Muzikant et al. 2002). For instance, verapamil causes QT prolongation but 
does not induce TdP, whereas procainamide and disopyramide cause TdP but are not 
potent inhibitors of the
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to develop a method capable of prediction of TdP of multiple mechanisms without 
complete knowledge of these mechanisms. 
 A useful method for classification of systems with multiple mechanisms 
without requiring their knowledge is SVM. This work explores the use of SVM as a 




nds, also identified from human studies, were collected 
om M
satisfying either criterion Ia or IIIa. Criterion Ia is the existence of clinical studies 
8  Selection of TdP- and non-TdP-causing compounds 
 TdP-causing (TdP+) compounds were collected from 
ArizonaCERT (ArizonaCERT). These compounds were identified from human 
studies and can be divided into 4 classes: Class 1 contains compounds with risk of 
TdP, class 2 includes compounds with possible risk of TdP, class 3 is composed of 
compounds to be avoided by congenital long QT patients and class 4 contains 
compounds which have been weakly associated with TdP. Only compounds from 
class 1, 2 and 3 were used for training the SVM system. Compounds in class 4 were 
not considered because it is unclear which of the compounds definitely induces TdP. 
Thus 67 TdP+ compounds were selected and used as the training set.  
 To objectively assess the prediction accuracy of our SVM system, an 
additional set of TdP+ compou
fr icromedex (MICROMEDEX 2003b), Drug Information Handbook (Lacy et al. 
2002), Meyler's side effects of drugs (Dukes 1996) and a list of compounds compiled 
by De Ponti et al (De Ponti et al. 2001), The selection criteria for the compounds are: 
(1) compounds with known TdP side effects and (2) compounds from De Ponti’s list 
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and/or case reports associating the compound with the occurrence of TdP/ventricular 
tachyarrhythmias. Criterion IIIa is the presence of official warnings in the labeling on 
2, 3 or 4 of the ArizonaCERT list. This gives an 
dependent validation set of 39 TdP+ compounds. 
 Like in the case of other classification systems, training of a SVM system 
requires information about non-TdP-causing (TdP-) compounds. In this work, 243 
edex, Drug Information 
8.2.2.2 Chemical descriptors 
 In this work, linear solvation energy relationships (LSER) descriptors (Kamlet 
et al. 1981; Kamlet et al. 1987; Abraham 1993) were used for the modeling of TdP-
causing potential of compounds. LSER descriptors describe solvent-solute 
interactions and contain three main terms: a cavity term, a polar term, and hydrogen-
bond term. The cavity term is a measure of the endoergic cavity-forming process, 
which is the free energy necessary to separate the solvent molecules, overcoming 
solvent-solvent cohesive interactions, and provides a suitably size cavity for the solute. 
The polar term measures the exoergic balance of solute-solvent and solute-solute 
QT prolongation or occurrence of TdP. The exclusion criteria are: (1) compounds 
known to be involved in QT prolongation without information about their effect on 
TdP, (2) compounds in class 1, 
in
TdP- compounds were obtained from the search of Microm
Handbook and American Hospital Formulary Service (AHFS)  (Bethesda 2001) for 
compounds with no reported case of TdP in humans. 39 of these compounds were 
randomly selected and used as part of the independent validation set to assess the 
prediction accuracy of the SVM system on TdP- compounds, while the rest were used 
in the training set. 
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dipolarity/polarizability interactions and the hydrogen-bond term measures the 
exoergic effects of the complexation between solutes and solvents.  
 LSER was initially developed for the estimation of the effects of different 
solvents on properties of specific solutes or the solubilities, lipophilicities, or other 
properties of a set of different solutes in a specific solvent. It has since been extended 
for analysis of biological properties including toxicological properties of 
mpou
cribed as a solvent system and LSER methods provide useful 
sights into important binding features (Cramer et al. 1992). Thus, the polar term 
may represent the binding action via dispersion forces of a chemical in the polar 
regions of a receptor molecule and the hydrogen bond term represents the hydrogen-
bonding effect between the chemical and the receptor molecule (Lowrey et al. 1997; 
Liu et al. 2003). Since toxicity of a compound involves the transport of the compound 
to a site and its interaction with a molecular target, LSER descriptors are thus likely to 
be useful for TdP modeling.  
 The LSER descriptors used in this study was calculated using our own 
developed software based on the method developed by Platts (Platts et al. 1999). The 
accuracy of these calculated descriptors for some of the compounds has been verified 
using the demo version of the software Absolv (Sirius 2000). These descriptors are 
co nds (Wilson et al. 1991; He et al. 1995; Sixt et al. 1995; Dai et al. 2001; Yu et 
al. 2002; Liu et al. 2003), cell permeation (Platts et al. 2000), intestinal 
absorption (Zhao et al. 2001) and blood-brain barrier penetration (Platts et al. 2001). 
LSER descriptors encode the size, polarity and hydrogen bonding capability of a 
chemical which have been found to be important for the passive transport of a 
chemical through biological membranes (Gratton et al. 1997; Kramer et al. 2001). In 
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excess molar refraction, combined dipolarity/polarizability, overall solute hydrogen 
bond acidity, overall solute hydrogen bond basicity and McGowan’s characteristic 
lume
8.2.2.3 Validation of SVM classification system 
 In this work, the SVM classification system was optimized and validated using 
leave-one-out (LOO) cross-validation. Y-randomization was also used to validate the 
trained SVM classification system. The randomization is repeated 10 times and LOO 
accuracies of the new classification system from each run are compared to that of the 
original classification system. If the scrambled training set gives significantly lower 
LOO accuracies than the original training set, the original classification system is 
unlikely to arise as a result of chance correlation. 
 The final SVM classification system was then tested by using the independent 
validation set to objectively assess its predictive capability. Prediction accuracy of the 
final SVM classification system using this independent validation was compared with 
those derived from three other classification methods useful for the prediction of 
multiple mechanisms. These methods are PNN, kNN and C4.5 DT. The three 
classification systems were trained using the same training set, descriptors and 






 A principal component analysis (PCA)  (Wold et al. 1987) on all of the five 
LSER descriptors was performed using the training set. PCA resulted in two principal 
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components (PCs) which explained 84.6% of the total variance in the five LSER 
descriptors. Component one and two explained 70.2% and 14.4% of the variance 
respectively. Figure 8.3 shows a score plot of the compounds in the training set using 
e first two PCs. Score plots are useful for comparing the distribution of compounds 
in the chemical space between two datasets and to identify clusters of compounds and 
single compounds that may be outliers (Wold et al. 1987; Doddareddy et al. 2006). 
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 Octreotide, a TdP+ compound, and desmopressin, a TdP- compound, was 
found to be far out to the right of the score space. Both of these compounds are large 
in size, with molecular weight of approximately 1019 and 1069 respectively. There is 
also a cluster of TdP- compounds at the top of the score plot. This cluster mainly 
contains the aminoglycoside antibiotics like amikacin and gentamicin together with 
two other compounds, acarbose and zanamivir. Other than the aminoglycosides’ 
cluster, the score plot showed that TdP+ and TdP- compounds cannot be easily 
 LOO cross-validation was used to derive the optimum sigma parameter for the 
Gaussian kernel used by SVM and the optimum SVM classification system was found 
to have a LOO TdP+ accuracy of 71.6% and LOO TdP- accuracy of 86.3%. Both of 
these accuracies are significantly greater than 50%, indicating that the trained SVM 
classification system is significantly better than a random classifier. 
 To determine whether it results from chance correlation, the SVM 
classification system was further tested by repeating y randomization for 10 times. 
The average LOO TdP+ accuracy from these ten scrambled classification systems is 
21.2% and the average LOO TdP- accuracy is 77.3%. Both of these accuracies are 
worse than that of the original SVM classification system, indicating that the SVM 
classification system is produced as a result of actual correlation between LSER 
descriptors and TdP-causing potential of the chemicals and not due to chance.  
 There has been no reported computational study of the TdP-causing potential 
of a compound. Thus to objectively assess the usefulness of SVM for TdP prediction, 
its prediction accuracy is compared with those obtained from three other classification 
methods, C4.5 DT, kNN and PNN, using the same independent validation set. The 
optimum parameters, k for kNN and σ for PNN, were found by using LOO cross-
separated using their PCs. 
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validation. The optimum parameters for SVM, PNN and kNN and the accuracy results 
are given in Table 8.5. SVM has the highest overall accuracy among the four 
classification methods. Its TdP+ accuracy of 97.4% is substantially higher than the 
other three classification methods which have TdP+ accuracies of 38.5-89.7%. Its 
TdP- accuracy of 84.6% is comparable to the other three methods which have TdP- 
accuracies of 84.6-92.3%. These results suggest that SVM is potentially useful for 
facilitating the prediction of TdP causing risk of investigative compounds and likely 
other ADRs with multiple mechanisms. In addition, the SVM classification system is 
ot mo
TdP+ TdP- 
n re flexible than is necessary and thus unlikely to overfit. 
 
Table 8.5 Results of various classification methods on independent validation set. 
Method Optimum Q (%) 
parameter TP FN SE (%) TN FP SP (%) 
C4.5 DT - 15 24 38.5 36 3 92.3 65.4 
kN 3 35 4 89.7 34 5 87.2 88.5 
PNN 0.1 28 11 71.8 33 6 84.6 78.2 
SVM 0.3 38 1 97.4 33 6 84.6 91.0 
N 
 
 In the training set, there are several aminoglycoside antibiotics grouped 
together in a cluster which does not overlap significantly with the main cluster of 
compounds. To examine whether this cluster of aminoglycoside antibiotics contribute 
in some way to the high TdP+ accuracy, a new SVM classification system was 
trained with all of the aminoglycoside antibiotics removed from the training set. The 
new SVM classification system gives the same TdP+ and TdP- accuracies as the 
original system. This suggests that the aminoglycoside antibiotics are not responsible 
for the high TdP+ accuracy of the SVM classification system. 
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 There are seven compounds incorrectly classified by our SVM system, which 
are shown in Figure 8.4. These include one TdP+ compound (prenylamine) and six 
TdP- compounds (medroxyprogesterone, medrysone, metirosine, penicillamine, 
pyridoxine, rimexolone). Their location on the score plot of the training set is shown 
in Figure 8.3 above. Prenylamine is incorrectly classified by SVM, PNN and C4.5 DT. 
Metirosine and pyridoxine are incorrectly classified by SVM, kNN and PNN while 
penicillamine is incorrectly classified by both SVM and PNN. Medroxyprogesterone, 
medrysone and rimexolone have a common steroidal structure and are consistently 
misclassified by all the four classification methods. This may indicate that the LSER 
escriptors are unable to fully describe the properties of steroidal compounds thus 
 
d
resulting in their misclassifications by all the four classification methods. 
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 To determine whether the LSER descriptors are sufficient for TdP prediction, 
we analyzed 490 commonly used descriptors for their relevance in TdP classification 
and used those essential descriptors to construct a separate SVM classification system. 
Results using that system are compared with the results using LSER descriptors. 
These descriptors can be broadly classified into four classes. The first class includes 
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descriptors for global properties of a molecule such as molecular weight, count of 
atoms, rings and rotatable bonds. The second class contains topological descriptors 
such as molecular connectivity indices (Kier et al. 1986), electrotopological 
indices (Kier et al. 1999), shape indices (Kier 1985) and flexibility indices (Kier 
1990). The third class is composed of geometric descriptors including molecular 
volume, surface area and polar surface area. The fourth class contains chemical 
descriptors such as dipole moment, polarizability and some of the VolSurf 
descriptors (Cruciani et al. 2000a). A preliminary screening was done to reduce the 
pool of descriptors by elim ptors that contained little information. 
Descriptors that have the same value for more than 50% o ounds were also 
removed. Backward elimination was then used to produce an optimum subset of 
descriptors. During backward elimination, LOO cross-validation was used to assess 
the performance of each subset of descriptors. In the end, the best subset of 
descriptors consists of 108 descriptors that are not highly correlated with one another. 
These 108 descriptors were used to train the SVM classification system and the 
resultant system has TdP+ and TdP- accuracies of 92.3% and 84.6% on the 
independent validation set. These results are comparable to that of the current study. 
This suggests that LSER descriptors are equally useful for prediction of TdP as those 
using a more diverse set of descriptors. 
.2.4 





 In this study, SVM classification system is compared with three other 
classification methods and the results suggest that SVM classification system has the 
best predictive ability among the four methods. All of these classification methods 
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algorithms than standard statistical methods. Thus to fully evaluate the performance 
of SVM classification system, a standard statistical method, logistic regression, was 
applied to the classification of the same TdP+ and TdP- datasets. The TdP+ 
prediction accuracy using the independent validation set using logistic regression is 
only 20.5%. In addition, y randomization validation tests showed that the LOO TdP- 
accuracy of the logistic regression model is less than the mean LOO TdP- accuracies 
of the scrambled models. Thus the logistic regression model, as a method for systems 
with unique mechanism, is not suitable for TdP classification which is intrinsically a 
multi-mechanism problem.  
 The possible reason for the usefulness of LSER descriptors for TdP prediction 
is that they roughly encode most of the essential characteristics related to the TdP 
causing capability of a compound. Excess molar refraction represents the tendency of 
a compound to interact with a receptor through n- and π-electron pairs and thus is a 
measure of the hydrophobic interaction between the compound and receptor. The 
combined dipolarity/polarizability, on the other hand, represents the ability of 
electrons to move and be delocalized in the chemical and is a measure of the polar 
interaction between the compound and receptor.  
 The overall solute hydrogen bond acidity, overall solute hydrogen bond 
basicity represents the ability of the compound to form hydrogen bonds with the 
ceptor. This, together with the hydrophobic and polar interactions encoded by the 
n and combined dipolarity/polarizability, determines the 
binding affinity of the chemical for the receptor.  
 The McGowan’s characteristic volume influences the passage of a chemical 
through biological membranes. A compound with a large volume may have difficulty 
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unable to reach its toxicity receptor. In addition, the binding site of a receptor is 
usually a cavity that can accommodate compounds of a specific range of sizes and 
shapes.  
 Currently, with the exception of C4.5 DT which is able to generate decision 
rules, the other three classification methods are unable to determine the relative 
importance of individual LSER descriptor. This limits the scope of the application of 
SVM classification systems in drug design to tasks such as high-throughput screening. 
With further improvement of SVM algorithm such as the introduction of weighting 
function to the descriptors (Chapelle et al. 2002), specific rules of the descriptors may 
 of TdP in patients. Thus a positive 
afer alternatives, like fexofenadine 
be derived which in turn extend the application range of SVM classification systems. 
 As with all other in silico predictions of toxicological properties of chemical 
compounds, prediction of TdP-causing potential by SVM should be assessed together 
with pharmacokinetic and pharmacodynamic properties of the chemical compounds in 
order to determine their clinical significance. This is because a potential TdP-causing 
drug is not the sole factor in precipitating TdP in a patient. Variability in drug 
concentrations, drug/drug interactions and individual patient’s susceptibility are some 
of the numerous factors that affect the occurrence
TdP-causing risk of a drug-like molecule may not preclude its use in the clinical 
setting (Malik et al. 2001). For example, both halofantrine and terfenadine can 
potentially cause TdP. However, halofantrine is still in use whereas terfenadine has 
been withdrawn from the US market as halofantrine is useful for resistant malaria 
treatment but for terfenadine, there are other s
available (Malik et al. 2001). Despite the limitations of in silico prediction of TdP, it 
may be used as part of the overall risk-benefit analysis of investigative drugs to 
evaluate their usefulness in the clinical setting. 
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8.2.5 Conclusion 
 As a statistical learning method for the prediction of systems with multiple 
mechanisms, SVM is potentially useful for facilitating the prediction of TdP causing 
risk of investigative drugs. The availability of more extensive information about 
various ADR-causing compounds and associated mechanisms and more 
comprehensive descriptors for toxicity prediction will enable the development of 
SVM and other computational methods into useful tools for facilitating the prediction 
of different types ADRs in early stage of drug development. 
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Chapter 9 
 (section 9.4) are also 
discussed. 
 
9.1 Major Findings 
 In chapters 4, 6 and 8, support vector machine (SVM) was shown to be a 
useful computational method for facilitating the prediction of ADMET properties like 
human intestinal absorption (HIA), p-glycoprotein (P-gp) substrates, cytochrome 
(CYP) P450 isoenzymes inhibitors and substrates, genotoxicity and torsade de pointes 
(TdP), without requiring the intrinsic mechanism knowledge of chemical compounds. 
Thus it is likely that SVM will be an efficient computational tool for the prediction of 
ADMET properties of chemical compounds. 
 In chapters 4 and 8, recursive feature elimination (RFE) was found to be 
capable of automatic selection of molecular descriptors and reduction of the noise 
generated by the use of overlapping and redundant molecular descriptors. This 
reduction appears to be helpful in enhancement of the performance of SVM for the 
prediction of ADMET properties of chemical compounds. 
Conclusions 
 
 This last chapter summarizes the major findings (section 9.1) and 
contributions (section 9.2) of this work to the progress of using machine learning 
approaches for pharmacokinetics and toxicity predictions. Limitations of the present 
work (section 9.3) and possible areas for future studies
 
CHAPTER 9: CONCLUSIONS 205
 In chapter 6, our study suggests that consensus classification systems give 
better predictive performance than single classification systems. This result is 
rlier studies. All of the ‘positive probability’ consensus SVM 
lassification systems (PP-CSVMs) for predicting inhibitors/substrates of the three 
inhibitors and substrates of various P450 isoenzymes. Thus CSVMs, 
articularly PP-CSVM, are potentially useful for developing filters for prediction of 
inhibitors and substrates of P450 isoenzymes and other ADMET properties. 
results suggest that general regression neural network 
apability than the corresponding MLR- 
ared with those developed 
by using a linear method, partial least squares (PLS). All of the GRNN- and SVR-
consistent with ea
c
P450 isoenzymes, CYP3A4, CYP2D6 and CYP2C9, show high prediction accuracies, 
with improved specificities compared to those of earlier studies. Our computational 
results suggest PP-CSVM is better than ‘positive majority’ consensus SVM 
classification system (PM-CSVM) for constructing consensus SVMs (CSVMs) for 
classifying 
p
 In chapter 5, our 
(GRNN) is a potentially useful method for developing QSPkR models from a diverse 
set of drug data. QSPkR models developed by using GRNN for three drug distribution 
properties, blood-brain barrier (BBB) penetration, human serum albumin (HSA) 
binding, and milk-plasma (M/P) distribution, were tested and compared with those 
developed by using a linear method, multiple linear regression (MLR), and a non-
linear method, multilayer feedforward neural network (MLFN). All the GRNN-
developed models showed better prediction c
or MLFN-developed models.  
 In chapter 7, our study suggests that both GRNN and support vector regression 
(SVR) are potentially useful for developing QSPkR models to predict drug clearance 
from a large diverse set of compound data. QSPkR models developed by using GRNN, 
SVR and k nearest neighbour (kNN) were tested and comp
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developed models show better prediction capability than the corresponding kNN- or 
PLS-developed models. The predictive capabilities of the QSPkR models developed 
in this study are comparable to those of previous studies and are further improved by 
using consensus modeling methods.  
 In chapter 7, we also found that a collection of constitutional, geometrical, 
topological and electrotopological descriptors seems to be more useful for modeling 
drug clearance than specialized descriptor sets such as 3DMoRSE, ATS, GETAWAY, 
RDF and WHIM. A possible reason is that an individual descriptor set tends to 
partially neglect some important features and thus the use of different types of 
descriptors may help to alleviate such type of feature bias. The three statistical 
learning methods, GRNN, SVR and kNN, appears to be capable of combining the 
forma
gle model. The ADMET property of a compound is 
in tion encoded in the different descriptor sets effectively to develop more 
predictive QSPkR models. 
 Non-linear methods, such as SVM, GRNN, and SVR, are useful for 
developing QSPkR/qSPkR models involving multiple mechanisms because they 
belong to the class of distance-based methods. In a diverse dataset, compounds having 
the same mechanism of actions will be close to one another in the chemical space and 
compounds having different mechanism of actions will be far apart. In distance-based 
methods, multiple localized models were developed for each mechanism and these 
were then combined into a sin
predicted by measuring the distance between the compound and the various localized 
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9.2 Contributions 
 This work has improved the quality of previous QSPkR/qSPkR models for 
ADMET prediction. All the QSPkR/qSPkR models developed in this work have 
higher prediction capability than the corresponding models developed by other 
 better generalization ability than the previous models and 
. 
esults from this work suggest that the use of multi-sigma GRNN models and PCA 
an partially solve this problem. The individual σ values for each descriptor provide a 
useful hint about its contribution to the ADMET properties. PCA, when coupled with 
workers. The use of known, relative new machine learning methods, such as SVM, 
SVR and GRNN, and consensus modeling was found to be useful for improving 
prediction capability of QSPkR/qSPkR models for HIA, P-gp substrates, BBB 
penetration, HSA binding, M/P, CYP isoenzymes substrates and inhibitors, total body 
clearance, and genotoxicity. A qSPkR model was also constructed for TdP, a rare but 
serious adverse drug reaction, which have not received sufficient attention. These 
models were also developed by using a larger number and more diverse groups of 
compounds, as well as compounds with known human ADMET data. Thus the 
models are expected to have
are directly applicable for the prediction of human ADMET property without the need 
for allometric scaling to convert predicted animal ADMET property to human 
ADMET property like in the previous models. Hence, the QSPkR/qSPkR models 
developed in this work are potentially useful to be incorporated as part of the strategy 
for reducing the cost and improving the speed of drug development. 
 This work introduces a novel principal component analysis (PCA) based 
method to improve the interpretability of QSPkR models. Most of the non-linear 
methods including neural networks are incapable of providing explicit relationships 
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specially designed artificial testing sets, may provide a rough guide for the influence 
 mol
ods to measure 
of ecular characteristics on ADMET properties. Hence the development of the 
novel PCA-based functional dependence study approach in this work has helped to 
improve the interpretability of non-linear models, which were previously difficult to 
interpret.  
  A new machine learning library, YMLL, and a new Microsoft Windows 
software, PHAKISO, were designed and developed in this work to enable 
QSPkR/qSPkR models to be developed and validated easily. The library and software 
were better than existing software, Torch and Weka, for developing QSPkR/qSPkR 
models because Torch and Weka were developed for general machine learning 
problems whereas YMLL and PHAKISO were developed specifically for 
QSPkR/qSPkR problems. Thus YMLL and PHAKISO contain algorithms which were 
more relevant for QSPkR/qSPkR problems. In addition, PHAKISO presents a user-
friendly graphical user interface to enable QSPkR/qSPkR models to be built with a 
few mouse clicks. Torch, on the other hand, does not have a graphical user interface 
and thus is difficult to be used by scientists who are not familiar with programming. 
Both Torch and Weka also have a limited number of descriptor selection methods, 
especially wrapper methods, and have a limited number of meth
prediction capabilities of QSPkR/qSPkR models. Hence the development of YMLL 
and PHAKISO in this work and the availability of both software for non-commercial 
uses are expected to aid scientists in creating QSPkR/qSPkR models rapidly and thus 
speed up the drug development process.  
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9.3 Limitations 
 The performance of machine learning methods critically depends on the 
diversity of compounds in a training dataset and the appropriate representation of 
these compounds. The datasets used in this work are not expected to be fully 
representative of all of the compounds possessing and not possessing a specific 
ies related specifically to conformational 
 present. In addition, molecular dipole moment is ill-defined since the 
associated “active conformation” for the dipole is unknown. The insufficient use of 3-
D descriptors may affect the prediction capability and interpretation of the 
ADMET property. This is particularly true for compounds not possessing a specific 
property given the vast chemical space of millions of known compounds in the 
currently available chemical database. Various degrees of inadequate compound 
representation in these studies likely affect, to a certain extent, the prediction accuracy 
of the developed QSPkR/qSPkR models. 
 In chapter 6, a potential problem is that the selection criteria for non-inhibitors 
and non-substrates of CYP isoenzymes may result in a small number of false 
negatives. However, the use of SVM was found to help in achieving a balance 
between training errors and prediction accuracies. The CSVMs are presently only 
suitable for distinguishing between inhibitors and non-inhibitors or substrates and 
non-substrates. The availability of more detailed experimental data will enable the use 
of multi-class SVM (Angulo et al. 2003) for the classification of non-inhibitors, weak 
inhibitors and strong inhibitors, or SVM regression (Smola et al.) for quantitative 
prediction of the Ki values of inhibitors. 
 Most of the descriptors used in this study are 1-D and 2-D in information 
content about the molecule. Some of the descriptors have some 3-D content such as 
molecular dipole moment, but propert
entropy, are not
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QSPkR/qSPkR models. For example, in BBB penetration, transport across a series of 
lass level where redundant and overlapping 
tures that often seem to present in molecules 
tightly packed biological membranes is involved. There are no meaningful 1-D and 2-
D descriptors that can distinguish between a long, thin and flexible conformation of a 
molecule from a spherical, balled-up and rigid confirmation of a molecule and this 
difference in conformational preference is a controlling factor for BBB penetration. 
 Some of the descriptors used in this study may be highly correlated and thus 
are very likely redundant in information content. Descriptors which are essentially the 
same do not necessarily equate to a large information content regarding distinct 
molecular properties. Hence the interpretation of the descriptors should be more 
appropriately conducted at the descriptor c
descriptors are grouped into one class. PCA can also be used to group descriptors 
sharing the same information content into one principal component (PC) and 
performing functional dependence study on the individual PCs rather than on the 
individual descriptors. 
 Currently, three-levels of characterizing a mechanism of action from a 
QSPkR/qSPkR model are usually reported in the literature. The first level is stating 
the specific groups and their interactions of a molecule responsible for activity. The 
second level is providing a pharmacophore needed for expressing the activity, and the 
last level is stating general molecular fea
exhibiting a given type of activity. All the QSPkR/qSPkR models that were developed 
in this study fall into the third, least specific category. 
 Examinations of incorrectly classified compounds in this work have 
consistently suggested that the current molecular descriptors are not sufficient to 
adequately represent some of the compounds that contain complex structural or 
chemical configurations (Figure 9.1). These include compounds containing long 
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flexible chains, highly polar tetrazole rings, multiple ionisable groups, polycyclic 
aromatic structures, complex two ring system with multiple heteroatoms, aromatic 
rings separated by a specific atom, compounds with multiple heteroatoms and 
compounds with complicated ring structure. Due to the limited coverage of the 
number of bond links in a heteroatom loop, topological descriptors are not yet capable 
of describing the special features of a complex multi-ring structure that contains 
multiple heteroatoms. It appears that none of the currently available descriptors can be 
used to fully represent molecules containing a long flexible chain. 
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9.4 Suggestions for Future Studies 
 Some of the ADMET properties are known to correlate to specific 
pharmacodynamic properties which lead to clinical significance. For instance, a drug 
with high BB ratio may not have effects in the brain either because of the absence of 
target receptors or insufficient potencies towards the target receptors in the brain. 
Conversely, a d relatively low BB ratio he brain 
because of its high potency towards specific receptors ( . 1980). Such 
correlations, which have not been adequately considered in machine learning methods 
so far, may need to be incorporated in developing QSPkR/qSPkR models for 
predicting those ADMET properties that are known to correlate to certain 
pharmacodynamic property. 
 In th ssumed that  
classification system are equally important. However, in a drug discovery project, 
these accuracies may have different importance at different stages of the design cycle. 
For example, in the initial target and hit identification phase, it may be more 
imp ds. Thus, it is more important to have a 
classification s  has very high sensitivity (smal  false negatives) 
and reasonably good specificity. At later stages, it becomes increasingly important to 
focus on a manageable number of candidates. Thus a classification system with very 
high specificity (small number of false positives) and reasonably good sensitivity may 
become more important. It is possible to alter the SVM classification systems to suit 
these different needs. There are two possible approaches for modifying the SVM 
classification sy e first approach uses differe error penalties 
(equation (2.14)) for D+ and D-. For example, a higher training error penalty for D+ 
and lower training error penalty for D- can be used to increase the sensitivity of the 
rug with a may still have effects in t
Hallstrom et al
is work, it is a sensitivity a of the SVMnd specificity 
 
ortant not to miss potential lea
ystem which l number of
stems. Th nt training 
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SVM classification systems. The second approach adds a correction factor to the 
ular structures. This will improve the interpretability of 
SVM decision function (equation (2.12)). A positive or negative correction factor will 
improve the sensitivity or specificity of the SVM classification system respectively. 
 There is a need to explore different combination of descriptors and to select 
more optimum set of descriptors by using more refined feature selection algorithms 
and parameters. However, indiscriminate use of many existing topological descriptors, 
which are overlapping and redundant to each other, may introduce noise as well as 
extending the coverage of some of the aspects of these special features. Thus, it may 
be necessary to introduce new descriptors for more appropriately representing these 
and other special features. The new descriptors should ideally be able to be 
translated back to the molec
the QSPkR/qSPkR models.  
 In this work, RFE is incorporated into SVM classification systems for dividing 
molecules into two classes according to specific ADMET property. This method can 
also be applied to the prediction of ADMET properties in a continuous fashion. Future 
studies can combine RFE with SVR for providing non-linear QSPkR of specific 
ADMET properties. 
 Genetic programming (GP), an evolutionary programming approach, has been 
found to be useful for the development of qSPkR models for oral bioavailability 
prediction of a diverse group of compounds (Bains et al. 2002). This is because GP 
implements the IF logic to capture multiple mechanism of action within a single 
model. Thus evolutionary programming approaches, which have the potential to 
identify and optimize all independent QSPkR models consistent with the training set 
data, may be potentially useful for the prediction of the ADMET properties of 
chemical compounds. 
 
CHAPTER 9: CONCLUSIONS 215
 The lack of structural diversity in the training sets may limit the applicability 
of the models developed by machine learning. However, it may be possible to use 
analog compound training sets to provide benchmarks as to what upper-level models 
are possible from a given method for a given endpoint. Future studies can model high 
analog datasets as a way to evaluate how much accuracy and reliability is lost in 
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1: HIA+ compounds. 
 
Table 
Acebutolol Diazepam Lornoxicam Praziquantel 
Acetami
cetylsa Mercaptoethane sulfonic Progesterone 
Acrivast Methadone Propiverine 






affeine Granisetron Nisoldipine Sulindac 
aptopr Telmisartan 
efadroxil Ibuprofen Nordiazepam Tenidap 
Cefatrizine Imipramine Norfloxacin Tenoxicam 
Ceftizoxime Isoniazid Ofloxacin Terazosin 
Cephalexin Isoxicam Omeprazole Testosterone 
nophen Diclofenac Meloxicam Prazosin 
licylic acid Dihydrocodeine A
acid 
ine Disulfiram 
Alprazolam Ethambutol Methotrexate Propranolol 
A
Aminopyrine Famciclovir Metoprolol Quinidine 
llin Felodipine Mexiletine A
Amrinone Fenclofenac Morphine Saccharin 
ne Flecainide Moxonidine Salicylic acid 
 Fluconazole Naloxone At
Betaxolol Flumazenil Naproxen Sotalol 
epam Fluvastatin Nefazodone Spironolactone 
Bumetanide Gallopamil Nicotine Stavudine 
on Glyburide Nicotinic acid Sudoxicam 
C
Camazepam Guanabenz Nitrendipine Sultopride 




Chloramphenicol Isradipine Ondansetron Theophylline 
Cicaprost Ketoprofen Tiagabine 
c Oxazepam Timolol 
Clofibrate Labetalol Oxprenolol Tolbutamide 
Clonidine Lamivudine Oxyfedrine Tolmesoxide 
Codeine Lamotrigine Phenglutarimide Topiramate 
Corticosterone Lansoprazole Phenytoin Torasemide 
Cycloserine Levodopa Pindolol Toremifene 
Cyproterone-acetate Levonorgestrel Piroxicam Tramadol 
Desipramine Loracarbef Piroximone Trapidil 






Table 2: HIA- compo
 
unds. 
Acarbose Chlorothiazide Lactulose Pirbuterol 





Azithromycin Erythromycin Metformin Rimiterol 
Azosemide Etoposide Methyldopa Streptomycin 
Aztreonam Famotidine Metolazone Sulfasalazine 
umatriptan 
retyliumtosylate Gabapentin Neomycin Terbutaline 
Bromocriptine Ganciclovir Netivudine Thiacetazone 
Capreomycin Gliclazide Olsalazine Tranexamicacid 
Cefetamet-pivoxil Guanoxan Ouabain  
Ceftriaxone Hydrochlorothiazide Pafenolol  
Cefuroxime Kanamycin Phenoxymethylpenicillin  
Lincomycin Pravastat
Amiloride Ciprofloxa Lisinopril Raffinose 
Ampicillin Doxorubicin Lovastatin Ranitidine 
Ascorbic- Eflornithine Mannitol Reproterol 
Atenolol Enalapril Metaproter Ribavirin 
Benazepril Fenoterol Mibefradil Sulpiride 





Table 3: P-glycoprotein substrates. 
Compound t Compound Set Se  
Corticosterone Training  ning Prazosin Trai
Doxorubicin ing  ine Training 
ning  ir Training 
ining  henylphosphon Training 
-deoxypodoph raining  Training 
ng  fan Training 
e Training  ining 
aining  in aining 
one aining  Training 
ining  ramycin raining 
ining  aniline ing 
ining  cin   aining 
raining  ing 
raining  ol       Training 
A azine Training 
ining  Training 
hodamine123 Training  Epirubicin Testing 
Digitoxigenin Training  Quinine Testing 
Staurosporine Training  Vincristine Testing 
Isosafrole Training  Cis-flupenthixol Testing 
Lovastatin Training  Digitoxin Testing 
Fexofenadine Training  Methylprednisolone Testing 
Nimodipine Training  Idarubicin Testing 
Nelfinavir   Training  Verapamil Testing 
Methadone Training  Pafenolol Testing 
Trifluoperazine Training  Digoxigenin Testing 
Monensin Training  Terfenadine Testing 
Train Promaz
Quinidine Trai Ritonav
Vinblastine Tra Tetrap ium 
Acetamido yllotoxin T Bisantrene 
Fluphenazine   Traini Endosul
Hydrocortison Estriol Tra
Digoxin Tr Ivermect Tr
Dexamethas Tr Leupeptin   
Daunomycin Tra Mith T
HOE33342   Tra Pararos Train
GF120918-1    Tra Rapamy Tr
Diltiazem T S9788    Train
Colchicine T Safing
Cyclosporin- Training  Phenox




Ondansetron Training  Spiperone Testing 









   
curonide  
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                                    n 
  








ining ine ing 
Dexniguldipine   Training  Methylres Testing 
Saquinavir Training  Celiprolol Testing 
S-farnesylc Training  Cepharanthi Testing 
Reserpine Training  Puromycin Testing 
LY335979 Training  Docetaxel Testing 
Mitoxantrone Training  Mitomycin-C Testing 
Topotecan Training  Morphin Testing 
Dipyridam Training  Valinomycin Testing 
Haloperidol Training  Teniposide Testing 
Estradiol Training  Epothilone_A Testing 
Azidopine Training  Acebutolol Validation
Toremifene   Training  Adriamycin Validation
Paclitaxel Training  Aldostero Validation
Thioridazine Training  Calphostin_C Validation
Morphine-6-glu Training  Catharantine Validation
Nifedipine Training  Chlorpromazi Validation
Actinomycin_D Training  CP100356  Validatio
Cefoperazone  Training  Depredil   Validation 
Triflupromazin Training  Domperidon Validation 
Amiodaron Training  Emetine Validation 
Cefazolin Training  Etoposide Validatio
Cefotetan Training  Gallopamil Validatio
Clotrimazole Training  Hydroxyrub Validation 
Erythromyci Training  k02 Validation 
Flunitrazepa Training  Losartan Validation 
Loperamide Training  Nicardipine Validation 
Methotrexa Training  Perphenazine Validation 
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Phenobarbital    n Training  Rifampicin Validatio




Table 4: P-glycoprotein non- s
Compound  mpound 
substrate . 
Set Co Set 
 (Penzotti et al. 2002) Training  NSC268251 Training 4
NSC667558 Training  NSC606532   Training 
NSC676602                                      Training  NSC617286   Training 
NSC667532 Training  NSC639677 Training 
Prednisolone Training  NSC648403   Training 
Aminodeoxy Training  NSC666331   Training 
Cortexolone Training  NSC671400 Training 
Methoxychlor Training  NSC686028    Training 
Chlorambucil Training  S_farnesyl_cysteine Training 
NSC674570 Training  Aminocarb Training 
NSC49899 Training  Atrazine Training 
Deoxypodophyllotoxin Training  Chaps Training 
PSC833   Training  Dialifos Training 
NSC630148 Training  Dieldrin Training 
NSC630721 Training  Leptophos Training 
3 (Penzotti et al. 2002) Training  Mirex      Training 
Progesterone Training  Phosmet     Training 
Aldoxycarb Training  Systeine_methylester   Training 
L767679 Training  Triforine Training 
BIBW22 Training  Trypan_blue   Training 
NSC633528 Training  Vinclozolin Training 
Nigericin Training  NSC667551 Training 
NSC653278 Training  NSC676615 Training 
NSC623083 Training  Epipodophyllotoxin Training 
NSC668354 Training  Deoxycorticosterone Training 
Reserpic_acid Training  1 (Penzotti et al. 2002) Testing 
Fluazifop-butyl Training  2 (Penzotti et al. 2002) Testing 
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NSC664565 Training  Farnesol Testing 




 17  
6616  
2 lotoxin  
ining ing 
NSC667560 Training  Mevinphos Testing 
Cytarabine Training  Paraquat Testing 
NSC615985 Training  Propiconazole Testing 
NSC678047 Training  NSC676593 Testing 
NSC676610 Training  NSC676618 Testing 
Carbaryl Training  NSC674508 Testing 
Aldicarb Training  NSC309132 Testing 
Carmustine Training  NSC364080 Validation
Cyclophospham Training  NSC630357 Validation
Epinephrine Training  NSC667533 Validation
Fluorouracil Training  NSC6766 Validation
Lindane Training  NSC67 Validation
NSC31462 Training  Podophyl Validation




Table 5: Blood brain barrier p  datas
pound Lo Set Remarks 
enetration et. 
Com g BB 
2 -0.04 a ing Tr in   
4 -1.3 is et al. 2001; Platts et 
-1.17 a ing 
-2.15  Kaznessis et al. 200
-0.67 a ing 
-0.66 l ation 
-0.12 a ing 
-0.18 a ing 
-1.15 l ation 
-1.57 a ing 
-1.54 a ing 
-1.12  al. 1994; Platts et a
-0.73 994; Platts et a
-0.27 a ing 
3 -0.28 Training   
24 -0.46 Validation   
25 -0.24 Training   
26 -0.02 Training   
27 0.69 Validation   
28 0.44 Training   
30 0.22 Training   
33 -0.3 Validation   
34 -1.34 Validation   
35 -1.82 Training   
69 -0.16 Training   
111-trichloroethane 0.4 Training   
111-trifluoro-2-chloroethane 0.08 Training   
1-hydroxymidazolam -0.07 Training   
Outlier  (Kazness al. 2001) 
11 Tr in   
12 Outlier  (Luco 1999; 1) 
13 Tr in   
14 Va id   
15 Tr in   
16 Tr in   
17 Va id   
18 Tr in   
19 Tr in   
20 Outlier  (Abraham et l. 2001) 
21 Outlier  (Abraham et al. 1 l. 2001) 




22-dimethylbutane 1.04 Training   
2-methy 0.97 Vali    
ethylpropanol 

























2-m -0.17 Training   
2-pr -0.15 Training   
3-m 0.9 Training   
3-m 1.01 Training   
4-hydrox -0.3 Validation   
9-O -0.67 Training   
Ace -0.15 Training   
Ace -0.5 Training   
Alp 0.04 Validation   
Am 0 Training   
Am 0.89 Training   
Am 0.04 Training   
Arg 0.03 Not used Descriptors cannot be computed 
Ate -1.42 Training   
Ben 0.37 Training   
Bre -0.09 Training   
Bro 1.38 Training   
But -0.08 Training   
C15 0.39 Training   
C17 1.2 Training   
C7 0.11 Training   
Caf Validation   
Car 0 Training   
Car -0.34 Training   
Carm -0.52 Training   
Chlorambucil -1.7 Training   
Chlorpromazine 1.06 Validation   
Cimetidine -1.42 Training   
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Clobazam 0.35 Training   
Clonidine 0.11 Training   



















CS2 0.6 Training   
Cyclohexane 0.92 Training   
Cyclopropane 0 Training   
Desipramine 1.2 Validation   
Desmethylclobazam 0.36 Validation   
Desmethy 1.06 Validation   
Desmonomethylprom 0.59 Validation   
Di-(2-fluoroe 0.13 Training   
Diazepam 0.5 Validation   
Dichlorometha -0.11 Training   
Didanosine -1.3 Training   
Diethyl 0 Training   
Divinyl et 0.11 Training   
Domperid -0.78 Training   
Enflurane 0.24 Training   
Ethanol -0.16 Training   
Ether 0 Validation   
Ethyl 0.2 Training   
Flum -0.29 Training   
Flun 0.06 Training   
Fluphenaz 1.51 Outlier  (P
Fluroxene 0.1 Training   
Haloperidol 1.34 Training   
Halothane 0.35 Training   
Heptane 0.81 Training   
Hexane 0.8 Training   
Hexobarbita 0.1 Training   
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Hydroxyzine 0.39 Training   
Ibuprofen -0.18 Training   











escriptors cannot be computed 






2  aznessis et al. 2001; Platts et al. 2001) 
 
Imipram 1.06 Training   
Indinavir -0.74 Training   
Indometacin -1.2 Training   
Isoflurane 0.42 Training   
Krypton -0.16 Not used D
Lupitidine -1.06 Training   
Mepyramine 0.49 Training   
Mesoridazine -0.36 Training   
Methane 0.04 Training   
Methohexital -0.06 Training   
Methoxyflur 0.25 Training   
Methylcyclope 0.93 Training   
Mianserin 0.99 Training   
Midazolam 0.36 Validation   
Mirtazapin 0.53 Validation   
Morphin -0.16 Training   
m-Xyl 0.2 Training   
Neon 0.2 Not used D
Nevirapine 0 Training   
Nitrogen 0.03 Outlier  (C
Nitrous oxide 0.03 Training   
Nor-1-chlor 1.37 Validation   
Nor-2-chlorp 0.97 Training   
Nordazepam 0.5 Training   
Northiori 0.75 Training   
Org 1296 1.64 Outlier  (K
Org 13011 0.16 Training   
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Org 30526 0.39 Training   

















0.52 Validation   
Org 34167 0 Training   
Org 4428 0.82 Training   
Org 5222 1.03 Validation   
Oxazepam 0.61 Validation   
o-Xylene 0.37 Training   
Paracetam -0.31 Training   
Paraxanthin 0.06 Training   
Pentane 0.76 Training   
Pentobarbital 0.12 Training   
Phenazone -0.1 Training   
Phenserine 1 Training   
Phenylbutazone -0.52 Training   
Phenytoin -0.04 Training   
Physostigm 0.079 Training   
Promazine 1.23 Training   
Propanol -0.16 Training   
Propanone -0.15 Validation   
Propranolo 0.64 Training   
p-Xyle 0.31 Training   
Quinidine -0. Training   
Ranitidine -1.23 Outlier  (Abraham et al. 1994; Platts e
Risperidone -0.02 Validation   
RO19-4603 -0.25 Training   
Salicylic acid -1.1 Training   
Salicyluric aci -0.44 Training   
SB 222200 0.3 Training   
SF6 0.36 Training   
SKF101468 0.25 Validation   
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SKF89124 -0.43 Training   
SKF93319 -1.3 Training   












escriptors cannot be computed 
 
 
aznessis et al. 2001; Platts et al. 2001) 
aznessis et al. 2001; Platts et al. 2001) 
 
0.1 Validation   
Teflurane 0.27 Training   
Temelastin -1.88 Training   
Terbutylchlo Training   
Theobrom -0.28 Validation   
Theophylline -0.29 Training   
Thiopental sod -0.14 Training   
Thioridaz 0.24 Outlier  (P
Tibolone 0.4 Training   
Tiotidine -0.82 Training   
Toluene 0.37 Training   
Triazolam 0.74 Training   
Trichloroet 0.34 Training   
Trichloromethan 0.29 Training   
Trifluoperaz 1.44 Training   
Valproic a -0.22 Training   
Verapamil -0.7 Training   
Xenon 0.03 Not used D
Y-G14 -0.3 Validation   
Y-G15 -0.06 Training   
Y-G16 -0.42 Training   
Y-G19 -1.3 Outlier  (K
Y-G20 -1.4 Outlier  (K
Zidovudine -0.72 Training   




Table 6: Human serum in bin se  
pound Log a Remarks 
album ding data t.
Com Khs Set 
















licic acid  
e 
 
igitoxin 0.13 Training   
Doxycycline 0.01 Validation   
Droperidol 0.43 Training   
-1.39 Training   
Acrivastine -0.02 Training   
Alprenolol 0.0 Validation   
Amoxicillin -1.21 Training   
Atenolol -0.48 Validation   
Bumetanide -0.03 Training   
Bupropion -0.05 Training   
Caffeine -0.92 Training   
Camptotheci -0.08 Training   
Carbamaz -0.1 Training   
Cefalexin -1.11 Validation   
Cefuroxime -1.33 Training   
Cefuroxime axetil -0.56 Training   
Chloramphenico -0.46 Training   
Chlorpromazin 1.1 Validation   
Chlorpropam -0.44 Training   
Cimetid -0.44 Training   
Ciproflo 0.14 Training   
Clofibra 0.27 Training   
Clonidin -0.13 Training   
Clotrimazol 1.34 Training   
Cromog -1.07 Training   
Dansylglycin -0.26 Training   




Ebselen -1.04 Not used Descriptors cannot be computed 















l 0.68 ing 
Etoposide -0.49 Training   
Flucytosine -1.11 Training   
Furosemide -0.13 Training   
Fusidic acid 0.33 Training   
Glibenclamid 0.68 Training   
Hydrochlo -0.42 Training   
Hydrocortiso -0.4 Validation   
Imipramine 0.75 Validation   
Indometaci 0.47 Training   
Itraconazole 1.04 Training   
Ketoconazole 0.84 Training   
Ketoprofen 0.03 Training   
Labetalol 0.14 Training   
Lamotrigine -0.13 Training   
Levofloxacin 0.14 Training   
Lidocaine -0.23 Training   
Methotrexate -0.77 Training   
Methylpredni -0.22 Validation   
Metoprolol -0.29 Training   
Minocyclin 0.21 Training   
Nadolol -0.4 Training   
Naproxen 0.25 Training   
Norfloxacin 0.14 Validation   
Novobiocin 0.35 Training   
Ondansetron 0.37 Training   
Oxprenolo -0.15 Validation   
Oxyphenbutaz -0.02 Validation   
Paracetamol -0.81 Training   
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-0.69 Validation   
Phenylbuta 0.19 Training   
Phenytoin 0 Training   
Pindolol -0.13 Validation   
Prazosin 0.06 Validation   
Prednisolone -0.4 Training   
Procaine -0.19 Training   
Progesterone 0.59 Training   
Promazine 0.92 Training   
Propranolol 0.28 Training   
Propylthioura -0.75 Training   
Quinidine 0.44 Training   
Quinine 0.49 Validation   
Ranitidine -0.1 Training   
Salicylic acid -0.66 Training   
Sancycline 0.21 Validation   
Scopolamin -0.34 Training   
Sotalol -0.44 Training   
Sulfaphenazole -0.21 Training   
Sulfasalazine 0.56 Training   
Sumatriptan -0.05 Training   
Terazosin -0.16 Training   
Terbinafine 1.17 Training   
Testosterone 0.74 Validation   
Tetracaine 0.32 Training   
Tetracycline -0.08 Validation   
Timolol -0.33 Training   
Tolazamide -0.42 Training   
Tolbutamide -0.22 Training   
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Triflupromazine 1.05 Training   
Trimethoprim -0.26 Training   
Tryptophan -0.78 Training   
Verapamil 0.52 
e 
Training   
Warfarin -0.04 Training   
Zidovudin -1.02 Training   
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Table 7: Milk-plasma distribution d
ound M/P Remarks 
ataset. 
Comp Set 
Acyclovir 2.35 Training   
Amitriptyline  
in  n  
e   
Ampicillin 0.295 Validation   
Aspirin 1.63 Training   
Astemizole 4.4 Training   
Atenolol 2.1 Validation   
Bupivacaine 0.34 Training   
Bupropion 5.545 Training   
Caffeine 0.711 Validation   
Cannabis 4.24 Training   
Carbamazepine 0.465 Training   
Carbamazepine 10,11-
epoxide 
0.79 Training   
Carbenicillin 0.02 Training   
Cefotaxime 0.16 Training   
Cefoxitin 0 Training   
Ceftriaxone 0.045 Training   
Cephalexin 0.012 Training   
Chloramphenicol 0.655 Training   
Chlorprothixene 1.48 Training   
Cimetidine 1.7 Training   
Ciprofloxacin 1.495 Training   
Citalopram 2.1 Training   
Clemastine 0.375 Training   
Clofazimine 1.35 Training   
Clomipramine 1.03 Training   
1.53 Validation  
Amoxycill 0.028 Validatio  
Amphetamin 5.15 Training  
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Clonazepam 0.33 Training   











0.9 Training   
 





e 3.555 ning 
Codeine 2.16 Validation   
Cotinine 0.78 Training   
Decarboetoxy Training   
Demethylcitalo 1.75 Validation   
Desipramine 0.915 Validation   
Desmeth 1.275 Validation   
Diazepam 0.7 Training   
Diltiazem 0.98 Training   
Disopyramide 0.9 Training   
Dothiepin 1.59 Validation   
Dothiepsul 1.18 Training   
Doxepin 1.37 Training   
Doxycycline 0.34 Training   
Erythromycin 
Ethanol 
0.455 Training   
Ethosuximide 0.8 Training   
Flunitrazepam 0.54 Training   
Fluoxetine 0.7 Validation   
Gentamicin 0.44 Training   
Haloperidol 0.64 Training   
Ibuprofen 0 Training   
Imipramine 0.76 Validation   
Indomethaci 0.19 Training   
Labetalol 1.7 Training   
Lamotrigine 0.42 Training   
Lidocaine 1.07 Training   
Loratadine 1.2 Training   
Lorazepam 0.205 Training   
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 sulfoxide  
one 9  
e roneous compound 
ne  
lvenlafaxine 
0.145 Training   
Mepindol 2.6 Validation   
Methadon 0.44 Training   
Methotrexate 0.04 Training   
Methyldopa 0.265 Training   
Metoprolol 2.55 Training   
Metronidazole 0.95 Training   
Mexiletine 1.34 Training   
Mianserin 2.2 Training   
Minoxidil 0.76 Training   
Moclobemi 0.72 Training   
Morphine 2.46 Training   
Nadolol 4.6 Training   
N-desmethyls 1.64 Training   
Nefopam 1.2 Training   
Nicotine 2.25 Training   
Nitrazepam 0.27 Validation   
Nitrendipine 0.35 Training   
Nitrofuranto 2.25 Training   
Nordothiepin 0.85 Training   
Nordothiepin 1.86 Validation   
Norethindr 0.1 Validation   
Norfluexetin 0.56 Not used Er
Norfluoxetine 0.56 Training   
Nortriptyli 1.18 Training   
Noscapine 0.29 Training   
O-desmethy 3.3 Training   
Oxazepam 0.1 Training   
Oxprenolol 0.37 Training   
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Paracetamol 0.88 Training   
Paroxetine 0.75 Training   
















Validation   
Penicillin V 0.37 Training   
Perfenazine 0.9 Training   
Phenacetin 0.67 Training   
Phenobarbito 0.5 Training   
Phenytoin 0.363 Training   
Prednisolon 0.13 Training   
Procainami 3.2 Training   
Propranolo 0.403 Training   
Quazepam 4.13 Training   
Quinapril 0.12 Training   
Rosarami 0.12 Training   
Roxithromycin 0.035 Training   
Sertraline 1.27 Validation   
Sotalol 5.4 Training   
Sulfamethox 0.1 Training   
Sumatriptan 4.9 Training   
Suprofen 0.014 Training   
Temazepam 0.14 Validation   
Tetracycline 0.95 Validation   
Theobromine 0.82 Training   
Theophylline 0.7 Training   
Tiapamil 0.44 Training   
Timolol 0.8 Training   
Tinidazole 1.005 Training   
Tolmetin 0.00 Training   
Triprolidine 0.53 Training   
Valproic acid 0.053 Training   
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Venlafaxine 3.8 Training   
Verapamil 0.6 Training   
Vigabatrin 1 Training   
Zolpidem 0.13 Training   
Zonisamide 0.93 
 
Training   




Table 8: CYP P450 dat . I – in n- hibitor datasets. S – substrates/non-
 datasets. 
Compound 3A4-I 3A4-S 2D9-I 2D9-S 2C9-I 2C9-S 
asets hibitor/no in
substrates
Abacavir P- P- P- P- P- P- 
Abecarnil P- P- P- P- P- P- 
Abiraterone P- P- P- P- P- P- 
Acebutolol P- P- P+ P- P- P- 
Aceclofenac P- P- P- P- P- P+ 
Acenocoumarol P- P+ P- P- P+ P+ 
Acetanilide P- P- P- P- P- P- 
Acetazolamide P+ P- P- P- P- P- 
Acetone P- P- P- P- P- P- 
Acetylsalicylic acid P- P- P- P- P- P+ 
Adinazolam P- P+ P- P- P- P- 
Ajmaline P- P- P+ P- P- P- 
Albendazole P- P+ P- P+ P- P+ 
Alfentanil P- P+ P- P- P- P- 
Almotriptan P+ P+ P+ P+ P- P- 
Alosetron P- P+ P- P- P- P+ 
Alpidem P- P+ P- P- P- P- 
Alprazolam P- P+ P- P- P- P- 
Alprenolol P- P- P+ P+ P- P- 
Ambroxol P+ P+ P- P- P- P- 
Amfetamine P- P- P- P+ P- P- 
Amiflamine P- P- P- P+ P- P- 
Amifloxacin P- P- P- P- P- P- 
Aminoglutethimide P- P- P- P- P- P- 
Aminopyrine P- P+ P- P+ P- P+ 
Amiodarone P+ P+ P+ P+ P+ P+ 
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Amitriptyline P+ P+ P+ P+ P+ P+ 
Amlodipine P+ P+ P+ P- P+ P- 
Amodiaqui
P+ P+ P+ 
ir P+ P+ P- P+ P- 





P+ P+ P+ P+ P+ 
P+ P+ 




ne P- P- P- P+ P- P- 
Amoxapine P- P- P+ 
Amprenav P+ 
Anastrozole P- P+ P- 
Aniline P- P- P- P- P- P- 
Anthraquinone P- P- P- P- P- P- 
Apomorphine P- P+ P- P- P- P- 
Aprepitant P- P- P- P- 
Aprindine P- P- P- P- P- 
Aranidip P- P- P- P- P- 
Argatroban P- P+ P- P- P- P- 
Aripiprazole P- P+ P- P+ P- P- 
Artemisinin P- P+ P- P+ P- P- 
Artesunate P- P- P- P- P- P- 
Astemizole P- 
Atamestane P- P- P- P- P- P- 
Atazanavir P- P- P- P- 
Atomoxetine P- P+ P- P+ P- P+ 
Atorvastatin P- P- 
Atovaquone P- P- P- P- P- 
Avasimibe P+ P- P- P- P- P- 
Avitriptan P- P+ P- P+ P- P- 
Azacyclonol P- P- P+ P- P- P- 
Azamulin P- P- P- P- P- 
Azapropazone P- P- P- P- P- 
Azatadine P- P- P- P- P- P- 
Azelastine P+ P+ P+ P+ P+ P- 
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P+ P- P- P- P- P- 
Barnidipine P+ P+ P+ P- P+ P- 
Beclometaso P- P- P- P- P- P- 
Benidipine P+ P- P+ P- P+ P- 
Benzbromaro P- P- P- P- P+ P- 
Benzene P- P- P- P- P- P- 
Benzfetamine P- P+ P- P- P- P- 
Benzydamine P- P+ P- P+ P- P- 
Bepridil P- P+ P+ P- P- P- 
Betamethas P+ P- P- P- P- P- 
Betaxolol P- P- P+ P+ P- P- 
Bexarotene P- P+ P- P- P- P- 
Bezafibrate P- P+ P- P- P- P- 
Bifluranol P- P- P- P- P- P- 
Bifonazole P+ P- P- P- P- P- 
Biperiden P- P- P+ P- P- P- 
Bisoprolol P- P+ P- P+ P- P- 
Boldenone P- P+ P- P- P- P- 
Bortezomib P- P+ P- P+ P- P+ 
Bosentan P- P+ P- P- P- P+ 
Brinzolamide P- P+ P- P- P- P- 
Brofaromine P- P- P- P+ P- P- 
Bromazepa P- P+ P- P- P- P- 
Bromocriptine P+ P+ P- P- P- P- 
Bromperid P- P+ P- P+ P- P- 
Bropirimine P- P- P- P- P- P- 
Brotizolam P- P+ P- P- P- P- 
Budesonide P- P+ P- P- P- P- 
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Budipine P- P- P+ P- P- P- 
Buflomedil P- P- P- P+ P- P- 
Bufuralol P- P+ P+ P+ P- P+ 












P- P+ P- P+ P- P- 
Bupranolol P- P- P+ P+ P- P- 
Buprenorp P+ P+ P+ P+ P+ P- 
Bupropion P- P+ P+ P- P- P- 
Buspirone P- P+ P- P+ P- P- 
Busulfan P- P+ P- P- P- P- 
Caffeine P- P+ P- P+ P- P+ 
Calcium fo P+ P- P- P- P- P- 
Candesartan P- P- P- P- P+ P+ 
Capravirine P- P- P- P- P- P- 
Captopril P- P- P- P+ P- P- 
Carbamazep P+ P+ P- P+ P+ P+ 
Carbaril P- P+ P- P+ P- P+ 
Carbimazol P- P- P- P- P- P- 
Carisoprodo P- P- P- P- P- P- 
Carteolol P- P- P- P+ P- P- 
Carvedilol P+ P+ P- P+ P- P+ 
Cathinone P- P- P+ P- P- P- 
Celecoxib P- P+ P+ P+ P- P+ 
Cerivastatin P+ P+ P+ P- P+ P- 
Cetirizine P+ P- P- P- P- P- 
Cevimeline P- P+ P- P+ P- P- 
Chenodeoxyc P- P+ P- P- P- P- 
Chloral hydr P- P- P- P- P- P- 
Chlorampheni P+ P- P+ P- P+ P- 
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P+ P- P- P- P- P- 
Chloroquine P+ P+ P+ P+ P- P- 
Chlorphena P- P+ P+ P+ P- P- 
Chlorproguan P- P- P- P- P- 
Chlorpromaz P+ P+ P+ P+ P+ P- 
Chlorpyrifos P+ P+ P- P+ P- P+ 
Chlorzoxazo P+ P+ P- P+ P- P- 
Cibenzoline P- P+ P- P+ P- P- 
Ciclospori P+ P+ P- P- P- P- 
Cilnidipin P- P+ P- P- P+ P- 
Cilostazol P- P+ P- P- P- P- 
Cimetidine P+ P+ P+ P- P+ P- 
Cinnarizine P- P- P- P+ P- P+ 
Ciprofibrat P- P+ P- P- P- P- 
Ciprofloxacin P+ P- P- P- P- P- 
Cisapride P+ P+ P+ P+ P- P+ 
Citalopram P- P+ P+ P+ P+ P- 
Clarithromycin P+ P+ P- P- P- P- 
Clemastine P+ P- P+ P- P- P- 
Clindamyci P+ P+ P- P- P- P- 
Clofazimine P+ P- P- P- P- P- 
Clofibrate P- P+ P- P- P- P- 
Clofibric acid P- P+ P- P- P- P- 
Clomethiaz P- P+ P- P- P- P- 
Clomipramine P- P+ P+ P+ P- P+ 
Clonazepam P- P+ P- P- P- P- 
Clopidogrel P- P+ P- P- P+ P- 
Clotrimazole P+ P+ P+ P- P+ P- 
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Clozapine P+ P+ P+ P+ P+ P+ 
Cocaine P+ P+ P+ P- P- P- 
Codeine P- P+ P+ P+ P- P- 
Colchicine P+ P+ P- P- P+ P- 
Colecalciferol P- P- P+ P- P+ P- 









P+ P+ P- P- P- P- 
Cortisol P+ P+ P- P- P- P- 
Cortisone P- P+ P- P- P- P- 
Cotinine P- P- P- P- P- P- 
Coumarin P+ P- P- P- P- P- 
Cyclobenza P- P+ P- P+ P- P- 
Cyclophosph P+ P+ P- P+ P- P+ 
Cyproterone P- P+ P- P- P- P- 
Dacarbazine P- P- P- P- P- P- 
Dalfopristin P+ P- P- P- P- P- 
Danazol P+ P- P- P- P- P- 
Dantrolene P- P+ P- P- P- P- 
Dapsone P- P+ P- P+ P- P+ 
Daunorubici P+ P- P- P- P- P- 
Dazoxiben P- P- P- P- P- P- 
Debrisoquine P- P- P+ P+ P- P- 
Delapril P+ P- P- P- P- P- 
Delavirdine P+ P+ P+ P+ P+ P+ 
Demethylcitalop P- P- P- P+ P- P- 
Desipramine P- P- P+ P+ P- P- 
Desloratadine P+ P- P+ P- P+ P- 
Desogestrel P- P- P- P- P- P+ 
Dexamethason P+ P+ P- P- P- P- 
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P+ P- P+ P- P+ P- 
Dextrome P- P+ P+ P+ P- P+ 
Dextropropo P+ P- P+ P- P+ P- 
Dextrorphan P- P+ P- P+ P- P- 
Diazepam P+ P+ P- P- P- P+ 
Diclofenac P+ P+ P- P- P+ P+ 
Dicouma P- P- P- P- P+ P+ 
Dieldrin P- P- P- P- P- P- 
Diethylca P- P- P- P- P- P- 
Diethylstilb P- P+ P- P- P- P- 
Difloxacin P- P- P- P- P- P- 
Digitoxin P- P+ P- P- P- P- 
Digoxin P+ P- P- P- P- P- 
Dihydralazine P+ P+ P- P- P- P- 
Dihydrocode P- P+ P- P+ P- P- 
Dihydroe P+ P+ P- P- P- P- 
Diltiazem P+ P+ P+ P+ P+ P+ 
Dimethyl P+ P- P+ P- P+ P- 
Diosmin P- P- P- P- P- P- 
Diphenhydr P- P- P+ P+ P- P- 
Dipotassium cl P- P+ P- P- P- P- 
Diprafenone P- P- P- P+ P- P- 
Dirithromyci P+ P- P- P- P- P- 
Disopyramide P- P+ P- P- P- P+ 
Disulfamide P+ P- P- P- P- P- 
Disulfiram P- P- P- P- P+ P- 
Ditiocarb sod P+ P- P- P- P- P- 
Docetaxel P+ P+ P- P- P- P- 
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Dofetilide P- P+ P- P- P- P- 
Dolasetron P- P+ P- P+ P- P+ 
Domperidone P+ P- P- P- P- P- 
Donepezil P- P+ P- P+ P- P- 
Dorzolamide P- P+ P- P- P- P+ 
Doxepin P- P+ P- P+ P- P+ 
Doxorubicin P+ P+ P+ P- P- P- 






P- P+ P- P- P- P- 
Drospirenone P+ P+ P- P- P+ P- 
Dutasteride P- P+ P- P- P- P- 
Ebastine P- P+ P- P- P- P- 
Ebrotidine P+ P- P- P- P- P- 
Ecabapid P- P+ P- P- P- P- 
Econazole P+ P- P- P- P- P- 
Efavirenz P+ P+ P+ P- P+ P- 
Efonidipine P+ P- P- P- P- P- 
Eletriptan P- P+ P- P- P- P+ 
Emedastine P- P+ P- P- P- P- 
Emivirine P- P+ P- P- P- P- 
Enalapril P- P+ P- P- P- P- 
Encainide P- P- P- P+ P- P- 
Enflurane P- P- P- P- P- P- 
Enoxacin P- P- P- P- P- P- 
Entacapone P+ P- P+ P- P+ P- 
Epinastine P- P+ P- P+ P- P- 
Epinephrine P- P- P- P- P+ P- 
Eplerenone P+ P+ P- P- P- P- 
Eprosartan P- P- P- P- P+ P- 
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Ergometrine P- P+ P- P- P- P- 
Ergotamine P+ P+ P- P- P- P- 













P- P+ P- P+ P+ P- 
Estradiol P- P+ P- P+ P- P+ 
Estrone P- P+ P- P- P- P+ 
Ethanol P- P+ P- P- P+ P- 
Ethinylestradi P+ P+ P- P- P- P- 
Ethosuximid P- P+ P- P- P- P- 
Ethotoin P- P- P- P- P- P- 
Ethylbenzene P- P- P- P- P- P- 
Ethylmorp P- P+ P- P+ P- P- 
Etomidate P- P- P- P- P- P- 
Etonogestre P- P+ P- P- P- P- 
Etoperidone P- P+ P+ P+ P- P+ 
Etoposide P+ P+ P- P- P- P- 
Etoricoxib P+ P+ P+ P+ P+ P+ 
Everolimus P- P+ P- P- P- P- 
Exemestane P- P+ P- P- P- P- 
Ezlopitant P- P+ P+ P+ P- P- 
Fadrozole P- P- P- P- P- P- 
Famotidine P+ P- P- P- P- P- 
Felbamate P- P+ P- P- P- P- 
Felodipine P+ P+ P+ P- P+ P- 
Fenfluramine P- P- P- P+ P- P- 
Fenofibrate P- P+ P- P- P- P- 
Fentanyl P+ P+ P- P- P- P- 
Fexofenadin P- P+ P+ P- P- P- 
Finasteride P- P+ P- P- P- P- 
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Flecainide P- P- P+ P+ P- P- 
Flosequinan P- P+ P- P- P- P- 
Flucloxacillin P- P+ P- P- P- P- 












P- P- P- P- P- P- 
Flunarizi P- P- P- P+ P- P+ 
Flunitraz P- P+ P- P- P- P+ 
Fluorouracil P- P- P- P- P+ P- 
Fluoxetine P+ P+ P+ P+ P+ P+ 
Fluparoxa P- P- P- P- P- P- 
Fluperlapine P- P- P+ P+ P- P- 
Fluphenazine P+ P- P+ P+ P- P- 
Flurazepam P- P- P- P- P- P- 
Flurbiprofen P- P- P- P- P+ P+ 
Flurithromyci P+ P- P- P- P- P- 
Flutamide P+ P+ P- P- P- P- 
Fluticasone P- P+ P- P- P- P- 
Fluvastatin P+ P+ P+ P+ P+ P+ 
Fluvoxamine P+ P- P+ P+ P+ P- 
Fosphenyto P- P- P- P- P- P- 
Frovatripta P- P- P- P- P- P- 
Furafylline P- P- P- P- P- P- 
Galantamin P- P+ P- P+ P- P- 
Gallopamil P+ P+ P- P- P- P- 
Ganaxolone P- P+ P- P- P- P- 
Gatifloxacin P- P- P- P- P- P- 
Gefitinib P- P+ P- P- P- P- 
Gemfibrozil P+ P+ P- P- P+ P- 
Gepirone P- P+ P- P+ P- P- 
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P+ P+ P- P- P+ P+ 
Gliclazide P- P- P- P- P- P+ 
Glimepiride P- P- P- P- P- P+ 
Glipizide P+ P- P- P- P- P+ 
Glyceryl trin P- P+ P- P- P- P- 
Granisetron P- P+ P- P- P- P- 
Grepafloxacin P+ P- P- P- P- P- 
Griseofulvin P- P- P- P- P- P- 
Guanabenz P- P- P- P- P- P- 
Guanoxan P- P- P- P+ P- P- 
Halofantrine P- P+ P+ P+ P- P- 
Haloperidol P+ P+ P+ P+ P- P- 
Halothane P- P+ P- P+ P- P+ 
Hexobarbital P- P- P- P- P- P+ 
Homochlor P+ P- P- P- P- P- 
Hydralazine P+ P- P- P- P- P- 
Hydrocodon P- P+ P- P+ P- P- 
Hydrocortison P- P+ P- P+ P- P- 
Hydroquinidin P- P- P+ P- P- P- 
Hydroxyamfetam P- P- P- P+ P- P- 
Hydroxychlor P- P- P+ P- P- P- 
Hydroxyzine P- P- P+ P- P- P- 
Ibuprofen P- P- P- P- P+ P+ 
Ibutilide P- P- P- P- P- P- 
Ifosfamide P+ P+ P- P- P- P+ 
Iloperidon P- P+ P- P+ P- P- 
Imatinib P+ P+ P+ P- P+ P- 
Imipramin P- P+ P+ P+ P- P+ 
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Imiquimod P- P+ P- P- P- P- 










P- P- P- P- P+ P+ 
Indoramin P- P- P- P+ P- P- 
Ipriflavone P+ P- P- P- P+ P- 
Irbesartan P+ P- P- P- P+ P+ 
Irinotecan P+ P+ P- P- P+ P- 
Isbogrel P- P- P- P- P- P- 
Isoconazole P- P- P- P- P- P- 
Isoflurane P- P- P- P- P- P- 
Isoniazid P+ P- P+ P- P+ P- 
Isosorbide din P- P+ P- P- P- P- 
Isradipine P- P+ P- P- P+ P- 
Itraconazole P+ P+ P- P- P+ P- 
Ivermectin P- P+ P- P- P- P- 
Josamycin P+ P- P- P- P- P- 
Ketamine P- P+ P- P+ P- P+ 
Ketoconazole P+ P+ P+ P- P+ P- 
Ketoprofen P- P- P- P- P+ P- 
Labetalol P- P- P+ P+ P- P- 
Lacidipine P- P+ P- P- P- P- 
Lansoprazole P+ P+ P+ P- P+ P+ 
Leflunomide P- P+ P- P- P+ P- 
Lercanidip P+ P+ P+ P- P- P- 
Letrozole P- P+ P- P- P- P- 
Levacetylm P- P+ P- P+ P- P+ 
Levobupivac P- P+ P- P- P- P- 
Levofloxa P- P- P- P- P- P- 
Levomeprom P- P- P+ P- P- P- 
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P- P+ P- P- P- P- 
Liarozole P- P- P- P- P- P- 
Lidocaine P- P+ P+ P+ P- P+ 
Lilopristone P+ P+ P- P- P- P- 
Linezolid P- P- P- P- P- P- 
Liothyronine P- P- P- P- P- P- 
Lisofyllin P- P+ P- P- P- P- 
Lisuride P- P+ P- P+ P- P- 
Litoxetine P- P- P- P- P- P- 
Lobeline P- P- P+ P- P- P- 
Lomefloxacin P- P- P- P- P- P- 
Lomustine P+ P- P+ P- P- P- 
Lopinavir P+ P+ P+ P- P+ P- 
Loratadine P+ P+ P+ P+ P+ P- 
Lornoxicam P- P- P- P- P+ P+ 
Losartan P+ P+ P- P- P+ P+ 
Losigamone P- P- P- P- P- P- 
Lovastatin P- P+ P+ P- P+ P- 
Lumefantr P- P+ P- P- P- P- 
Malathion P+ P- P- P- P- P- 
Manidipine P+ P+ P+ P- P+ P- 
Maprotiline P- P- P+ P+ P- P- 
m-Chloropheny P- P- P- P+ P- P- 
Mebendazole P- P- P- P- P- P- 
Medazepam P- P- P- P- P- P- 
Medifoxamine P- P+ P- P- P- P- 
Medroxyproge P- P+ P- P- P- P- 
Mefenamic acid P- P- P- P- P+ P+ 
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Mefloquine P+ P+ P- P- P- P- 
















P- P- P+ P- P- P- 
Mephenyto P- P- P- P- P+ P+ 
Mepyramine P- P- P+ P- P- P- 
Mequitazin P+ P- P- P+ P- P- 
Mestranol P- P- P- P- P- P+ 
Metamfetam P- P- P- P+ P- P- 
Methadon P+ P+ P+ P+ P- P+ 
Methaqualo P- P+ P- P- P- P- 
Methiocar P- P+ P- P+ P- P- 
Methomyl P- P- P- P- P- P- 
Methoxsalen P+ P- P+ P- P+ P- 
Methoxyflu P- P+ P- P- P- P- 
Methylergom P- P+ P- P- P- P- 
Methylphenid P- P+ P+ P- P- P- 
Methylphe P- P- P- P- P- P- 
Methylpredni P+ P+ P- P- P- P- 
Metoclopram P+ P+ P+ P+ P- P- 
Metoprolol P- P- P+ P+ P- P- 
Metronidaz P+ P- P- P- P+ P+ 
Metyrapone P+ P- P- P- P- P- 
Mevastatin P- P- P- P- P- P- 
Mexazolam P- P+ P- P- P- P- 
Mexiletine P- P- P- P+ P- P- 
Mianserin P- P+ P+ P+ P- P+ 
Mibefradil P+ P+ P+ P- P- P- 
Miconazole P+ P+ P+ P- P+ P- 
Midazolam P+ P+ P+ P- P+ P+ 
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P+ P+ P+ P- P- P- 
Milameline P- P- P- P+ P- P- 
Milnacipran P- P- P- P- P- P- 
Minaprine P- P- P- P+ P- P- 
Minoxidil P- P- P- P- P- P- 
Mirtazapine P+ P+ P+ P+ P- P+ 
Mitoxantrone P+ P- P- P- P- P- 
Mizolastine P+ P+ P+ P+ P+ P- 
Moclobemide P- P- P+ P- P+ P- 
Modafinil P- P+ P- P- P+ P- 
Molindone P- P- P- P+ P- P- 
Montelukast P- P+ P- P- P- P+ 
Moracizine P- P- P- P- P- P- 
Morphine P- P+ P- P+ P- P+ 
Mosapride P- P+ P- P- P- P- 
Nafcillin P- P- P- P- P- P- 
Nalidixic acid P- P- P- P- P- P- 
Naproxen P- P- P- P- P- P+ 
Nateglinide P- P+ P- P- P+ P+ 
Nefazodone P+ P+ P+ P- P- P- 
Nefiracetam P- P+ P- P- P- P- 
Nelfinavir P+ P+ P+ P+ P+ P+ 
Nevirapine P+ P+ P- P+ P- P+ 
Nicardipine P+ P+ P+ P+ P+ P- 
Niclosamid P- P- P+ P- P- P- 
Nicotine P- P+ P- P+ P- P+ 
Nifedipine P+ P+ P+ P+ P+ P- 
Niludipine P- P+ P- P- P- P- 
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Nilutamide P- P- P- P- P- P- 
Nilvadipine P+ P+ P- P- P- P- 
Nimodipine P+ P+ P- P- P+ P- 













P+ P+ P- P- P- P- 
Nitrendipin P+ P+ P- P- P+ P- 
Nitrosamine P- P- P- P- P- P- 
Norcodeine P- P- P- P+ P- P- 
Nordazepam P- P+ P- P- P- P- 
Norethisterone P- P- P- P- P- P- 
Norfloxacin P+ P- P- P- P- P- 
Norfluoxetin P+ P- P+ P+ P+ P- 
Nortriptyline P- P+ P+ P+ P- P- 
Ofloxacin P- P- P- P- P- P- 
Olanzapine P+ P- P+ P+ P+ P- 
Olopatadine P- P+ P- P- P- P- 
Oltipraz P+ P- P- P- P- P- 
Omapatrilat P- P- P- P- P- P- 
Omeprazol P+ P+ P+ P+ P+ P+ 
Onapristone P+ P+ P- P- P- P- 
Ondansetron P- P+ P+ P+ P+ P+ 
Opipramol P- P- P- P+ P- P- 
Orphenadri P+ P+ P+ P+ P+ P- 
Oxamniquin P- P- P+ P- P- P- 
Oxcarbazepin P- P- P- P- P- P- 
Oxiconazole P+ P- P- P- P- P- 
Oxodipine P- P+ P- P- P- P- 
Oxomemazi P- P- P- P- P- P- 
Oxprenolol P- P- P+ P- P- P- 
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Oxybutynin P+ P+ P+ P- P- P- 
Oxycodone P- P- P- P+ P- P- 








P+ P+ P- P- P- P- 
Papaverine P+ P- P- P+ P- P- 
Paracetamol P+ P+ P- P+ P- P+ 
Parathion P+ P+ P- P+ P+ P- 
Paraxanthine P- P- P- P- P- P- 
Parecoxib P- P- P- P- P+ P- 
Pargyline P- P- P+ P- P- P- 
Paroxetine P+ P- P+ P+ P+ P- 
Pefloxacin P- P- P- P- P- P- 
Penbutolol P- P- P- P+ P- P- 
Pentamidin P- P- P+ P- P- P- 
Pentazocine P- P- P- P+ P- P- 
Pentobarbital P- P- P- P- P- P- 
Pentoxify P- P- P- P- P- 
Pergolide P+ P- P+ P- P- P- 
Perhexiline P- P- P+ P+ P- P- 
Perospirone P- P+ P- P+ P- P- 
Perphenazine P+ P+ P+ P+ P+ P+ 
Pethidine P- P- P- P+ P- P- 
Phenacetin P- P+ P- P+ P- P+ 
Phenazone P- P+ P- P- P- P+ 
Phencyclidine P+ P+ P- P- P- P- 
Phenformin P- P- P- P+ P- P- 
Phenobarbit P- P- P- P- P- P+ 
Phenol P- P- P- P- P- P- 
Phenprocoum P- P- P- P- P+ P+ 
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Phensuximide P- P- P- P- P- P- 
Phenylbutazone P- P- P- P- P+ P+ 
Phenytoin P- P- P- P+ P+ P+ 
Pilocarpine P+ P- P- P- P- P- 
Pilsicainide P+ P- P- P- P- P- 
Pimobendan P- P+ P- P- P- P- 
Pimozide P+ P+ P+ P- P- P- 
Pinacidil P- P+ P- P+ P- P- 







P+ P+ P- P- P+ P- 
Pipemidic a P- P- P- P- P- P- 
Piroxicam P+ P- P- P- P+ P+ 
Plomestane P- P- P- P- P- P- 
Pramipexole P- P- P+ P- P- P- 
Pranidipine P- P+ P- P- P- P- 
Prasterone P- P+ P- P- P- P- 
Pravastatin P+ P+ P+ P- P+ P- 
Praziquantel P- P+ P+ P+ P- P+ 
Prednisolone P+ P+ P- P- P- P- 
Prednisone P+ P+ P- P- P- P- 
Pregnenolone P- P+ P- P+ P- P- 
Primaquine P+ P+ P+ P+ P- P- 
Primidone P- P- P- P- P- P- 
Proadifen P+ P- P+ P- P+ P- 
Probenecid P- P- P- P- P+ P- 
Procainamide P- P- P- P+ P- P- 
Progesterone P- P+ P- P+ P+ P+ 
Proguan P- P+ P- P- P- P+ 
Promazine P- P+ P- P+ P- P+ 
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Promethazine P- P- P+ P+ P- P- 
Propafenone P- P+ P+ P+ P- P- 
Propanol P- P- P- P- P+ P- 
Propofol P+ P+ P+ P+ P+ P+ 
Propranolol P- P+ P+ P+ P- P- 








P- P- P- P- P- P- 
Pyrimetha P- P- P+ P- P+ P- 
Quercetin P+ P+ P+ P- P+ P- 
Quetiapine P- P+ P- P+ P+ P+ 
Quinelorane P+ P- P- P- P- P- 
Quinine P+ P+ P+ P- P- P- 
Quinupristin P+ P- P- P- P- P- 
Rabeprazole P+ P+ P- P- P+ P- 
Raloxifene P+ P- P- P- P- P- 
Ranitidine P+ P- P+ P+ P- P- 
Ranolazine P- P+ P- P- P- P- 
Rebamipide P- P+ P- P- P+ P- 
Reboxetine P+ P+ P+ P- P- P- 
Remacemide P+ P- P- P- P- P- 
Remoxipride P- P- P- P+ P- P- 
Repaglinide P- P+ P- P- P- P+ 
Reserpine P+ P- P- P- P- P- 
Resiquimo P- P+ P- P- P- P- 
Rifabutin P- P+ P- P- P- P- 
Rifampicin P- P+ P- P- P- P+ 
Rifamycin P- P- P- P- P- P- 
Rifapentine P- P- P- P- P- P- 
Riluzole P- P- P+ P- P- P- 
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Risperidone P+ P+ P+ P+ P- P- 









P- P- P- P- P- P- 
Rogletimide P- P- P- P- P- P- 
Rokitamycin P+ P- P- P- P- P- 
Ropinirol P- P+ P+ P- P- P- 
Ropivacaine P- P+ P- P+ P- P- 
Roquinimex P- P+ P- P- P- P- 
Rosiglitazo P+ P- P+ P- P+ P+ 
Rosuvastatin P- P- P- P- P- P+ 
Roxatidine P- P- P- P- P- P- 
Roxithrom P+ P+ P- P- P- P- 
Rupatadine P- P+ P- P- P- P- 
Salbutamol P+ P- P- P- P- P- 
Salicylic aci P- P+ P- P- P- P- 
Salmeterol P- P+ P- P- P- P- 
Saquinavir P+ P+ P+ P+ P+ P- 
Secobarbital P- P- P- P- P- P- 
Selegiline P+ P+ P+ P+ P+ P+ 
Seratrodast P+ P+ P+ P- P+ P+ 
Sertindole P+ P+ P+ P+ P- P- 
Sertraline P+ P+ P+ P+ P+ P+ 
Sevoflurane P- P+ P- P- P- P- 
Sibutramine P- P+ P- P- P- P- 
Sildenafil P+ P+ P- P+ P+ P+ 
Simvastatin P+ P+ P+ P- P+ P- 
Sirolimus P+ P+ P- P- P- P- 
Sparteine P- P- P+ P+ P- P- 
Spironola P+ P- P- P- P- P- 
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Stiripentol P+ P- P+ P- P+ P- 
Styrene P- P- P- P- P- P- 
Sufentanil P- P+ P- P- P- P- 
Sulconazole P+ P- P+ P- P+ P- 














P- P- P- P- P+ P- 
Sulfadimidine P- P- P- P- P+ P- 
Sulfadoxine P- P- P- P- P+ P- 
Sulfafurazole P- P- P- P- P+ P- 
Sulfamerazine P- P- P- P- P+ P- 
Sulfamethiz P+ P- P- P- P+ P- 
Sulfamethoxazo P+ P+ P- P- P+ P+ 
Sulfamoxole P- P- P- P- P+ P- 
Sulfanilamide P- P- P- P- P+ P- 
Sulfaphenazole P+ P- P- P- P+ P- 
Sulfapyridin P- P- P- P- P+ P- 
Sulfasalazin P- P- P- P- P- P- 
Sulfatroxazole P- P- P- P+ P- 
Sulfinpyraz P+ P+ P- P- P+ P+ 
Sulindac P- P- P- P- P+ P- 
Sulpiride P+ P- P- P- P- P- 
Suprofen P- P- P- P- P+ P+ 
Tacrine P- P- P- P- P- P- 
Tacrolimus P+ P+ P- P- P- P- 
Tadalafil P- P+ P- P- P- P- 
Tamoxifen P+ P+ P+ P+ P+ P+ 
Tamsulosin P- P+ P- P+ P- P- 
Tasosartan P- P+ P- P- P- P- 
Tauromustine P- P+ P- P+ P- P+ 
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P- P+ P- P- P- P- 
Tecastemiz P+ P+ P- P- P- P- 
Tegafur P- P- P- P- P- P+ 
Tegaserod P+ P- P+ P+ P+ P- 
Telmisartan P- P- P- P- P- P- 
Temazepam P- P+ P- P- P- P+ 
Teniposide P+ P+ P- P- P+ P- 
Tenofovir P- P- P- P- P- P- 
Tenoxicam P- P- P- P- P+ P+ 
Terbinafine P- P+ P+ P- P- P+ 
Terfenadine P+ P+ P+ P+ P+ P- 
Terguride P- P+ P- P+ P- P- 
Testolactone P- P- P- P- P- P- 
Testosterone P+ P+ P- P+ P- P+ 
Tetracycline P+ P- P- P- P- P- 
Tezosentan P- P- P- P- P+ P- 
Thalidomide P- P- P- P- P- P- 
Theobromine P- P- P- P- P- P- 
Theophyll P+ P+ P- P+ P- P+ 
Thiamazol P+ P- P+ P- P+ P- 
Thioridazi P- P- P+ P+ P- P- 
Thiotepa P- P- P- P- P- P- 
Tiabendazole P- P- P- P- P+ P- 
Tiagabine P- P+ P- P+ P- P- 
Tiaramide P- P- P- P- P- P+ 
Ticlopidine P+ P+ P+ P- P+ P- 
Tienilic acid P- P- P- P- P+ P+ 
Timolol P- P- P+ P+ P- P- 
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Timoprazole P+ P- P- P- P- P- 
Tinidazole P- P+ P- P- P- P- 













P- P- P- P- P- P- 
Tipranavir P- P+ P- P- P- P- 
Tirilazad P- P+ P- P- P- P- 
Tocainide P- P- P- P- P- P- 
Tolbutamide P- P- P- P- P+ P+ 
Tolcapone P- P+ P- P- P+ P- 
Tolperisone P- P- P+ P+ P- P- 
Tolterodine P- P+ P- P+ P- P+ 
Toluene P- P- P- P- P- P- 
Topiramate P- P- P- P- P- P- 
Torasemide P- P- P- P- P- P+ 
Toremifene P- P+ P- P- P- P+ 
Tramadol P- P+ P- P+ P- P- 
Tranylcypro P- P- P- P- P- P- 
Trapidil P- P- P- P- P- P- 
Trazodone P- P+ P- P+ P- P- 
Tretinoin P- P+ P- P- P- P- 
Triazolam P- P+ P- P- P- P- 
Trichloroethyl P- P+ P- P- P- P- 
Trichlorom P- P- P- P+ P- P+ 
Trifluoperazine P- P- P- P- P- P- 
Trifluperido P- P- P- P+ P- P- 
Trimetazidi P- P- P- P- P- P- 
Trimethadion P- P+ P- P- P- P+ 
Trimethoprim P+ P+ P+ P- P+ P+ 
Trimetrex P- P+ P- P- P- P- 
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P- P- P+ P- P- P- 
Triprolidine P- P- P+ P- P- P- 
Trofosfam P- P+ P- P- P- P- 
Troglitazon P+ P+ P+ P+ P+ P+ 
Troleando P+ P+ P- P- P- P- 
Tropisetron P- P+ P+ P+ P- P+ 
Trospium chlo P- P- P+ P- P- P- 
Valdecoxib P+ P+ P+ P+ P+ P+ 
Valproic acid P+ P- P+ P- P+ P+ 
Valsartan P- P- P- P- P+ P- 
Valspoda P+ P+ P- P- P- P- 
Vanoxerine P- P+ P- P- P- P- 
Venlafaxine P+ P+ P+ P+ P- P+ 
Verapamil P+ P+ P+ P- P+ P+ 
Vesnarinon P- P+ P- P- P- P- 
Vinblastine P+ P+ P+ P- P- P- 
Vincristin P+ P+ P+ P- P- P- 
Vindesine P+ P+ P- P- P- P- 
Vinorelbin P+ P+ P+ P+ P- P- 
Voriconazo P+ P+ P- P- P+ P+ 
Vorozole P- P- P- P- P- P- 
Warfarin P- P+ P- P+ P+ P+ 
Yohimbine P- P+ P+ P+ P- P- 
Zafirlukast P+ P- P+ P- P+ P+ 
Zaleplon P- P+ P- P- P- P- 
Zaltoprofen P+ P- P- P- P+ P+ 
Zatosetron P- P+ P- P- P- P- 
Zidovudine P- P+ P- P- P- P+ 
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Zileuton P+ P+ P+ P- P+ P+ 
Ziprasidone P+ P+ P+ P- P- P- 
Zolmitriptan P- P- P- P- P- P- 
Zolpidem P+ P+ P+ P+ P+ P+ 
Zonisamide P- P+ P- P- P- P- 
Zopiclone P- P+ P- P- P- P+ 
Zotepine P- P+ P- P+ P- P- 
Zoxazolamine P- P- P- P- P- P- 





Table 9: Total clearance dataset. 
ompound Total c nce (ml/min/kg) Set C leara
Chlorpropamide 0.04 ining Tra
Droxicam 0.05 ining 
n 0.07 ining 
0.09 ining 
 0.11 ining 
0.14 ining 
0.14 ining 
ordazepam 0.17 Training 
thosuximide 0.19 Training 
Delorazepam 0.21 Training 
Ceftriaxone 0.23 Training 
Sulfasalazine 0.24 Training 
Liothyronine 0.25 Training 
Cefpiramide 0.28 Training 
Sulfafurazole 0.28 Training 
Tolbutamide 0.29 Training 
Fluconazole 0.30 Training 
Sulfamethoxazole 0.31 Validation 
Olmesartan 0.32 Training 
Cefonicid 0.33 Training 
Amobarbital 0.35 Training 
Benazeprilat 0.35 Training 
Flurbiprofen 0.35 Training 
Topiramate 0.37 Training 
rhein 0.38 Training 
Ertapenem 0.40 Training 






















Borocaptate 0.43 Training 
Fosinoprila 0.46 Training 
Phenazone 0.46 Training 
Phenytoin 0.46 Training 
Mecillinam 0.48 Training 
Ketorolac 0.50 Training 
Lamotrigine 0.51 Training 
Doxycycline 0.52 Training 
Glipizide 0.52 Training 
Ceforanide 0.56 Training 
Diazepam 0.56 Training 
Rufloxacin 0.57 Training 
Rosiglitazone 0.58 Training 
Tinidazole 0.58 Training 
Raltitrexed 0.59 Validation
Brodimoprim 0.60 Training 
Dapsone 0.60 Training 
Tamsulosin 0.62 Training 
Cefotetan 0.63 Validation
Nevirapine 0.63 Training 
Etoricoxib 0.70 Training 
Cefodizime 0.71 Training 
Torasemide 0.71 Training 
Theophylline 0.73 Training 
Vigab 0.74 Training 




Acivicin 0.78 Training 
















Cefazolin 0.84 Training 
Alprazolam 0.86 Training 
Modafinil 0.88 Training 
Minocycline 0.89 Training 
Trimetrexa 0.89 Training 
Tiaprofenic a 0.91 Validation
Trimazosin 0.94 Training 
Terodiline 0.95 Training 
Cefoperazon 0.96 Training 
Levetiracet 0.96 Training 
Procyclidine 0.97 Training 
Tegafur 0.98 Training 
Prednisolon 1.00 Training 
Chlortalidon 1.02 Training 
Aprepitant 1.07 Training 
Oxazepam 1.08 Training 
Edetate 1.09 Training 
Lorazepam 1.10 Validation 
Terazosin 1.10 Training 
Carbamazep 1.11 Training 
Ibuprofen 1.12 Training 
Mizolastine 1.15 Training 
Iohexol 1.17 Training 
Carbenicillin 1.18 Training 
Pidotimod 1.19 Training 























Alendronic acid 1.22 Validation
Ifosfamide 1.23 Training 
Metronidazol 1.26 Training 
Temazepam Training 
Azosemide 1.29 Training 
Cefixime 1.30 Training 
Glibenclamide 1.30 Training 
Piracetam 1.30 Training 
Tolmetin 1.30 Training 
Latamoxef 1.32 Training 
Iobitridol 1.33 Validation
Zoledronic ac 1.33 Training 
Flunitraz 1.34 Training 
Tobramycin 1.35 Training 
Indometacin 1.40 Training 
Tamoxifen 1.40 Training 
Ticarcillin 1.41 Validation
Flufenam 1.43 Training 
Pioglitazone 1.43 Training 
Valdecoxib 1.43 Validation
Ioxilan 1.44 Training 
Levocarnit 1.45 Training 
Trovafloxaci 1.46 Training 
Linezolid 1.49 Training 
Candesartan 1.50 Training 
Iopromide 1.53 Validation
Acetylcystei 1.55 Training 
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Foscarnet 1.58 Training 
Tolcapone 1.58 Training 
Temozolom 1.59 Training 
Cefozopran 1.60 Training 
Dicloxacillin 1.60 Training 
Gabapentin 1.60 Validation
Hydroxyca 1.60 Training 
Zanamivir 1.60 Training 
Tranexamic 1.61 Training 
Furosemid 1.66 Training 
Bezafibrate 1.67 Training 
Tetracyclin 1.67 Training 
Trandolaprilat 1.67 Training 
Pentostatin 1.68 Training 
Chlorphenam 1.70 Validation
Gemfibrozil 1.70 Training 
Remoxipride 1.70 Training 
Rofecoxib 1.70 Training 
Etanidazole 1.73 Training 
Methadone 1.77 Training 
Tiagabine 1.78 Training 
Ceftizox 1.79 Training 
Fleroxacin 1.79 Training 
Cefepime 1.83 Training 
Cefmetazo 1.84 Validation
Tertatolol 1.86 Validation
























Cefsulodin 1.92 Training 
Pefloxacin 1.93 Validation
Cefpirome 1.98 Validation
Lincomycin 1.98 Training 
Cefetamet 2.00 Validation
Rosoxacin 2.00 Training 
N-acetylhomo Validation
Bromfenac 2.10 Training 
Cefuroxime 2.10 Validation
Methotrexate 2.10 Validation 
Trazodone 2.10 Training 
Troxacitabine 2.13 Training 
Anagrelide 2.14 Training 
Pheniramine 2.14 Training 
Sotalol 2.14 Training 
Cefclidin 2.15 Training 
Clodronic aci 2.20 Training 
Thalidomide 2.20 Validation
Piritrexim 2.21 Training 
Cefmenoxime 2.22 Validation 
Ibandronic 2.29 Validation 
Cidofovir 2.30 Training 
Finasteride 2.30 Training 
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Nolatrexed 2.36 Training 
Cefpodoxime 2.38 Training 
Eplerenone 2.38 Training 
Cinoxacin 2.50 Training 
Irbesartan 2.51 Validation 
Azlocillin 2.52 Validation
Norfloxacin 2.52 Training 
Donepezil 2.53 Training 
Atenolol 2.54 Training 
Cyclophospha 2.54 Validation 
Pantoprazol 2.57 Training 
Levofloxacin 2.58 Validation 
Amoxicillin 2.60 Validation
Chlorambuci 2.60 Training 
Tocainide 2.60 Validation 
Thiampheni 2.62 Validation
Bumetanide 2.64 Training 
CI-921 2.67 Training 
Isosorbide mono 2.67 Validation
Urapidil 2.69 Training 
Disopyram 2.70 Training 
Mezlocillin 2.71 Training 
Sparfloxacin 2.71 Training 
Baclofen 2.72 Training 
Brotizolam 2.74 Training 
Biapenem 2.77 Training 
Bosentan 2.81 Training 


















Gatifloxacin 2.85 Training 
Cefoxitin 2.89 Validation
Cefadroxil 2.90 Training 
Tazobactam Training 
Nadolol 2.94 Training 
Tenofovir 2.97 Training 
Cerivastatin 2.98 Training 
Cilastatin 3.00 Validation
Prazosin 3.00 Training 
Thiopental 3.02 Training 
Fludarabine 3.06 Training 
Imipenem 3.08 Training 
Frovatriptan 3.09 Training 
Efavirenz 3.10 Validation
Ampicillin 3.11 Training 
Temafloxacin 3.19 Training 
HI-6 3.20 Validation
Risperid 3.20 Training 




Cilazaprilat 3.33 Training 
Dronabino 3.33 Training 
Imatinib 3.33 Validation
Tianeptine 3.43 Training 
Ganciclovi 3.46 Training 
Drotaverine 3.47 Training 
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Meropenem 3.49 Training 




















Lumefantrine 3.57 Training 
Moxiflox 3.57 Validation
Pirenzepine 3.57 Training 
Clavulanic ac 3.60 Training 
Hexobarbi 3.60 Training 
Prednison 3.60 Validation
Atomoxetin 3.63 Training 
Bicalutamide 3.67 Training 
Piperacillin 3.68 Training 
2-fluoro-arab 3.70 Training 
Adefovir 3.72 Validation 
Cadralazine 3.79 Validation
Trapidil 3.79 Training 
Esomeprazol 3.81 Training 
Sematilide 3.86 Training 
Quinidine 3.87 Training 
Tirofiban 3.87 Training 
Lisinopril 3.89 Training 
Terbutaline 4.00 Validation 
Fosfomycin 4.02 Training 
Levacetylme Validation
Pimozide 4.10 Training 
Enprofylline 4.16 Training 
Amantadine 4.17 Validation
Flomoxef 4.17 Training 
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Busulfan 4.18 Training 
Cisapride 4.21 Training 
Pimagedin 4.27 Training 
Cefuzonam 4.28 Training 
Hydrocortisone 4.29 Training 
Cefalexin 4.30 Validation
Amsacrine 4.33 Training 
Dexrazoxane 4.42 Training 
Loracarbef 4.45 Validation 
Recainam 4.47 Validation
Chlorothiazide 4.50 Training 
Spiraprilat 4.52 Training 
Thiotepa 4.60 Training 
Argatroba 4.70 Validation 
Betaxolol 4.70 Validation 
Cefradine 4.80 Training 
Enalaprilat 4.90 Training 
Lamivudine 4.95 Validation
Paracetamol 5.00 Training 
Ribavirin 5.00 Training 
Clindamyc 5.05 Training 
Loprazolam 5.09 Validation 
Phencyclidin 5.17 Training 
Melphalan 5.20 Training 
Citalopram 5.21 Validation
Dofetilide 5.23 Training 
Nifedipine 5.23 Training 
Levosimen 5.29 Training 
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Zolpidem 5.41 Training 
Clozapine 5.49 Training 
Methylpredn 5.49 Training 
Isoniazid 5.55 Training 
Flecainide 5.60 Validation 
Zalcitabine 5.61 Training 
Metrifonate 5.67 Training 
Clonidine 5.70 Training 
Sultopride 5.71 Validation 
Doxapram 5.75 Training 
Ketanserin 5.86 Training 
Amlodipin 5.90 Validation
Diclofenac 5.90 Training 
Rabeprazol 6.00 Training 
Rolipram 6.00 Validation
Sildenafil 6.00 Training 
Tolterodine 6.03 Training 
Cefaclor 6.10 Training 
Oxacillin 6.10 Validation
Milrinone 6.17 Training 
Perindopril 6.19 Training 
Lansoprazole 6.23 Training 
Mexiletine 6.30 Training 
Moexipril 6.30 Training 
Naratriptan 6.35 Training 
Cefapirin 6.36 Training 


















 beta-hydroxy acid 
ne  
6.43 Training 
Alprenolol 6.47 Training 
Olanzapine 6.48 Validation
Eletriptan 6.50 Validation
Bupivacaine 6.59 Training 
Ciprofloxa 6.62 Training 
Alfuzosin 6.67 Training 
Toborinone 6.67 Validation
Cefalotin 6.70 Validation
Rilmenidin 6.73 Training 
Roxatidine 6.73 Training 
Actisomide 6.79 Training 
Paroxetine 6.80 Validation
Nafcillin 6.89 Training 
Fluocortolon 7.00 Training 
Chloroquine 7.09 Training 
Metoclopram 7.13 Training 
Ropivacain 7.14 Validation
Treprostinil 7.14 Training 
Zileuton 7.14 Validation
Tasosartan 7.17 Training 
Ritipenem 7.21 Training 
Diphenhydra 7.30 Training 
Pseudoephedri 7.33 Training 
Talipexole 7.38 Training 
Triazolam 7.55 Training 
Celecoxib 7.59 Training 
















Bufuralol 7.70 Training 
Amisulpride 7.80 Training 
Salbutamol 7.89 Training 
Metformin 7.91 Validation
Procainamide 7.98 Training 
Atropine 8.00 Training 
Famciclovir 8.00 Validation 
Zatebradin 8.00 Training 
Ethambutol 8.05 Training 
Oxybutynin 8.10 Training 
Timolol 8.10 Training 
Pramipexole 8.20 Validation 
Mitomyci 8.23 Training 
Stavudine 8.24 Training 
Mirtazapine 8.25 Training 
Propiverine 8.32 Training 
Azelastine 8.33 Validation 
Domperidone 8.33 Validation
Losartan 8.34 Training 
Carteolol 8.40 Training 
Ketoconazo 8.40 Training 
Crisnatol 8.44 Training 
Pravastatin 8.50 Validation
Pyridostigm 8.57 Validation
Cimetidine 8.63 Training 
Ritodrine 8.67 Training 
Carvedilol 8.70 Validation





















Doxofyllin 8.93 Training 
Famotidine 8.95 Training 
Tezosentan 9.05 Training 
Repaglinide 9.17 Training 
Lidocaine 9.20 Training 
Acetylsali 9.30 Training 
Penciclovir 9.36 Training 
Methylphenida 9.44 Training 
Isradipine 9.52 Validation
Molsidomine 9.52 Validation
Fluoxetin 9.60 Training 
Mitoxantrone 9.60 Training 
Nizatidine 9.63 Training 
Amiloride 9.70 Training 
Chlorpromaz 9.80 Training 
Tebufelone 9.88 Training 
Allopurinol 9.90 Validation 
Nitrofurantoin 9.90 Training 
Fluphenaz 10.00 Training 
Ketobemidone 10.00 Training 
Dexmedetomid 10.01 Training 
Nedocrom 10.20 Training 
Triflusal 10.71 Training 
Tolamolol 10.80 Training 
Perindoprila 10.95 Training 
Acebutolol 11.00 Validation
Codeine 11.00 Training 























Moclobemid 11.19 Training 
Ropinirole 11.19 Validation
Entacapone 11.22 Training 
Doxifluridine 11.43 Training 
Oxycodone 11.43 Training 
Eprosartan 11.55 Validation
Felodipine 11.59 Training 
Amitriptyline 11.67 Training 
Topotecan 11.78 Training 
Haloperidol 11.80 Validation
Fentanyl 11.96 Training 
Enoximone 12.02 Training 
Nicorandil 12.29 Training 
Trandolapril 12.38 Training 




Alosetron 12.93 Training 
Abecarnil 13.00 Training 
Cytarabin 13.00 Training 
Abacavir 13.07 Training 
Triamcinolone 13.07 Training 
Captopril 13.33 Training 
Methohex 13.33 Training 
Mebendazole 13.40 Training 
 
APPENDIX 312













Propranolol 13.67 Training 
Doxepin 14.00 Validation
Nalmefene 14.40 Training 
Vinpocetine 15.00 Training 
Didanosine 15.25 Training 
Fluticasone 15.61 Validation
Etidocaine 15.86 Training 
Trimipramin 15.90 Training 
Terguride 16.00 Training 
Fluvastatin 16.18 Training 
Mosapride 16.19 Training 
Ketamine 16.30 Validation 
Doxorubici 16.46 Training 
Carmustine 16.70 Training 
Neostigmine 16.70 Training 
Pethidine 17.00 Training 
Coumarin 17.30 Training 
Dixyrazine 17.54 Training 
Terbinafine 17.86 Training 
Carbidopa 18.00 Validation 
Lorcainide 18.00 Training 
Methoxsale 18.00 Training 
Cetiedil 18.33 Validation
Tegaserod 18.33 Training 
Nicotine 18.50 Training 
Propanthel 18.86 Training 
Rizatriptan 18.90 Training 













Sumatriptan 19.15 Training 
Hydromo 19.16 Training 
Carbimide 20.00 Training 
Fendiline 20.00 Validation
Mesna 20.50 Training 
Fluvoxamine 21.40 Training 
Midodrine 23.00 Training 
Fenretinide 23.48 Training 
Naloxone 23.50 Training 
Perphenazin 23.81 Training 
Morphine 24.50 Training 
Rivastigmi 25.71 Training 
Zidovudine 26.00 Training 
Quinapril 26.43 Training 
Nandrolone 26.67 Training 
Labetalol 28.10 Training 
Buspirone 28.30 Training 
Emivirine 28.57 Training 
Ibutilide 29.00 Training 
Amineptine 29.55 Training 
Nalbuphine 29.70 Training 
Phenylephrine 29.90 Training 
Cocaine 32.00 Training 
Tizanidine 33.33 Training 
Bupropion 36.00 Training 
Dopexamine 36.00 Training 
Sertraline 38.00 Training 
Butorphanol 40.00 Training 
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Acadesine 41.67 Training 
Oxaprozin 48.33 Training 








Dobutamin 59.00 Training 
Capecit 59.73 Training 
Prilocaine 64.00 Training 
N-(4-metho 98.86 Training 
Articaine 126.19 Training 
Exemestan 145.00 Training 
Encainide 177.14 Training 





Table 10: GT+ compounds. 










Moexipril Z e iopheneacetonitrile 
oic acid Morphine Z an 
phenecarboxaldehyde 


















Chloramphenicol Omeprazole 1-pyrenemethanol 2-nitrothiophene 
Chloroquine Oxcarbazepime 7-bromoindole 2,3,5-tribromothiophene 
Chlorpheniramine Pantoprazole 9-anthracenylmethyl 2,4,6-
trimethylbenzoate 
2-acetyl-5-chlorothiophene





















in  hracene cetonitrile 
Clofibrate Pergolide 3-amino-9-ethylcarbazole 
 cene dibromothiophene 
Dantrolene Phenoxybenzamine 2-amino-1-
Dexrazoxane Phenylephrine 
Diazepam Pilocarpine  2,3-dihydrothieno-(3,4-B)-
 













Clarithromyc Peperacillin 2-aminoant 2-thiophenea
Ethyl 2-
thiophenecarboxylate 















Doxycycline Pyrazinamide 8-aminoquinoline 4-keto-4,5,6,7-
tetrahydrothianaphthene 
Doxylamine Pyrilamine 1-hydroxypyrene 2-acetyl-3-






Epinephrine Quetiapine aphthalene 3-(diethylamino)phenol 
Erythromycin Rabeprazole 2-chloroaniline 
Esomeprazole Ranitidine -dichloroquinolinium 4-methoxy-2-
il e 
Fosphenytoin Riluzole Phthalazine 
e  
Furosemide Rivastigmine 2-fluoroaniline 
n e  










Imipramine Temozolomide 2-(2-aminophenyl)indole 
 e ndole ,4-
1,5-dihydroxyn











Grepafloxacin Ropivacaine Harmine 2,4-difluoroaniline 
Griseofulvi Rosiglitazon 2-phenylbenzimidazole 1,8-diaminonaphthalene 
m-phenetid
Halothane Sulfanilam 7-methylindole 2-amino-4
butylphenol 
Hydrochlorothiazide Sulfasalazine 6-methox 5-amino-2-methoxyp






Indomethacin Theophyllin 5-amino-2-methyli 2,5-dimethyl-1
phenylenediamine 




















Lamivudine Timolol 2-acetyl-5-bromoth Enoxacin 










Mebendazole Trientine 2-bromo-5-chlorothiophe  




Table 11: GT- compounds. 


















Alprostadil Mycophenolate 2,8-quinolinediol Thieno-(3,2-B)-pyridin-7-
ol 
Amantadine Nafarelin 4-acridinol Trans-3-(3-thienyl)acrylic 
acid 
Amiloride Nalidixic acid 5-carboxyfluorescein Trans-2-(4-
dimethylamino)styryl)ben
zothiazole 
Aminolevulinic acid Naltrexone 2-aminobenzimidazole 5,5-dibromo-2,2-
biothiophene 






















Amphotericin B Nefazodone Acyclovir rthiophene-5,5-
Amprenavir Nelfinavir ene-2-
carboxylic acid 
e  nyl)glycine 
Argatroban Niacin Etofylline 
ne
Atorvastatin Nicotine ine ianaphthene 
Azelaic acid Nilutamide 2,7-diaminofluorene 
 zolo(3,4-
D)pyrimidine 
Azithromycin Nisoldipine 6-aminoindazole phene 
Balsalazide Norfloxacin Acridine orange -dibromo-3-
Beclomethasone Olanzapine Aminopterin ibromo-3-
phene 
Benazepril Olopatadine Bisbenzimide 
hene 
cine 







Anagrelid Nevirapine Ellagic acid D-R-(2-thie
Cephalothin Sodium 




Atovaquone Nifedipine 1-aminopyrene 3-(2-thienyl)-L-alanine 
3-bromo-4-
methylthiophene 
Azelastine Nimodipine 4-amino-pyra P trans-2-(2-
nitrovinyl)thiophene 
3-butylthio







Benzoyl peroxide Olsalazine Coumarin, 7 L-R-(3-thienyl)gly
L-R-(2-thienyl
3-carboxylic acid 




Bisoprolol Oseltamivir ethyltryptamine Perphenazine N-m
Bitolterol Oxaprozin Sangivamycin hydrate rcidin 
Brimonidine Oxiconazole Sulfaquinoxaline 
rboxaldehyde 
raquino
Buspirone Pamidronate 2-ethylanthracene inone 
e line 















Carteolol Pramipexole 5-chlorobenzotriazole nyl-
l 
nzimidaz
Cefdinir Primidone 5-fluoroindole perazine 
Tube
Disperse orange 11 




Butaconazol Paricalcitol 3-aminoquino Ethyl 2-aminobenzoate 
Butenafine Paroxeti 1-ethylnaph 2,4,6-trimethylaniline
Butorphan Pemirolast 6-aminoquino 2-amino-4-chlorobenzoic 
acid 
Cabergoline Perindopril 4,7-phenanthroli o-anisidine 
Caffeine Phenylpropa 4-amino-2-chloro-6,7 9-aminoacri
Calcipotrien Phenytoin 5-aminoquinoline 4,4¢-
bis(diethylamino)benz
enone 
Calcitriol Phytonadio Folic acid N-phenylanthranilic a
Candesartan Pimozide Indole-3-propion 7-diethylamino-4
methylcoumarin
















Cefotaxime Promethazine 5-methylbenzimidazole 





Ceftriaxone Raloxifene 9-bromoanthracene moaniline 
10- ine 
Celecoxib Repaglinide 3-chloroaniline 
zine 
Cetirizine Rifapentine 1-methyl-2-phenylindole 
thylamino)ethanol 
e yl-4,7-diphenyl-


















Cefprozil Propofol 2,6-dimethylquinolin 3,4-dimethylaniline 
Ceftazidime Pseudoephed 8,8-diquinolyl disu 2,5-dimethylaniline 
Ceftibuten Pyridostigm 5-benzyloxyindole 3-dimethylaminophenol














































Diltiazem Terazosin 3-aminophenol 




















































Eflornithine Tocainide xy- -
iperazine 
ethylamino)benzopheno


















































Fenofibrate Vancomycin 2-(phenylsulfonyl)aniline 
Fenoldopam Venlafaxine rothiophene N,N’-bis(2-
nedia
mine 
Fexofenadine Zafirlukast 4-(butylamino)benzoic 
acid 
ide perhydroisoquinoline 
Fluconazole Zileuton hlorothiophene 
l te thene ne 
Fluoxetine Zolpidem 3-bromothiophene 
Fluticasone Zonisamide 3-methoxythiophene ethyldodecylamine 






























Flumazeni Zoledrona 3-bromothianaph 2-benzylaminopyridi
Solvent blue 59 
N-m
Fluvastatin 6-carboxyflu 3-thiophenea 2-aminoterephthalic acid 
Fluvoxamine N-chloroacet 3-thi 4-(methylamino)benzoic 






























Ethyl 2-thiopheneacetate yl-o-anisidine 
ne y-1,10-








3- iophene ino-2-naphthoic acid


















































































































Linezolid Pseudocoralyne 2-thiopheneethylamine Guanazole 
ophene 
f 
l ether hydrazide methylhomoveratrylamine





ndolylacetyl)- hiophene zoic 
Mefloquine ethyl 
thyl sulfide 
2-(3-thienyl)ethanol 3-amino-2-naphthoic acid 
















































































































Table 12: TdP+ com
Compound Set  Compound Set 
pounds. 
Amantadine  Ritodrine Training Training 
Amiodarone 
in 
Bepridil  Sibutramine 
Chloral hydrate Training  Sotalol Training 
rfloxacin 
Cisapride Training  Tacrolimus Training 
n Trai  
Cocaine Training 
Disopyramide Training  Thioridazine Training 
Dobutamine Training  Tizanidine Training 
Dofetilide Training  Venlafaxine Training 
Domperidone Training  Voriconazole Training 
Dopamine Training  Ziprasidone Training 
Droperidol Training  Adenosine phosphate Validation 
Ephedrine Training  Ajmaline Validation 
Epinephrine Training  Aprindine Validation 
Erythromycin Training  Astemizole Validation 
Felbamate Training  Atropine ation 
ne Training Validation 
Flecainide Training Validation 
Foscarnet sodium hloroquine Validation 
osphenytoin Training  Clindamycin Validation 
Gatifloxacin Training  Diphenhydramine Validation 
Granisetron Training  Emedastine Validation 
Halofantrine Training  Grepafloxacin Validation 
Haloperidol Training  Halothane Validation 
Training  Salbutamol Training 
Azithromyc Training 
Training 
 Salmeterol Training 
Training 
Chlorpromazine Training  Spa Training 











Hydrochlorothiazide Training  Hydroquinidine Validation 



















drine n camsilate 
ing  ation
Indapamide Training  Maprotilin Validation
Isoprenaline Training  Mefloquine Validation
Isradipine Training  Mianserin Validation
Levofloxaci Training  Mibefradil Validation
Mesoridazine Training  Mizolas Validation
Methadone Training  Olanzapine Validation
Midodrine Training  Papaverine Validation
Moexipril Training  Prenylamine Validation
Moxiflox Training  Probucol Validation
Nicardipine Training  Prochlorperaz Validation
Norepinephri Training  Promethazine Validation
Octreotide Training  Quinine Validation
Ondansetron Training  Sematilide Validation
Orciprenali Training  Sertindole Validation
Pentamidine Training  Spiramycin Validation 
Phentermin Training  Sultopride Validation 
Phenylephrin Training  Terfenadine Validation 
Phenylpropano Training  Terodiline Validation 
Pimozide Training  Tiapride Validation 
Procainamide Training  Trazodone Validation 
Pseudoephe Training  Trimetapha Validation 
Quetiapine Training  Vasopressin Validation 
Quinidine Training  Vincamine Validation 




Table 13: TdP- compoun
d 
ds. 
Compoun Set  Compound Set 
Abacavir Training  Methotrexate Training 
Acarbose Training  Methoxsalen 
ide sterone 













eclometasone Training  Phenazopyridine Training 
Bendroflumethiazide Training  Phenelzine Training 
Benzonatate Training  Phytomenadione Training 
Training 
Acetazolam Training  Methyltesto Training 
Acetohydroxam Training  Methylthion Training 
Acetylcysteine Training  Miconazole Training 
Adapalene Training  Mifepristone Training 
Albendazole Training  Miglitol Training 
Alendronic Training  Minocycline Training 
Alitretinoin Training  Misoprost Training 
Allopurinol Training  Monoethanolamin Training 
Amcinonide Training  Montelukast Training 
Amifostine Training  Nalidixic Training 
Amikacin Training  Natamycin Training 
Amiloride Training  Nelfinavir Training 
Aminosalicyli Training  Neomycin Training 
Amoxicillin Training  Nevirapine Training 
Ampicillin Training  Nitrofural Training 
Anakinra Training  Olsalazine Training 
Anastrozol Training  Orlistat Training 
Azelaic acid Training  Oxcarbazep
Aztreonam Training  Oxytetracycline Training 
Bacampicill Training  Paracetamol Training 
Baclofen Training  Paromomyc Training 




Betaine Training  Piperacillin Training 

















Train  Pramipexole Train
Bumetanid Training  Prednicarbate Training 
Butenafine Training  Procarbazine Training 
Calcipotriol Training  Pyrantel Training 
Calcium folinate Training  Pyrazinamide Training 
Carbenicillin Training  Raloxifene Training 
Carmustine Training  Riboflavin Training 
Cefaclor Training  Rifampic Training 
Cefamandole Training  Rifapentine Training 
Cefapirin Training  Risedronic ac Training 
Cefazolin Training  Ritonavir Training 
Cefdinir Training  Salsalate Training 
Cefditoren Training  Saquinavir Training 
Cefixime Training  Secbutabarb
Cefoperazo Training  Simvastatin Training 
Cefotetan Training  Spectinomycin Training 
Cefoxitin Training  Spironolacto Training 
Cefpodoxim Training  Stanozolol Training 
Cefprozil Training  Streptomyci Training 
Ceftazidime Training  Streptozo Training 
Ceftibuten Training  Sulfadiazine Training 
Ceftizoxime Training  Sulfafurazole Training 
Ceftriaxone Training  Sulfamethoxa Training 
Chlorzoxa Training  Sulfasalazine Training 
Cinoxacin Training  Testolactone Training 
Clobetasol Training  Tetracycline Training 
Clocortolone Training  Theophyllin Training 
Clopidogrel Training  Thiamazole Training 
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 acetonide  
Training  Thiotepa Training 
Cycloserine Training  Tiabendazole Training 
Cytarabine Training  Tiludronic aci Training 
Dacarbazine Training  Tioguanin Training 
Danazol Training  Tobramycin Training 
Dapsone Training  Tolazamide Training 
Desmopressi Training  Tolcapone Training 
Dexrazox Training  Tolnaftate Training 
Diclofenamide Training  Tranexamic Training 
Dicloxacill Training  Trichlormethiazi Training 
Dicoumaro Training  Trientine Training 
Dicyclove Training  Trifluridin Training 
Diethylstilb Training  Troleandom Training 
Diiodohyd Training  Trometamol Training 
Dirithromycin Training  Unoprostone Training 
Dorzolamid Training  Uramustine Training 
Eflornithin Training  Ursodeoxycholic acid Training 
Estradiol Training  Valrubicin Training 
Estrone Training  Vincristine Training 
Ethambutol Training  Vinorelbine Training 
Ethinylestra Training  Warfarin Training 
Etidronic acid Training  Zafirlukast Training 
Finasteride Training  Zanamivir Training 
Floxuridine Training  Zidovudine Training 
Fluconazole Training  Zoledronic ac Training 
Flucytosine Training  Alclometason Validation
Flunisolide Training  Benzocaine Validation
Fluocinolone Training  Cefadroxil Validation
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Fluocinonide  Training  Cefalexin Validation




























Fluvastatin Training  Cefuroxime Validation
Fosfomycin Training  Clotrimazole Validation
Furazolidone Training  Demeclocyc Validation
Furosemi Training  Dienestrol Validation
Gabapenti Training  Doxycycline Validation
Gemfibrozil Training  Ethionamid Validation
Gentamicin Training  Ethosuximi Validation
Glibenclamide Training  Ethotoin Validation
Glimepiride Training  Guaifenesin Validation
Glipizide Training  Ketorolac Validation
Griseofulvin Training  Levonorgestr Validation
Guanabenz Training  Lovastatin Validation
Hydroflumethiazide Training  Medroxyprog Validation
Hydroquinone Training  Medrysone Validation
Hydroxycarba Training  Metirosine Validation
Irinotecan Training  Metronidazole Validation
Isoniazid Training  Mometason Validation
Kanamyci Training  Nandrolone Validation
Lactulose Training  Nitrofurantoi Validation
Lamotrigine Training  Norethiste Validation
Letrozole Training  Norgestrel Validation
Levamisole Training  Pemoline Validation
Lincomycin Training  Penicillamin Validation
Liothyronine Training  Primidone Validation
Lomustine Training  Propylthiouracil Validation 
Loracarbef Training  Pyridoxine Validation 
Loteprednol Training  Rimexolone Validation 
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Training  Sulconazol Validation 
Meclocyclin Training  Sulfanilamide Validation 
Melphalan Training  Testosterone Validation 
Mercaptopurin Training  Ticarcillin Validation 
Mesalazine Training  Trimethopri Validation 
Methazolami Training  Zileuton Validation 
Methenamine Training    
 
 
